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A B S T R A C T
Background
Miscarriage occurs in 10% to 15% of pregnancies. The traditional treatment, after miscarriage, has been to perform surgery to remove
any remaining placental tissues in the uterus (’evacuation of uterus’). However, medical treatments, or expectant care (no treatment),
may also be effective, safe, and acceptable.
Objectives
To assess the effectiveness, safety, and acceptability of any medical treatment for incomplete miscarriage (before 24 weeks).
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register (13 May 2016) and reference lists of retrieved papers.
Selection criteria
We included randomised controlled trials comparing medical treatment with expectant care or surgery, or alternative methods of
medical treatment. We excluded quasi-randomised trials.
Data collection and analysis
Two review authors independently assessed the studies for inclusion, assessed risk of bias, and carried out data extraction. Data entry
was checked. We assessed the quality of the evidence using the GRADE approach.
Main results
We included 24 studies (5577 women). There were no trials specifically of miscarriage treatment after 13 weeks’ gestation.
Three trials involving 335 women compared misoprostol treatment (all vaginally administered) with expectant care. There was no
difference in complete miscarriage (average risk ratio (RR) 1.23, 95% confidence interval (CI) 0.72 to 2.10; 2 studies, 150 women,
random-effects; very low-quality evidence), or in the need for surgical evacuation (average RR 0.62, 95% CI 0.17 to 2.26; 2 studies,
308 women, random-effects; low-quality evidence). There were few data on ’deaths or serious complications’. For unplanned surgical
intervention, we did not identify any difference between misoprostol and expectant care (average RR 0.62, 95% CI 0.17 to 2.26; 2
studies, 308 women, random-effects; low-quality evidence).
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Sixteen trials involving 4044 women addressed the comparison of misoprostol (7 studies used oral administration, 6 studies used
vaginal, 2 studies sublingual, 1 study combined vaginal + oral) with surgical evacuation. There was a slightly lower incidence of complete
miscarriage with misoprostol (average RR 0.96, 95% CI 0.94 to 0.98; 15 studies, 3862 women, random-effects; very low-quality
evidence) but with success rate high for both methods. Overall, there were fewer surgical evacuations with misoprostol (average RR
0.05, 95% CI 0.02 to 0.11; 13 studies, 3070 women, random-effects; very low-quality evidence) but more unplanned procedures
(average RR 5.03, 95% CI 2.71 to 9.35; 11 studies, 2690 women, random-effects; low-quality evidence). There were few data on
’deaths or serious complications’. Nausea was more common with misoprostol (average RR 2.50, 95% CI 1.53 to 4.09; 11 studies, 3015
women, random-effects; low-quality evidence). We did not identify any difference in women’s satisfaction between misoprostol and
surgery (average RR 1.00, 95% CI 0.99 to 1.00; 9 studies, 3349 women, random-effects; moderate-quality evidence). More women
had vomiting and diarrhoea with misoprostol compared with surgery (vomiting: average RR 1.97, 95% CI 1.36 to 2.85; 10 studies,
2977 women, random-effects; moderate-quality evidence; diarrhoea: average RR 4.82, 95% CI 1.09 to 21.32; 4 studies, 757 women,
random-effects; moderate-quality evidence).
Five trials compared different routes of administration, or doses, or both, of misoprostol. There was no clear evidence of one regimen
being superior to another.
Limited evidence suggests that women generally seem satisfied with their care. Long-term follow-up from one included study identified
no difference in subsequent fertility between the three approaches.
Authors’ conclusions
The available evidence suggests that medical treatment, with misoprostol, and expectant care are both acceptable alternatives to routine
surgical evacuation given the availability of health service resources to support all three approaches. Further studies, including long-
term follow-up, are clearly needed to confirm these findings. There is an urgent need for studies on women who miscarry at more than
13 weeks’ gestation.
P L A I N L A N G U A G E S U M M A R Y
Medical treatments for incomplete miscarriage
What is the issue?
Miscarriage is when a pregnant woman loses her baby before the baby would be considered able to survive outside the womb, i.e. before
24 weeks’ gestation. Miscarriage occurs in about 10% to 15% of pregnancies and the signs are bleeding, usually with some abdominal
pain and cramping. The traditional management of miscarriage was surgery but this Cochrane Review asks if medical treatments can
be another management option for the woman.
Why is this important?
The cause of miscarriage is often unknown, but most are likely to be due to abnormalities in the baby’s chromosomes. Women
experiencing miscarriage may be quite distressed, and there can be feelings of emptiness, guilt, and failure. Fathers can also be affected
emotionally. Traditionally, surgery (curettage or vacuum aspiration) has been the treatment used to remove any retained tissue and it is
quick to perform. It has now been suggested that medical treatments (usually misoprostol) may be as effective and may carry less risk
of infection.
What evidence did we find?
We searched for evidence on 13 May 2016 and identified 24 studies involving 5577 women, and all these studies were of women at less
than 13 weeks’ gestation. There were a number of different ways of giving the drugs and so there are limited data for each comparison.
Overall, the review found no real difference in the success between misoprostol and waiting for spontaneous miscarriage (expectant
care), nor betweenmisoprostol and surgery. The overall success rate of treatment (misoprostol and surgery) was over 80% and sometimes
as high as 99%, and one study identified no difference in subsequent fertility between methods of medication, surgery or expectant
management. Vaginal misoprostol was compared with oral misoprostol in one study which found no difference in success, but there
was an increase in the incidence of diarrhoea with oral misoprostol. However, women on the whole seemed happy with their care,
whichever treatment they were given.
What does this mean?
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The review suggests that misoprostol or waiting for spontaneous expulsion of fragments are important alternatives to surgery, but
women should be offered an informed choice. Further studies are clearly needed to confirm these findings and should include long-
term follow-up. There is an urgent need for studies on women who miscarry at more than 13 weeks’ gestation.
3Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Misoprostol compared to expectant care for incomplete miscarriage
Patient or population: incomplete miscarriage
Setting: hospitals in Australia, Sweden, United Kingdom
Intervention: misoprostol
Comparison: expectant care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with expectant
care
Risk with M isoprostol
Complete miscarriage Study populat ion RR 1.23
(0.72 to 2.10)
150
(2 RCTs)
⊕©©©
VERY LOW 1,2,3
579 per 1000 712 per 1000
(417 to 1000)
Moderate
687 per 1000 845 per 1000
(494 to 1000)
Surgical evacuat ion Study populat ion RR 0.62
(0.17 to 2.26)
308
(2 RCTs)
⊕⊕©©
LOW 12
312 per 1000 193 per 1000
(53 to 704)
Moderate
327 per 1000 202 per 1000
(56 to 738)
Unplanned surgical in-
tervent ion
Study populat ion RR 0.62
(0.17 to 2.26)
308
(2 RCTs)
⊕⊕©©
LOW 12
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312 per 1000 193 per 1000
(53 to 704)
Moderate
327 per 1000 202 per 1000
(56 to 738)
Women’s views/
acceptability of method
Study populat ion - (0 study) - No data
see comment see comment
Nausea Study populat ion - (0 study) - No data
see comment see comment
Vomit ing Study populat ion - (0 study) - No data
see comment see comment
Diarrhoea Study populat ion - (0 study) - No data
see comment see comment
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High-quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 One study blinded (placebo-controlled), but the other unblinded.
2 High levels of heterogeneity.
3 Only two trials, including a total of 150 women.
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B A C K G R O U N D
Description of the condition
Miscarriage is generally defined as the spontaneous loss of a preg-
nancy prior to 24 weeks’ gestation, that is, before the fetus is usu-
ally viable outside the uterus (Shiers 2003). The clinical signs of
miscarriage are vaginal bleeding, usually with abdominal pain and
cramping. If the pregnancy has been expelled, the miscarriage is
termed ’complete’ or ’incomplete’ depending on whether or not
tissues are retained in the uterus. If a woman bleeds but her cervix
is closed, this is described as a ’threatened miscarriage’ as it is of-
ten possible for the pregnancy to continue and not to miscarry
(RCOG 2006; Shiers 2003); if the pregnancy is in the uterus but
the cervix is open, this is described as an ’inevitable miscarriage’,
i.e. it will not usually be possible to save the pregnancy and fe-
tus. The now widespread use of ultrasound in early pregnancy,
either for specific reasons (e.g. bleeding) or as a routine proce-
dure, reveals pregnancies that are destined to inevitably miscarry,
because they are ’non-viable’ (Sawyer 2007; Weeks 2001). Non-
viable pregnancies are either a ’missed miscarriage’ if an embryo
or fetus is present but is dead, or an ’anembryonic pregnancy’ if
no embryo has developed within the gestation sac.
Regardless of the type of miscarriage, the overall incidence is con-
sidered to be between 10% and 15%, although the real incidence
may be greater (Shiers 2003). Most miscarriages occur within the
first 12 weeks of pregnancy and are called ’early miscarriage’, with
those occurring after 13 weeks being known as ’late miscarriage’.
The cause of miscarriage is generally unknown, but most are likely
to be due to chromosomal abnormalities. The risk of miscarriage
has been reported to be higher in older women, and where there
are structural abnormalities of the genital tract, infection, and ma-
ternal complications such as diabetes, renal disease, and thyroid
dysfunction. Also, some environmental factors have been linked
with miscarriage, including alcohol and smoking (Shiers 2003).
Miscarriage can sometimes lead to haemorrhage and infection,
and it can be an important cause of morbidity, and even mortality,
particularly in low-income countries (Lewis 2007).
Women experiencing miscarriage may be overwhelmed by the
symptoms and also quite distressed (Shiers 2003). Psychological
problems can follow a miscarriage, and these can include loss of
self-esteem resulting from the woman’s feeling of inability to rely
on her body to give birth (Swanson 1999). Emotional responses
described include those of emptiness, guilt, and failure (Swanson
1999). There can also be depression, anxiety, grief, and anger (Klier
2002; Thapar 1992). A number of other consequences, includ-
ing sleep disturbance, social withdrawal, anger, and marital distur-
bance, may occur following miscarriage (Lok 2007). Fathers can
also be affected emotionally (Klier 2002).
Description of the intervention
Traditionally, all pregnancies that had miscarried were considered
by clinicians as potentially incomplete. Therefore, surgical curet-
tage (’evacuation of the uterus’) was performed routinely to re-
move any retained placental tissue. If no tissue was obtained, then
a retrospective diagnosis of complete miscarriage was made. Surgi-
cal curettage was the ’gold standard management’ for miscarriage
for many years because it is quickly performed and it is possible to
completely remove any retained products of conception (Ankum
2001). Histological examination of the removed tissues also al-
lowed exclusion of trophoblastic disease, e.g. hydatidiform mole -
although this is quite rare.New clinical approaches have evolved to
try to minimise unnecessary surgical interventions whilst aiming
tomaintain low rates ofmorbidity andmortality frommiscarriage.
These approaches have included ultrasound imaging to diagnose
complete miscarriage and thus avoid treatment, or more conser-
vative treatments of incomplete miscarriage, such as drug (med-
ical) treatment or no active treatment (expectant management)
(Ankum 2001; Luise 2002). Various types of medical treatment
could be suitable as alternatives to routine surgical treatment for
miscarriage and these include the use of prostaglandins, or other
uterotonic (uterus-contracting) drugs or anti-hormone therapy.
How the intervention might work
a) Prostaglandins, e.g. misoprostol, prostaglandin
F2alpha
Misoprostol is a synthetic prostaglandin E1 analogue and is mar-
keted for the prevention and treatment of peptic ulcers. Recog-
nised as a potent method for pregnancy termination (Costa 1993;
Norman 1991), it is inexpensive, stable at room temperature, and
has few systemic effects, although vomiting, diarrhoea, hyperten-
sion, and even potential teratogenicity (causing fetal malforma-
tion) when misoprostol fails to induce the abortion, have been
reported (Fonseca 1991).
Misoprostol has been shown to be an effective myometrial stim-
ulant of the pregnant uterus, selectively binding to EP-2/EP-3
prostanoid receptors and stimulating contractions, which push the
products or pregnancy out. It is rapidly absorbed orally and vagi-
nally. Vaginally-absorbed serum levels are more prolonged, and
vaginal misoprostol may have locally-mediated effects (Zieman
1997).Misoprostol could be especially useful in low-income coun-
tries, where transport and storage facilities are inadequate, and the
availability of uterotonic agents and blood is limited. Its use in
obstetrics and gynaecology has been explored, especially to induce
first and second trimester abortion (Costa 1993; Norman 1991),
for the induction of labour (Alfirevic 2014; Hofmeyr 2010), and
for the prevention of postpartum haemorrhage (Tuncalp 2012).
The stimulatory actions of misoprostol on the early pregnancy
uterus could, in theory, help to expel retained tissue from the uterus
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after miscarriage, and provide an attractive medical alternative to
surgical treatment of incomplete miscarriage (Chung 1995). It is
important to distinguish between the use of misoprostol for in-
complete miscarriage and its use for termination of viable preg-
nancies.
b) Other uterotonics, e.g. ergometrine, oxytocin
Ergometrine (extracted from the rye fungus, ergot) will promote
contraction of involuntary muscles throughout the body (Hawk
1985; Kawarabayashi 1990), and oxytocin promotes strong rhyth-
mic contractions of the uterus (Arthur 2007; Mota-Rojas 2007).
Both drugs could potentially have a role in expelling tissue after
miscarriage.
c) Progesterone antagonist
A number of progesterone antagonists are now available, and these
drugs will interfere with the production, or functioning, or both,
of progesterone. The progesterone antagonist, mifepristone, has
an established role in the termination of first and second trimester
pregnancy (Jain 2002), and may also be effective in promoting
expulsion of retained placental tissues following miscarriage (Tang
2006b).
Why it is important to do this review
Bleeding in early pregnancy is themost common reason forwomen
to present to the gynaecology emergency department, and inmany
of these women, miscarriage will be diagnosed (Ramphal 2006). It
is now clear that routine surgical evacuation of the uterus follow-
ing miscarriage may not be indicated, and the subsequent risk of
infection, haemorrhage, cervical damage, uterine perforation, and
risks of anaesthesia may not be justified (Harris 2007). In order to
optimise clinical management of this common condition, it is im-
portant to establish whether the use of medical treatment (drugs),
or expectant management (no routine treatment) may offer a safer
alternative for women with incomplete miscarriage, and whether
there are specific circumstances where one type of treatment plan
is superior to others.
We initially aimed to systematically review medical treatments for
both non-viable pregnancies and incomplete miscarriages com-
bined. On further reflection, this seemed illogical. Non-viable
pregnancies contain viable trophoblast (placental) tissue, which
produces hormones, which may in theory make these pregnancies
more susceptible to anti-hormone therapy and more resistant to
uterotonic (stimulating uterine contractions) therapy than preg-
nancies in which (incomplete) miscarriage has already taken place.
Therefore, this review focuses on the management of incomplete
miscarriage. Another Cochrane Review has covered non-viable
pregnancies (Neilson 2006).
Other relevant Cochrane Reviews on the treatment of miscarriage
include: ’Expectant care versus surgical treatment for miscarriage’
(Nanda 2012), ’Surgical procedures for evacuating incomplete mis-
carriage’ (Tuncalp 2010), ’Anaesthesia for evacuation of incomplete
miscarriage’ (Calvache 2012), and ’Follow-up for improving psycho-
logical well being for women after a miscarriage’ (Murphy 2012).
There is also a series of Cochrane Reviews on the possible pre-
vention of miscarriage (Aleman 2005; Bamigboye 2003; Empson
2005; Haas 2013; de Jong PG 2014; Wong 2014; Balogun 2016).
In addition, there are Cochrane Reviews on medical and surgical
interventions for induced abortions (Dodd 2010; Kulier 2011;
Lohr 2008; Wildschut 2011; Say 2010).
O B J E C T I V E S
To assess the effectiveness, safety, and acceptability of any medical
treatment for incomplete miscarriage (before 24 weeks).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only included randomised controlled trials (RCTs). Cluster-
randomised trials were eligible for inclusion, although we did not
identify such trials. We excluded quasi-RCTs and cross-over trials.
We also excluded conference proceedings and abstracts.
Types of participants
Participants were women being treated for spontaneous miscar-
riage (pregnancy loss at less than 24 weeks), either where there was
ultrasound evidence of retained tissue (incomplete miscarriage) or
where the diagnosis had been made on clinical grounds alone, and
where there would be uncertainty whether the miscarriage was
complete or incomplete. In communities in which termination
of pregnancy was illegal or unavailable, this could have included
women who had undergone unsafe abortion.
We excluded women with non-viable pregnancies (i.e. where the
embryo or fetus had died in utero, but in whom miscarriage had
not yet occurred) as they are covered by another Cochrane Review
(Neilson 2006).
We also excluded studies on induced abortion of a live fetus and
for fetal anomaly as these are covered in other Cochrane Reviews (
Dodd 2010; Kulier 2011; Lohr 2008;Wildschut 2011; Say 2010).
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Types of interventions
We considered trials if they compared medical treatment of in-
complete miscarriage with other methods (e.g. expectant manage-
ment, placebo, or any other intervention including surgical evac-
uation, either curettage or vacuum aspiration). We also included
comparisons between different routes of administration of drugs
(e.g. oral versus vaginal), or between different drugs or doses of
drug, or duration or timing of treatment, if data existed.
Types of outcome measures
Primary outcomes
1. Complete miscarriage (diagnosis of complete miscarriage
based on findings at surgery, or ultrasound examination, or both,
after a specific period, or cessation of symptoms and signs, or
both).
2. Surgical evacuation.
3. Death or serious complications (e.g. uterine rupture,
haemorrhage, sepsis, coagulopathy, uterine perforation,
hysterectomy, organ failure, intensive care unit admission).
Secondary outcomes
1. Unplanned surgical intervention (i.e. a second evacuation
in the surgical group but a first evacuation in the medical or
expectant group).
2. Blood transfusion.
3. Haemorrhage (blood loss greater than 500 mL, or as
defined by trial authors).
4. Blood loss.
5. Anaemia (haemoglobin (Hb) less than 10 g/dL, or as
defined by trial authors).
6. Days of bleeding.
7. Pain relief.
8. Pelvic infection.
9. Cervical damage.
10. Digestive disorders (nausea or vomiting or diarrhoea).
11. Hypertensive disorders.
12. Duration of stay in hospital.
13. Psychological effects.
14. Subsequent fertility.
15. Women’s views/acceptability of method.
16. Pathology of fetal/placental tissue.
17. Costs.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
The Information Specialist searched Cochrane Pregnancy and
Childbirth’s Trials Register on 13 May 2016.
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter, including the detailed search strategies for CENTRAL,MED-
LINE, Embase, and CINAHL, the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about Cochrane Pregnancy and Childbirth in
the Cochrane Library and select the ’Specialized Register’ section
from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full-text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Ongoing studies).
Searching other resources
We searched reference lists at the end of papers for further studies.
We did not apply any language or date restrictions.
Data collection and analysis
Formethods used in the previous version of this review, seeNeilson
2013.
For this update, we used the following methods for assessing the
21 reports that we identified as a result of the updated search.
The followingMethods sectionof this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
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Selection of studies
Two review authors (CRK, SB) independently assessed for inclu-
sion all the potential studies we identified as a result of the search
strategy. We would have resolved any disagreement through dis-
cussion or, if had been required, through consultation with a third
person.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors (CRK, SB) extracted the data using the agreed form. We
would have resolved any disagreement through discussion or, if
had been required, through consultation with a third person. We
entered data into Review Manager 5 software (RevMan 2014),
and checked for accuracy.
Had any information regarding any of the above been unclear, we
would have attempted to contact authors of the original reports
to provide further details.
Assessment of risk of bias in included studies
Two review authors (CRK SB) independently assessed risk of bias
for each study using the criteria outlined in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011). We would
have resolved any disagreement through discussion or, if had been
required, through consultation with a third person.
(1) Random sequence generation (checking for possible
selection bias)
We have described for each included study the method used to
generate the allocation sequence in sufficient detail to allow an
assessment of whether it should produce comparable groups.
We have assessed the methods as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high, or unclear risk of bias for participants;
• low, high, or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high, or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data, including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion, where reported, and whether
missing data were balanced across groups or were related to out-
comes. Where sufficient information was reported, or could be
supplied by the trial authors, we planned to re-include missing
data in the analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ’as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
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• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we planned to assess the likely magni-
tude and direction of the bias andwhether we considered it is likely
to impact on the findings. In future updates, we will explore the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
For this update, we assessed the quality of the evidence using
the GRADE approach as outlined in the GRADE Handbook in
order to assess the quality of the body of evidence relating to the
following outcomes for the two main comparisons: misoprostol
versus expectant care and misoprostol versus surgery.
1. Complete miscarriage
2. Surgical evacuation
3. Unplanned surgical intervention
4. Women’s views/acceptability of method (for misoprostol
versus surgery only)
5. Nausea
6. Vomiting
7. Diarrhoea
We used GRADEproGuidelineDevelopmentTool to import data
from Review Manager 5 in order to create ’Summary of findings’
tables (RevMan 2014). We produced a summary of the interven-
tion effect and a measure of quality for each of the above out-
comes using the GRADE approach. The GRADE approach uses
five considerations (study limitations, consistency of effect, im-
precision, indirectness, and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high-quality’ by one level for serious (or by two
levels for very serious) limitations, depending on assessments for
risk of bias, indirectness of evidence, serious inconsistency, impre-
cision of effect estimates, or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratios
(RRs) with 95% confidence intervals (CIs).
Continuous data
For continuous data, we used the mean difference (MD) if out-
comes were measured in the same way between trials. We used
the standardised mean difference (SMD) to combine trials that
measured the same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
along with individually-randomised trials, however, we did not
identify any cluster-randomised trials. If we identify any such trials
in future updates, we will adjust their sample sizes using the meth-
ods described in the Cochrane Handbook for Systematic Reviews of
Interventions (Section 16.3.4) using an estimate of the intracluster
correlation coefficient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population (Higgins
2011). If we use ICCs from other sources, we will report this and
conduct sensitivity analyses to investigate the effect of variation in
the ICC. If we identify both cluster-randomised trials and individ-
ually-randomised trials, we plan to synthesise the relevant infor-
mation. Wewill consider it reasonable to combine the results from
both if there is little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely.We will also ac-
knowledge heterogeneity in the randomisation unit and perform
a sensitivity analysis to investigate the effects of the randomisation
unit.
Cross-over trials
These are considered inappropriate studies for this review.
Dealing with missing data
For included studies, we noted levels of attrition. In future updates,
if we include more eligible studies, we will explore the impact of
including studies with high levels of missing data in the overall
assessment of treatment effect by using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses. The denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
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Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I², and Chi² statistics. We regarded heterogeneity as
substantial if I² was greater than 30% and either Tau² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity. If we identified substantial heterogeneity
(above 30%), we planned to explore it by prespecified subgroup
analysis.
Assessment of reporting biases
With this update, there were several outcomes in the meta-anal-
ysis that included 10 or more studies. Therefore, we investigated
reporting biases (such as publication bias). We assessed funnel plot
asymmetry visually.
Data synthesis
We carried out statistical analysis using the Review Manager 5
software (RevMan 2014). We used a fixed-effect meta-analysis for
combiningdatawhere itwas reasonable to assume that studieswere
estimating the same underlying treatment effect, i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the
underlying treatment effects differed between trials, or if we de-
tected substantial statistical heterogeneity, we used a random-ef-
fects meta-analysis to produce an overall summary if we consid-
ered an average treatment effect across trials to be clinically mean-
ingful. We treated the random-effects summary as the average of
the range of possible treatment effects and we discuss the clinical
implications of treatment effects differing between trials. If the
average treatment effect was not clinically meaningful, we planned
not to combine trials. If we used random-effects analyses, we pre-
sented the results as the average treatment effect with 95% CIs,
and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
When we identified substantial heterogeneity, we investigated it
using subgroup analyses and sensitivity analyses. We considered
whether an overall summary was meaningful, and if it was, used
random-effects analysis to produce it.
For misoprostol versus expectant care, and misoprostol versus
surgery, we subgrouped studies by the route of administration of
misoprostol (vaginal, oral, sublingual, rectal, combined).
For the remaining comparisons, we carried out the following sub-
group analyses on all outcomes.
1. Women less than 13 weeks’ gestation versus women
between 13 and 23 weeks’ gestation versus gestation not
specified.
We assessed subgroup differences by interaction tests available
within Review Manager 5 (RevMan 2014). We reported the re-
sults of subgroup analyses quoting the Chi² statistic and P value,
and the interaction test I² value.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effect of
trial quality assessed by concealment of allocation, high attrition
rates, or both, with poor quality studies being excluded from the
analyses in order to assess whether this makes any difference to
the overall result. We did not carry this out due to lack of data in
separate comparisons.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
We identified 164 reports in the original search (September
2009) that covered medical interventions for miscarriage before
24 weeks’ gestation, both for women with incomplete miscarriage
and women with intrauterine fetal death.We identified 30 reports
from an updated search on 23 July 2012. We identified 21 reports
from an updated search on 13 May 2016.
We included 24 trials, involving 5577 women in the review (Bique
2007; Blanchard 2004; Blohm 2005; Chigbu 2012; Clevin 2001;
Dabash 2010; Dao 2007; Diop 2009; Ganguly 2010;Montesinos
2011; Moodliar 2005; Ngoc 2005; Niinimaki 2006; Pang 2001;
Paritakul 2010; Patua 2013; Sahin 2001; Shelley 2005; Shochet
2012; Shwekerela 2007; Taylor 2011; Trinder 2006; Weeks 2005;
Zhang 2005); and two trials are ongoing (ISRCTN65305620;
NCT01033903). We excluded the remaining trials (reasons listed
in table of Characteristics of excluded studies).
Included studies
Twenty of the 24 included studies involved only women with
incomplete miscarriage (Bique 2007; Blanchard 2004; Blohm
2005; Chigbu 2012; Clevin 2001; Dabash 2010; Dao 2007; Diop
2009; Montesinos 2011; Moodliar 2005; Ngoc 2005; Pang 2001;
Paritakul 2010; Patua 2013; Sahin 2001; Shelley 2005; Shochet
2012; Shwekerela 2007; Taylor 2011; Weeks 2005). Seventeen of
the studies took place in low-income countries, mainly in Africa
and Southeast Asia. Three studies included both women with in-
complete miscarriage and women with an intrauterine fetal death
(Niinimaki 2006; Trinder 2006; Zhang 2005). One of these stud-
ies reported the findings for incomplete miscarriage separately
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from those for intrauterine fetal death (Trinder 2006), and for
the other two studies, the authors kindly sent us the separated
data (Niinimaki 2006; Zhang 2005). One study included women
with early pregnancy failure, which encompassed the anembry-
onic gestation, embryonic or fetal death, inevitable miscarriage,
and incomplete miscarriage (Ganguly 2010). This study reported
the findings for incomplete miscarriage separately from the other
pregnancy failure types for the primary outcome. There are a fur-
ther 12 studies that recruited both women with incomplete mis-
carriage and women with intrauterine fetal death, and we have
tried to contact these authors for the separated data, but as yet
have been unsuccessful. We have therefore excluded these studies
from this review.
All of the 24 included trials addressed medical treatment for in-
complete miscarriage before 13 weeks and we found no relevant
studies addressing this question for women between 13 and 23
weeks’ gestation.
Fourteen of the studies used ultrasound to confirm the diag-
nosis (Blanchard 2004; Blohm 2005; Clevin 2001; Dao 2007;
Ganguly 2010; Montesinos 2011; Moodliar 2005; Ngoc 2005;
Niinimaki 2006; Pang 2001; Paritakul 2010; Patua 2013; Zhang
2005). The other studies used clinical assessment for the diagno-
sis (Bique 2007; Chigbu 2012; Shelley 2005; Shwekerela 2007;
Trinder 2006;Weeks 2005), or clinical examination supplemented
by ultrasound,whennecessary (Dabash 2010;Diop 2009; Shochet
2012; Taylor 2011). The trials assessed completeness of miscar-
riage at follow-up, either by ultrasound or clinical assessment, and
at times that varied from three days to eight weeks. We have in-
cluded the specific information in the Characteristics of included
studies and also at the beginning of the ’Results’ section for each
comparison.
Excluded studies
There are 148 excluded studies and these are listed in the refer-
ence section under ’Excluded studies’. The table Characteristics of
excluded studies states the reasons for exclusion from this review.
These reasons mainly include: study not randomised; study in-
cluding women with non-viable pregnancies or intrauterine fetal
death only; and studies including women having termination of
pregnancy. We have also excluded studies where we have been un-
able to contact the authors for data separated by incomplete mis-
carriage and intrauterine fetal death (Bagratee 2004; Demetroulis
2001; Hinshaw 1997; Johnson 1997; Louey 2000 [pers comm];
Machtinger 2004;Ngai 2001;Nielsen 1999; Shaikh2008).Where
authors have kindly responded, but have been unable to supply
their data separated by incomplete miscarriage and intrauterine
fetal death, we have also been compelled to exclude such studies
(Chung 1999; Kong 2013; Petersen 2013).
Risk of bias in included studies
Overall, the risk of bias of studies was generally low, although in
most studies it was not possible to blind participants and clinicians.
It was unclear whether any of the studies were free of selective
reporting bias as we did not assess the trial protocols (Figure 1).
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
13Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
We excluded studies where group allocation was not random. We
considered the random sequence generation to be at low risk of
bias in all studies except three (Chigbu 2012; Sahin 2001; Shochet
2012), where itwas unclear.We considered allocation concealment
to be at low risk of bias in all studies except six (Chigbu 2012;
Clevin 2001;Ngoc 2005; Patua 2013; Sahin 2001; Shochet 2012),
where it was unclear.
Blinding
We considered blinding to be at low risk of performance bias in
only one study (Blohm 2005), and low risk for detection bias in
three studies (Blohm 2005; Ganguly 2010; Patua 2013). There
was unclear risk of performance bias in two studies (Pang 2001;
Shochet 2012), and for detection bias it was unclear in four studies
(Clevin 2001;Moodliar 2005; Pang 2001; Shochet 2012). For the
remainder of the studies, we considered blinding to be at high risk
of bias. However, for many studies we considered it impossible
to blind, especially where medical treatment was being compared
with surgery.
Incomplete outcome data
Loss to follow-up and exclusions after randomisation were low
in all studies except six; for three, we considered them unclear
(Clevin 2001; Patua 2013; Shochet 2012), and another three, we
considered to be at high risk of bias (Montesinos 2011; Pang 2001;
Weeks 2005). In theMontesinos 2011 study, 16.1%of women did
not return for assessment and were not included in analyses. In the
Pang 2001 study, it appeared that intention-to-treat analysis was
not used and the data could not be re-included. In theWeeks 2005
study, there was complete follow-up at six days, but by two weeks
there was a 33% loss to follow-up in the misoprostol group and
45% in the group having surgery. This was explained by women
not returning from their communities for follow-up.
Selective reporting
It was unclear to us whether any of the studies were free of selective
reporting bias as we were unable to assess the protocols for the
studies.
Other potential sources of bias
Seventeen out of the 24 studies appeared to be free of other
sources of bias (Blanchard 2004; Chigbu 2012; Clevin 2001;
Dabash 2010; Dao 2007; Diop 2009; Ganguly 2010;Montesinos
2011; Ngoc 2005; Niinimaki 2006; Pang 2001; Paritakul 2010;
Patua 2013; Shelley 2005; Shochet 2012; Shwekerela 2007; Taylor
2011), and for the remainder, it was unclear.
Effects of interventions
See: Summary of findings for themain comparisonMisoprostol
compared to expectant care for incomplete miscarriage; Summary
of findings 2 Misoprostol compared to surgery for incomplete
miscarriage
All 24 studies assessed the medical treatment of incomplete mis-
carriage for women at less than 13 weeks’ gestation. There were
no studies involving women between 13 and 23 weeks’ gestation,
and none where gestation was not specified.
For the comparisons of misoprostol (by any route of administra-
tion versus expectant care or versus surgery), we used random-
effects meta-analyses because of the clinical heterogeneity around
route of administration. For other meta-analyses, we used the
fixed-effect model, except where significant heterogeneity was in-
dicated (see Assessment of heterogeneity above). Please note we
did not conduct any subgroup analyses on gestation for all com-
parisons due to lack of data.
1. Misoprostol versus expectant care (3 studies, 335
women, Analyses 1.1 to 1.7)
For women less than 13 weeks’ gestation
Three studies involving 335 women addressed this comparison for
women with incomplete miscarriage (Blohm 2005; Shelley 2005;
Trinder 2006). There were two further studies that involved both
women with incompletemiscarriage and women with intrauterine
fetal deaths, but to date we have been unable to obtain the data
separated by incomplete miscarriage and intrauterine fetal death
for these studies (Bagratee 2004; Ngai 2001).
Diagnosis of incomplete miscarriage and assessment of complete
miscarriage after treatment were made using clinical judgement in
two studies (Shelley 2005; Trinder 2006), and using ultrasound in
one study (Blohm 2005). Assessment of the outcome of complete
miscarriage wasmade at differing times in the three studies: Blohm
2005 assessed at one week and Shelley 2005 at 10 to 14 days. As
Trinder 2006 assessed at eight weeks, we have not included these
data (there was an assessment at two weeks, but the findings were
not reported separately for women with incomplete miscarriage
and women with intrauterine fetal death). We have written to the
authors to seek these data.
All the studies looked at vaginal misoprostol compared with ex-
pectant care (Blohm 2005; Shelley 2005; Trinder 2006). There
were no studies assessing other routes of administration.
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The studies are at low risk of bias overall. However, blinding of
participants and clinicians was only used in one (Blohm 2005).
We chose to use random-effects meta-analyses for all the outcomes
in this comparison as we believe there is clinical heterogeneity as
we will be potentially pooling differing routes of administration
(vaginal, oral, rectal, and sublingual). We have therefore, reported
the average risk ratio (RR) or mean difference (MD). Although
there are currently only data from studies using vaginal misopros-
tol, we believe other studies will be undertaken in the future and
will be added at future updates to this review. We have assessed
the individual routes of administration of misoprostol for effec-
tiveness (below, in Comparisons 3 to Comparison 8).
Primary outcomes
Complete miscarriage
Only two of the three studies assessed this outcome (Blohm 2005;
Shelley 2005), with the primary outcome for the third study be-
ing infection at 14 days (Trinder 2006). We rated the quality
of the evidence as very low (Summary of findings for the main
comparison), mainly due to high levels of heterogeneity, a small
number of women involved (n = 150), and only one of the two
studies being blinded.
There was no difference identified in complete miscarriage be-
tweenmisoprostol and expectant care (average risk ratio (RR) 1.23,
95% confidence interval (CI) 0.72 to 2.10; 2 studies, 150 women,
random-effects (Tau² = 0.12; Chi² P = 0.02; I² = 81%)) (Analysis
1.1, very low-quality evidence). In terms of clinical impact, the
success rate with misoprostol ranged from 80% to 81% and for
expectant care from 52% to 85%. The heterogeneity may result
from the different times at which complete miscarriage was as-
sessed with expectant care. One study assessed at one week and
found a success rate of 52%(Blohm 2005); the other study assessed
at two weeks and found a success rate of 85% (Shelley 2005).
Surgical evacuation
We rated the quality of the evidence as low (Summary of findings
for themain comparison),mainly due to high levels of heterogene-
ity and only one of the two studies being blinded. We also did not
identify a difference in the need for surgical evacuation between
misoprostol and expectant care (average RR 0.62, 95% CI 0.17 to
2.26; 2 studies, 308 women, random-effects (Tau² = 0.78; Chi² P
= 0.003; I² = 89%)) (Analysis 1.2, low-quality evidence).
Death or serious complication
The outcome of death or serious complication showed no differ-
ence either (RR 2.91, 95%CI 0.12 to 70.05; 1 study, 126 women)
(Analysis 1.3), although the review is underpowered to assess this
outcome.
Secondary outcomes
Unplanned surgical intervention
We rated the quality of the evidence as low (Summary of findings
for the main comparison), mainly due to high levels of hetero-
geneity and only one of the two studies being blinded. We did not
identify a difference in unplanned surgical intervention between
misoprostol and expectant care (average RR 0.62, 95% CI 0.17 to
2.26; 2 studies, 308 women, random-effects (Tau² = 0.78; Chi² P
= 0.003; I² = 89%)) (Analysis 1.4, low-quality evidence).
Blood transfusion
We did not identify a difference in the number of blood transfu-
sions undertaken (RR 3.07, 95% CI 0.13 to 74.28; 3 studies, 332
women), although only one study was estimable (Analysis 1.5).
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There was no information reported on days of bleeding.
Pain relief
We did not identify a difference in pain relief (average RR 1.12,
95%CI 0.67 to 1.88; 2 studies, 308 women, random-effects (Tau²
= 0.10; Chi² P = 0.08; I² = 67%)) (Analysis 1.6).
Pelvic infection
We did not identify a difference in pelvic infection (average RR
2.42, 95%CI 0.59 to 9.98; 3 studies, 333 women, random-effects
(Tau² = 0.00; Chi² P = 0.43, I² = 0%)) (Analysis 1.7).
Cervical damage
There was no information reported on cervical damage.
Digestive disorders (including nausea, vomiting, diarrhoea)
There was no information reported on digestive disorders.
Hypertensive disorders
There was no information reported on hypertensive disorders.
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Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
There was no information reported on women’s views.
Pathology of fetal/placental tissue
There was no information reported on pathology of fetal/placental
tissue.
Costs
There was no information reported on costs.
2. Misoprostol versus surgery (16 studies, 4044
women, Analyses 2.1 to 2.17)
For women less than 13 weeks’ gestation
Sixteen studies involving 4044 women addressed this compari-
son for women with incomplete miscarriage at less than 13 weeks’
gestation (Bique 2007; Chigbu 2012; Dabash 2010; Dao 2007;
Ganguly 2010; Montesinos 2011; Moodliar 2005; Patua 2013;
Sahin 2001; Shelley2005; Shochet 2012; Shwekerela 2007; Taylor
2011; Trinder 2006; Weeks 2005; Zhang 2005). One of these
studies was a comparison of misoprostol versus surgery versus ex-
pectant management (Trinder 2006), and therefore the compar-
ison is described in the appropriate sections (here and the prior
Section 1. Misoprostol versus expectant management).
The included studies were of low risk of bias overall (Figure 1),
with most having adequate sequence generation and concealment
allocation, although for Sahin 2001 and Shochet 2012, it was
unclear. Blinding was not possible in any of the studies when
comparing medical treatment with surgery. Only two studies had
incomplete data and both related to the study being undertaken
in rural settings where women in the community did not return
for follow-up checks (Montesinos 2011; Weeks 2005). We were
unclear about the possibility of selective reporting bias as we did
not assess any of the study protocols. Six of the 12 studies appeared
to be free of other biases (Dabash 2010; Dao 2007; Montesinos
2011; Shelley 2005; Shwekerela 2007; Taylor 2011).
Diagnosis of incomplete miscarriage and assessment of complete
miscarriage after treatment was made using clinical judgement in
five studies (Bique 2007; Chigbu 2012; Shelley 2005; Shwekerela
2007; Weeks 2005), using ultrasound in eight studies (Dabash
2010; Dao 2007; Ganguly 2010; Montesinos 2011; Moodliar
2005; Patua 2013; Sahin 2001; Zhang 2005), and other studies
sometimes used ultrasound. Assessment of the outcome of com-
plete miscarriage was made at differing times in the studies: one
study assessed 24 hours after the last dose of misoprostol or the
surgical evacuation (Patua 2013), 11 studies assessed at one week
(Bique 2007; Chigbu 2012; Dabash 2010; Dao 2007; Ganguly
2010; Montesinos 2011; Shochet 2012; Shwekerela 2007; Taylor
2011; Weeks 2005; Zhang 2005), and three studies assessed
around 10 to 14 days (Moodliar 2005; Sahin 2001; Shelley 2005).
Trinder 2006 assessed at eight weeks and so we have not included
these data (there was an assessment at two weeks in this study, but
the findings were not reported separately for women with incom-
plete miscarriage and women with intrauterine fetal death). We
have written to the authors to seek these data.
We have chosen to use random-effects meta-analyses for all the
outcomes in this comparison as we believe there is clinical hetero-
geneity as we will be potentially pooling differing routes of ad-
ministration (vaginal, oral, vaginal + oral, rectal, and sublingual).
Although there are currently only data from studies using vaginal
misoprostol, we believe other studies will be undertaken in the
future and will be added to future updates of this review. We have
assessed the individual routes of administration of misoprostol for
effectiveness compared with surgery below in Comparisons 7 to
11.
Primary outcomes
Complete miscarriage
We rated the quality of the evidence as very low (Summary of
findings 2), mainly due to high heterogeneity, the trials being in-
evitably unblinded, and suspicion of publication bias. There ap-
peared to be fewer complete miscarriages with misoprostol com-
pared with surgery (average RR 0.96, 95% CI 0.94 to 0.98, 15
studies; 3862 women, random-effects (Tau² = 0.00; Chi² P <
0.00001, I² = 73%)) (Analysis 2.1), although the upper CI was at
0.98. The funnel plot suggests there could be some missing stud-
ies or that there is a lack of smaller studies demonstrating a RR
greater than one, so the findings need to be interpreted with cau-
tion (Figure 2). However, from the clinical perspective, the success
rate was very good for both misoprostol and surgery. Misopros-
tol achieving between 80% and 99% success across studies, and
surgery achieving between 91% and 100% success across stud-
ies. The interaction test identified no difference between the sub-
groups of differing routes of misoprostol administration compared
with surgery for this outcome (interaction test (IT) P = 0.08, I² =
56.1%) (Analysis 2.1).
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Figure 2. Funnel plot of comparison: 2 Misoprostol versus surgery, outcome: 2.1 Complete miscarriage.
Surgical evacuation
We rated the quality of the evidence as very low (Summary of
findings 2), due to high heterogeneity, the trials being inevitably
unblinded, and the possibility of publication bias. There were
fewer surgical evacuations with misoprostol (average RR 0.05,
95% CI 0.02 to 0.11; 13 studies, 3070 women, random-effects
(Tau² = 1.64; Chi² P < 0.00001; I² = 92%)) (Analysis 2.2). The
funnel plot is asymmetrical, suggesting that smaller studies of
lower methodological quality are showing an exaggerated effect
size (Figure 3). The interaction test suggested there may be dif-
ferences between the subgroups of differing routes of misoprostol
administration compared with surgery for this outcome (IT P =
0.002, I² = 79.8%) (Analysis 2.2). However, many of the sub-
groups have little or no data, and when comparing just the two
main subgroups (oral misoprostol and vaginal misoprostol), there
is no longer any subgroup difference.
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Figure 3. Funnel plot of comparison: 2 Misoprostol versus surgery, outcome: 2.2 Surgical evacuation.
Death or serious complication
We did not identify any difference between misoprostol and
surgery (RR 1.00, 95%CI 0.04 to 22.64; 5 studies, 1248 women),
but only one study was estimable, and the review is underpowered
to assess this outcome (Analysis 2.3).
Secondary outcomes
Unplanned surgical intervention
We rated the quality of the evidence as low (Summary of findings
2), due to the trials being inevitably unblinded and the potential
of publication bias. There was more unplanned surgery withmiso-
prostol (average RR 5.03, 95% CI 2.71 to 9.35; 11 studies, 2690
women, random-effects (Tau² = 0.00; P = 0.62; Tau², I² = 0%))
(Analysis 2.4). The funnel plot displays a potential bias in that
there is variation of effect estimates regardless of the study size.
This leads to a consideration that there is something affecting the
outcome that is not being measured, which is a form of reporting
bias (Figure 4).
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Figure 4. Funnel plot of comparison: 2 Misoprostol versus surgery, outcome: 2.4 Unplanned surgical
intervention.
Blood transfusion
We did not identify any difference for the number of blood trans-
fusions undertaken between misoprostol and surgery (average RR
1.73, 95% CI 0.19 to 16.08; 4 studies, 430 women (Tau² = 0.00;
Chi² P = 0.62; I² = 0%)) (Analysis 2.5).
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
Tau²
We did not identify any difference in anaemia (average RR 0.83,
95%CI 0.17 to 4.12; 2 studies, 731 women, random-effects (Tau²
= 0.18; P = 0.28; I² = 14%)) (Analysis 2.7).
Days of bleeding
There were more days of bleeding with misoprostol than with
surgery (average mean difference (MD) 2.12, 95% CI 1.18 to
3.07; 3 studies, 211women, random-effects (Tau² = 0.19; Chi² P =
0.26; I² = 25%)) (Analysis 2.8). This differencewas also considered
clinically significant.
Pain relief
We did not identify a difference with the use of pain relief between
women who had misoprostol and women who had surgery (aver-
age RR 1.48, 95% CI 0.67 to 3.25; 4 studies, 525 women, ran-
dom-effects (Tau² = 0.50; Chi² P < 0.00001; I² = 90%)) (Analysis
2.9).
Pelvic infection
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Wedid not identify a difference in the incidence of pelvic infection
between women who had misoprostol and those who had surgery
(average RR 0.70, 95% CI 0.25 to 1.99; 7 studies, 907 women,
random-effects (Tau² = 0.00; Chi² P = 0.60; I² = 0%)) (Analysis
2.10).
Cervical damage
We did not identify a difference in cervical damage, although only
one study assessed this outcome (RR 0.07, 95% CI 0.00 to 1.25;
1 study, 189 women) (Analysis 2.11).
Digestive disorders (including nausea, vomiting, diarrhoea)
We rated the quality of the evidence for vomiting and diarrhoea
as moderate (Summary of findings 2), due to the trials being in-
evitably unblinded. We rated the quality of the evidence for nau-
sea specifically, as low due to trials being inevitably unblinded and
high heterogeneity.
More women had nausea with misoprostol compared with surgery
(average RR 2.50, 95% CI 1.53 to 4.09; 11 studies, 3015 women,
random-effects (Tau² = 0.31 Chi² P = 0.005; I² = 60%)) (Analysis
2.15, low-quality evidence). This is likely to be clinically signif-
icant. The funnel plot does not show existence of a publication
bias (Figure 5).
Figure 5. Funnel plot of comparison: 2 Misoprostol versus surgery, outcome: 2.15 Nausea.
More women had vomiting with misoprostol compared with
surgery (average RR 1.97, 95% CI 1.36 to 2.85; 10 studies, 2977
women, random-effects (Tau² = 0.00; Chi² P = 0.48; I² = 0%))
(Analysis 2.16, moderate-quality evidence). This may be less clin-
ically significant than the nausea. The funnel plot does not show
existence of a publication bias (Figure 6).
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Figure 6. Funnel plot of comparison: 2 Misoprostol versus surgery, outcome: 2.16 Vomiting.
More women had diarrhoea with misoprostol compared with
surgery (average RR 4.82, 95% CI 1.09 to 21.32; 4 studies, 757
women, random-effects (Tau² = 0.00; Chi² P = 0.98; I² = 0%))
(Analysis 2.17, moderate-quality evidence).
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
We rated the quality of the evidence as moderate (Summary of
findings 2), due to the trials being inevitably unblinded.
We did not identify a difference in women’s satisfaction between
misoprostol and surgery when expressed by whether they were
satisfied or not (average RR 1.00, 95% CI 0.99 to 1.00; 9 studies,
3349 women, random-effects (Tau² = 0.00; Chi² P = 0.64; I²
= 0%)) (Analysis 2.13). Women were very satisfied overall, and
satisfaction with misoprostol ranged from 91% to 99% across
studies, and satisfaction with surgery ranged from 95% to 100%.
When assessed using visual analogue scales, there were more
women satisfied with surgery (average standardised mean differ-
ence (SMD) 1.01, 95% CI 0.01 to 2.00; 2 studies, 131 women,
random-effects (Tau² =0.41;Chi² P =0.03; I² = 78%)), but the dif-
ference was small and probably not clinically significant (Analysis
2.14). Taken with the findings above, it appears that overall most
women are satisfied with the treatment they received.
Pathology of fetal/placental tissue
There was no information reported on pathology of fetal/placental
tissue.
Costs
There was no information reported on costs.
3. Vaginal misoprostol versus expectant care (3
studies, 335 women, Analyses 3.1 to 3.7)
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For women less than 13 weeks’ gestation
Three studies involving 335 women addressed this comparison for
women with incomplete miscarriage (Blohm 2005; Shelley 2005;
Trinder 2006). There were two further studies that involved both
women with incompletemiscarriage and women with intrauterine
fetal deaths, but to date we have been unable to obtain the data
separated by incomplete miscarriage and intrauterine fetal death
for these studies (Bagratee 2004; Ngai 2001).
The studies are of low risk of bias overall. However, blinding of
participants and clinicians was only used in one (Blohm 2005),
and not the other two studies (Shelley 2005; Trinder 2006).
Diagnosis of incomplete miscarriage and assessment of complete
miscarriage after treatment was made using clinical judgement in
two studies (Shelley 2005; Trinder 2006), and using ultrasound in
the third (Blohm 2005). Assessment of the outcome of complete
miscarriage wasmade at differing times in the three studies: Blohm
2005 assessed at one week, Shelley 2005 at 10 to 14 days, and
Trinder 2006 at eight weeks (although there was an assessment at
two weeks, findings were not reported separately for women with
incomplete miscarriage and women with intrauterine fetal death).
We have written to the authors to see if they have earlier data for
incomplete miscarriage.
Primary outcomes
Complete miscarriage
Only two of the three studies assessed this outcome (Blohm 2005;
Shelley 2005), with the primary outcome for the third study being
infection at 14 days (Trinder 2006).
We did not identify a difference in complete miscarriage between
vaginal misoprostol and expectant care (average RR 1.23, 95%
CI 0.72 to 2.10; 2 studies, 150 women, random-effects (Tau² =
0.12; Chi² P = 0.02; I² = 81%)) (Analysis 3.1). From the clinical
perspective, the success rate with vaginal misoprostol ranged from
80% to 81% and for expectant care from 52% to 85%. The het-
erogeneity may result from the different times at which complete
miscarriage was assessed with expectant care. One study assessed
at one week and found a success rate of 52% (Blohm 2005), and
the other study assessed at 10 to 14 days and found a success rate
of 85% (Shelley 2005).
Surgical evacuation
We also did not identify a difference in the need for surgical evac-
uation between vaginal misoprostol and expectant care (average
RR 0.62, 95% CI 0.17 to 2.26; 2 studies, 308 women, random-
effects (Tau² = 0.78; Chi² P = 0.003; I² = 89%)) (Analysis 3.2).
Death or serious complication
The outcome of death or serious complication showed no differ-
ence (RR 2.91, 95% CI 0.12 to 70.05; 1 study, 126 women), al-
though the review is underpowered to assess this outcome (Analysis
3.3).
Secondary outcomes
Unplanned surgical intervention
We did not identify a difference in unplanned surgical interven-
tions between vaginal misoprostol and expectant care (average RR
0.62, 95%CI 0.17 to 2.26; 2 studies, 308 women, random-effects
(Tau² = 0.78; Chi² P = 0.003; I² = 89%)) (Analysis 3.4).
Blood transfusion
We did not identify a difference in the number of blood transfu-
sions undertaken (RR 3.07, 95% CI 0.13 to 74.28; 3 studies, 332
women), although only one study was estimable (Analysis 3.5).
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There was no information reported on days of bleeding.
Pain relief
We did not identify a difference in pain relief (average RR 1.12,
95%CI 0.67 to 1.88; 2 studies, 308 women, random-effects (Tau²
= 0.10; Chi² P = 0.08; I² = 67%)) (Analysis 3.6).
Pelvic infection
We did not identify a difference in pelvic infection (RR 2.81, 95%
CI 0.77 to 10.33; 3 studies, 333 women) (Analysis 3.7).
Cervical damage
There was no information reported on cervical damage.
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Digestive disorders (including nausea, vomiting,
diarrhoea)
There was no information reported on digestive disorders.
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
There was no information reported on women’s views.
Pathology of fetal/placental tissue
There was no information reported on pathology of
fetal/placental tissue.
Costs
There was no information reported on costs.
4. Vaginal misoprostol versus surgery (6 studies, 549
women, Analyses 4.1 to 4.13)
For women less than 13 weeks’ gestation
Six studies involving 549 women addressed this comparison for
women with incomplete miscarriage (Ganguly 2010; Moodliar
2005; Patua 2013; Shelley2005; Trinder 2006;.Zhang 2005). Two
further studies involved both women with incomplete miscarriage
andwomenwith intrauterine fetal deaths, but to date we have been
unable to obtain the data separated by incomplete miscarriage and
intrauterine fetal death for these studies, and so we have excluded
these studies (Demetroulis 2001; Louey 2000 [pers comm]).
The studies were of low risk of bias overall (Figure 1).However, the
nature of the intervention and comparison meant it was not pos-
sible to blind participants or clinicians, and it was mostly unclear
whether the studies had selective reporting bias, or other biases.
Diagnosis of incomplete miscarriage and assessment of complete
miscarriage after treatment was made using clinical judgement in
two studies (Shelley 2005; Trinder 2006), and using ultrasound in
four studies (Ganguly 2010; Moodliar 2005; Patua 2013; Zhang
2005). Assessment of the outcome of complete miscarriage was
made at differing times in the studies: Patua 2013 assessed 24hours
after the last dose of misoprostol or surgical evacuation; Ganguly
2010 assessed at day 3 and day 8 for misoprostol, and day 2 and
day 8 for surgical evacuation; Zhang 2005 assessed at three days;
Shelley 2005 at 10 to 14 days; Moodliar 2005 at two weeks; and
Trinder 2006 at eight weeks (although there was an assessment at
two weeks, findings were not reported separately for women with
incomplete miscarriage and women with intrauterine fetal death).
We have written to the authors to seek these data.
Primary outcomes
Complete miscarriage
Fewer women had complete miscarriage with vaginal misoprostol
compared with surgery (RR 0.89, 95% CI 0.84 to 0.95; 5 studies,
364 women) (Analysis 4.1). However, from the clinical perspec-
tive the success rate was high in both groups, vaginal misoprostol
ranged from 80% to 91% and for surgery from 89% to 100%.
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Surgical evacuation
Fewer women had surgical evacuation with vaginal misoprostol
compared with women who were given surgery straight away (av-
erage RR 0.16, 95% CI 0.07 to 0.35; 4 studies, 411 women, ran-
dom-effects (Tau² = 0.52; Chi² P = 0.002; I² = 80%)) (Analysis
4.2). This finding was perhaps not surprising as the comparison
group was surgical intervention, but it is an important outcome
to assess as clinical management would be to use surgery if miso-
prostol failed. This reduction in the use of surgery with vaginal
misoprostol helps to confirm the success of this intervention. The
reasons for the heterogeneity were unclear.
Death or serious complication
We did not identify a difference in the composite outcome of
death or serious complications (RR 1.00, 95%CI 0.04 to 22.64; 2
studies, 132 women, (although only one was estimable); however,
the review is underpowered to assess this outcome (Analysis 4.3).
Secondary outcomes
Unplanned surgical intervention
In the vaginal misoprostol group, there was a higher incidence of
unplanned surgical intervention (average RR 4.29, 95% CI 1.24
to 14.87; 4 studies, 411 women (Tau² = 0.67; Chi² P = 0.16;
I² = 42%)) (Analysis 4.4). Again, this finding is unsurprising, as
surgery is the comparative intervention and one would anticipate
that few additional operations would be required if surgery was
successful.
Blood transfusion
We did not identify a difference in the number of blood transfu-
sions undertaken (RR 1.82, 95% CI 0.21 to 15.70; 3 studies, 241
women) (Analysis 4.5).
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
We did not identify a difference in anaemia (RR 1.71, 95% CI
0.24 to 12.24; 1 study, 36 women) (Analysis 4.6).
Days of bleeding
Women treated with vaginal misoprostol had more days of bleed-
ing than women treated with surgery (MD 2.76, 95% CI 1.55 to
3.97; 2 studies, 131 women) (Analysis 4.7).
Pain relief
Women treated with vaginal misoprostol used more pain relief
than women treated with surgery (RR 1.75, 95% CI 1.21 to 2.54;
3 studies, 313 women) (Analysis 4.8).
Pelvic infection
We did not identify a difference in pelvic infection (RR 1.27, 95%
CI 0.37 to 4.42; 4 studies, 338 women) (Analysis 4.9).
Cervical damage
There was no information reported on cervical damage.
Digestive disorders (including nausea, vomiting,
diarrhoea)
We did not identify a difference in the number of women with
nausea (RR 1.37, 95% CI 0.58 to 3.22; 3 studies, 156 women)
(Analysis 7.24), vomiting (RR 1.48, 95% CI 0.25 to 8.93; 2
studies, 131 women) (Analysis 7.25), or diarrhoea (RR 4.30,
95% CI 0.52 to 35.36; 2 studies, 131 women) (Analysis 7.26).
Hypertensive disorders
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There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
Womenweremore satisfiedwith surgery (average SMD1.01, 95%
CI 0.01 to 2.00; 2 studies, 131 women, random-effects (Tau² =
0.41; Chi² P = 0.03; I² = 78%)), but the difference was small and
based on just two small studies (Analysis 4.10). Reasons for the
heterogeneity were unclear.
Pathology of fetal/placental tissue
There was no information reported on pathology of fetal/placental
tissue.
Costs
There was no information reported on costs.
5. Oral misoprostol versus surgery (7 studies, 1884
women, Analyses 5.1 to 5.11)
For women less than 13 weeks’ gestation
Seven studies involving 1884 women addressed this comparison
for women with incomplete miscarriage (Bique 2007; Chigbu
2012; Dao 2007; Montesinos 2011; Shwekerela 2007; Taylor
2011; Weeks 2005). We identified a further study involving both
women with incompletemiscarriage and women with intrauterine
fetal deaths, but the authors, although they were able to supply
additional data, were unable to separate outcomes by women with
incomplete miscarriage and women with intrauterine death and
so we excluded this study (Chung 1999).
The included studies were of low risk of bias overall (Figure 1),
with all having adequate sequence generation and concealment
allocation. Blinding was not possible when comparing medical
treatment with surgery. Four of the studies had little loss to follow-
up and exclusions after randomisation (Bique 2007; Chigbu 2012;
Dao 2007; Shwekerela 2007).However, one study, although it had
no loss to follow-up at six days, had considerable loss to follow-
up at one to two weeks (33% in the misoprostol group and 45%
in the group having surgery) which was not similar between the
groups (Weeks 2005). This seemed to arise fromwomen returning
home to their communities and not coming back for follow-up
appointments, and this was fully discussed by the authors (Weeks
2005). Sensitivity analysis was not undertaken because outcomes
at six days did not appear to be subject to bias.
Diagnosis of incomplete miscarriage and assessment of complete
miscarriage after treatment was made using clinical judgement
in four studies (Bique 2007; Chigbu 2012; Shwekerela 2007;
Weeks 2005), and using ultrasound, if necessary, in three studies
(Dao 2007; Montesinos 2011; Taylor 2011). Assessment of the
outcome of complete miscarriage was made at seven days in all
seven studies (Bique 2007; Chigbu 2012; Dao 2007; Montesinos
2011; Shwekerela 2007; Taylor 2011; Weeks 2005).
Primary outcomes
Complete miscarriage
There was no difference identified in the number of complete
miscarriages with oralmisoprostol comparedwith surgery (average
RR 0.98, 95% CI 0.95 to 1.00; 7 studies, 1884 women, random-
effects (Tau² = 0.00; Chi2 = 0.004; I2 = 69%)) (Analysis 5.1). In
addition, in terms of clinical impact, the success rate was high in
both groups, for oral misoprostol it ranged from 91% to 99% and
surgery ranged from 91% to 100%.
Surgical evacuation
Fewer women had surgical evacuation with oral misoprostol (av-
erage RR 0.04, 95% CI 0.02 to 0.07; 7 studies, 1884 women,
random-effects (Tau² = 0.38. Chi² P = 0.006; I² = 67%)) (Analysis
5.2). The reasons for the heterogeneity were unclear.
Death or serious complication
There were no data for this outcome.
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Secondary outcomes
Unplanned surgical intervention
There weremore women needing unplanned surgical intervention
in the oral misoprostol group (RR 6.27, 95% CI 2.57 to 15.31; 6
studies, 1584 women) (Analysis 5.3).
Blood transfusion
It was not possible to produce a RR with the data (Analysis 5.4).
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There was no information reported on days of bleeding.
Pain relief
There was less pain relief required with oral misoprostol than with
surgery (RR 0.85, 95%CI 0.77 to 0.92; 1 study, 212 women), but
the difference was small and most women used pain relief whether
they had misoprostol or surgery (Analysis 5.5).
Pelvic infection
We did not identify a difference in pelvic infection (RR 0.26, 95%
CI 0.03 to 2.41; 2 studies, 489 women) (Analysis 5.6).
Cervical damage
Wedid not identify a difference in cervical damage (RR 0.07, 95%
CI 0.00 to 1.25; 1 study, 189 women) (Analysis 5.7).
Digestive disorders
More women experienced nausea (RR 3.24, 95% CI 2.10 to 4.98;
6 studies, 1700 women) (Analysis 5.9), and vomiting (RR 1.99,
95%CI 1.18 to 3.34; 6 studies, 1687 women) with oral misopros-
tol compared with surgery (Analysis 5.10), but we did not identify
a difference in the incidence of diarrhoea (RR 5.79, 95% CI 0.70
to 47.64; 2 studies, 626 women) (Analysis 5.11).
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
We did not identify a difference in women’s satisfaction (RR 0.99,
95% CI 0.98 to 1.01; 7 studies, 1875 women) (Analysis 5.8).
Pathology of fetal/placental tissue
There was no information reported on pathology of fetal/placental
tissue.
Costs
There was no information reported on costs.
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6. Vaginal plus oral misoprostol versus surgery (1
study, 80 women, Analyses 6.1 to 6.4)
For women less than 13 weeks’ gestation
One study involving 80 women assessed this comparison (Sahin
2001).
The study was at high risk of bias with uncertainty around se-
quence generation, allocation concealment, selective reporting
bias, and other potential biases, and it was not possible to blind
participants and clinicians.
Assessment of incomplete miscarriage was undertaken using ul-
trasound and assessment of outcomes was undertaken at 10 days.
Primary outcomes
Complete miscarriage
There was no difference identified in incomplete miscarriage (RR
0.95, 95% CI 0.87 to 1.04; 1 study, 80 women) (Analysis 6.1). In
clinical terms, the success in this one study was 95% with medical
treatment and 100% with surgery.
Surgical evacuation
There was less need for surgical evacuation with misoprostol than
with surgery (RR 0.04, 95% CI 0.01 to 0.18; 1 study, 80 women)
(Analysis 6.2).
Death or serious complication
Not reported.
Secondary outcomes
Unplanned surgical intervention
There was no information reported on unplanned surgical inter-
vention.
Blood transfusion
There was no information reported on blood transfusion.
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There were fewer days of bleeding with surgery compared with
vaginal plus oral misoprostol (MD 1.55, 95% CI 0.58 to 2.52; 1
study, 80 women) (Analysis 6.3).
Pain relief
There was no information reported on pain relief.
Pelvic infection
We did not identify a difference in pelvic infection (RR 0.50, 95%
CI 0.05 to 5.30; 1 study, 80 women) (Analysis 6.4).
Cervical damage
There was no information reported on cervical damage.
Digestive disorders (including nausea, vomiting,
diarrhoea)
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There was no information reported on digestive disorders.
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
There was no information reported on women’s views.
Pathology of fetal/placental tissue
There was no information reported on pathology of fetal/placental
tissue.
Costs
There was no information reported on costs.
7. Sublingual misoprostol versus surgery (2 studies,
1534 women, Analyses 7.1 to 7.8)
For women less than 13 weeks’ gestation
Two studies involving 1534 women addressed this comparison
for women with incomplete miscarriage (Dabash 2010; Shochet
2012).
Dabash 2010 was of low risk of bias overall (Figure 1), having ad-
equate sequence generation and concealment allocation. Blinding
was not possible when comparing medical treatment with surgery.
However, for the second study (Shochet 2012), it was unclear how
sequence generation and allocation concealment were conducted.
Diagnosis of incomplete miscarriage and assessment of complete
miscarriage after treatmentwasmade using clinical judgement and
use of ultrasound, as needed, in both studies. Assessment of the
outcome of complete miscarriage was made at one week follow-
up in both studies.
Primary outcomes
Complete miscarriage
There was no difference identified in the number of complete
miscarriages (RR 0.96, 95% CI 0.95 to 0.98; 2 studies, 1534
women) (Analysis 7.1), with the success rate being 94% to 98%
with sublingual misoprostol and 99% to 100% with surgery.
Surgical evacuation
There was less need for surgical evacuation with misoprostol than
with surgery (RR 0.02, 95%CI 0.01 to 0.04; 1 study, 695 women)
(Analysis 7.2).
Death or serious complications
Not reported.
Secondary outcomes
Unplanned surgical intervention
In the sublingual misoprostol group, there was a higher incidence
of unplanned surgical intervention (average RR 5.98, 95% CI
0.72 to 49.43; 1 study, 695 women) (Analysis 7.3). Again, this
finding is unsurprising, as surgery is the comparative intervention
and one would anticipate that few additional operations would be
required if surgery was successful.
Blood transfusion
There was no information reported on blood transfusion.
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Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
We did not identify a difference in anaemia (RR 0.33, 95% CI
0.03 to 3.18; 1 study, 695 women) (Analysis 7.4).
Days of bleeding
There was no information reported on days of bleeding.
Pain relief
There was no information reported on pain relief.
Pelvic infection
There was no information reported on pelvic infection
Cerivcal damage
There was no information reported on cervical damage.
Digestive disorders
Women in the misoprostol group were more likely to experience
gastrointestinal issues compared to thewomen in the surgery group
(RR 3.90, 95%CI 1.81 to 8.42; 1 study, 516 women) (Analysis
7.5). More women experienced nausea in the misoprostol group
(RR 1.86, 95%CI 1.48 to 2.32; 2 studies, 1159 women) (Analysis
7.7), and vomiting (RR 2.42, 95% CI 1.43 to 4.10; 2 studies,
1159 women) (Analysis 7.8).
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
We did not identify a difference in women’s satisfaction towards
their method (RR 0.99, 95% CI 0.98 to 1.01; 2 studies, 1474
women) (Analysis 7.6).
Pathology of fetal/placental tissue
There was no information reported on pathology of
fetal/placental tissue.
Costs
There was no information reported on costs.
8. Vaginal misoprostol versus oral misoprostol (1
study, 201 women, Analyses 8.1 to 8.7)
For women less than 13 weeks’ gestation
One study involving 201 women addressed this comparison for
women with incomplete miscarriage (Pang 2001). One further
study involved both women with incomplete miscarriage and
women with intrauterine fetal deaths, but to date we have been
unable to obtain the data separated by incomplete miscarriage and
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intrauterine fetal death for this study, and so we have excluded it
from this review (Machtinger 2004).
The risk of bias in Pang 2001 was at low risk in terms of having
adequate sequence generation and concealment allocation, and
appeared to be free of other potential sources of bias, however, it
was not clear whether participants, clinicians and assessors were
blinded to the intervention given (Figure 1).
Assessment of incomplete miscarriage was undertaken using ul-
trasound and assessment of outcomes was undertaken at one day
after treatment.
Primary outcomes
Complete miscarriage
We did not identify a difference in the number of complete mis-
carriages (RR 0.94, 95% CI 0.76 to 1.16; 1 study, 198 women)
(Analysis 8.1), with the success rate being 61% with vaginal miso-
prostol and 65% with oral misoprostol, both assessed on day one.
Surgical evacuation
We did not identify a difference in surgical evacuation (RR 1.11,
95% CI 0.77 to 1.60; 1 study, 198 women) (Analysis 8.2).
Death or serious complications
Not reported.
Secondary outcomes
Unplanned surgical intervention
Wedidnot identify a difference in unplanned surgical intervention
(RR 0.36, 95% CI 0.01 to 8.80; 1 study, 186 women) (Analysis
8.3).
Blood transfusion
There was no information reported on blood transfusion.
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There as no information reported on days of bleeding.
Pain relief
We did not identify a difference in pain relief (RR 1.43, 95% CI
0.93 to 2.17; 1 study, 186 women) (Analysis 8.4).
Pelvic infection
There was no information reported on pelvic infection
Cerivcal damage
There was no information reported on cervical damage.
Digestive disorders
We did not identify any differences in the number of women
experiencing nausea (RR 0.63, 95% CI 0.26 to 1.54; 1 study
involving 198 women) (Analysis 8.5), and vomiting (RR 0.36,
95% CI 0.07 to 1.75; 1 study, 198 women) (Analysis 8.6).
There was a reduction in the incidence of diarrhoea for women
using vaginal misoprostol compared with oral misoprostol (RR
0.21, 95% CI 0.12 to 0.36; 1 study, 198 women) (Analysis 8.7).
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Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
There was no information reported on women’s views.
Pathology of fetal/placental tissue
There was no information reported on pathology of
fetal/placental tissue.
Costs
There was no information reported on costs.
9. Oral misoprostol 600 ug versus oral misoprostol
1200 ug (2 studies, 469 women, Analyses 9.1 to 9.8)
For women less than 13 weeks’ gestation
Two studies involving 469 women addressed this comparison
for women with incomplete miscarriage (Blanchard 2004; Ngoc
2005).
Blanchard 2004 was on thewhole at low risk of bias, with adequate
sequence generation, concealment of allocation, low loss to follow-
up, and other sources of bias were not apparent. However, there
was no blinding of participants, clinicians and assessors, and it was
unclear whether there was selective reporting bias. Ngoc 2005 was
similar, but it was unclear whether there was adequate allocation
concealment (Figure 1).
Primary outcomes
Complete miscarriage
Wedid not identify a difference in completemiscarriage (RR 1.00,
95% CI 0.93 to 1.07; 2 studies, 464 women) (Analysis 9.1).
Surgical evacuation
We did not identify a difference in surgical evacuation (RR 0.76,
95% CI 0.29 to 1.99; 1 study, 295 women) (Analysis 9.2). The
success rate with the single 600 ug dose ranged from 66% to 95%,
and the success rate with the repeat 600 ug dose (total 1200 ug)
ranged from 67% to 94%.
Death or serious complication
One study provided data (Ngoc 2005), but it was not possible to
produce a RR (Analysis 9.3).
Secondary outcomes
Unplanned surgical intervention
We did not identify a difference in the number of unplanned
surgical interventions (RR 0.76, 95% CI 0.29 to 1.99; 1 study,
295 women) (Analysis 9.4).
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Blood transfusion
There was no information reported on blood transfusion.
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There was no information reported on days of bleeding.
Pain relief
There was no information reported on pain relief.
Pelvic infection
There was no information reported on pelvic infection.
Cervical damage
There was no information reported on cervical damage.
Digestive disorders
We did not identify a difference between the two doses of oral
misoprostol for nausea (average RR 1.19, 95% CI 0.57 to 2.46; 2
studies, 463 women, random-effects (Tau² = 0.19; Chi² P = 0.07;
I² = 70%)) (Analysis 9.6), or vomiting (RR 1.01, 95% CI 0.60 to
1.72; 2 studies, 463 women) (Analysis 9.7).
There was a reduction in the incidence of diarrhoea for women
allocated to one dose of misoprostol (RR 0.73, 95% CI 0.55 to
0.97; 1 study, 294 women) (Analysis 9.8). The CI and the data
being fromone small study, makes the clinical significance unclear.
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
We did not identify a difference in women’s satisfaction (RR
1.02, 95% CI 0.96 to 1.09; 2 studies, 460 women) (Analysis
14.5).
Pathology of fetal/placental tissue
There was no information reported on pathology of
fetal/placental tissue.
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Costs
There was no information reported on costs.
10. Oral mifepristone + vaginal misoprostol versus
surgery (1 study, 19 women, Analyses 10.1 to 10.2)
Niinimaki 2006 included women with many kinds of miscarriage
(missed abortion, anembryonic pregnancies, incomplete miscar-
riage) but the authors were able to send us the data split by the
types of miscarriage. The study also involved women at less than
24 weeks’ gestation, some of whom were less than 13 weeks and
some not.
For women less than 13 weeks’ gestation
For the 16 women who were less than 13 weeks’ gestation, treat-
ments were equally successful with 10/10 (100%) women in the
medical group and 6/6 (100%) women in the surgical group
achieving complete miscarriage. There were no additional surgical
evacuations required and none of the womenhad pelvic infections.
For women 13 to 23 weeks’ gestation
For the three women who were between 13 and 24 weeks’ ges-
tation, treatments again were equally successful with 1/1 (100%)
women in the medical group and 2/2 (100%) women in the sur-
gical group achieving complete miscarriage. There were no addi-
tional surgical evacuations required and none of the women had
pelvic infections.
11. Vaginal prostaglandin E1 (gemeprost) versus
surgery (1 study, 34 women, Analyses 11.1)
For women less than 13 weeks’ gestation
One study involving 34 women compared vaginal prostaglandin
E1 (gemeprost) with surgery (Clevin 2001). The study was of
uncertain risk of bias. It had adequate sequence generation and
low risk of other potential sources of bias. However, the allocation
concealment was unclear, as was the completeness of the outcome
data and potential for selective reporting bias. It was not possible
to blind participants and clinicians.
Primary outcomes
None of the prespecified primary outcomes were reported.
Secondary outcomes
Unplanned surgical intervention
Although data were reported on this outcome it was not possible
to report a RR (Analysis 11.1).
Blood transfusion
There was no information reported on blood transfusion.
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There was no information reported on days of bleeding.
Pain relief
There was no information reported on pain relief.
Pelvic infection
There was no information reported on pelvic infection.
Cervical damage
There was no information reported on cervical damage.
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Digestive disorders
There was no information reported on digestive disorders.
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
There was no information reported on women’s views/acceptabil-
ity of method.
Pathology of fetal/placental tissue
There was no information reported on pathology of
fetal/placental tissue.
Costs
There was no information reported on costs.
12. Sublingual misoprostol versus oral misoprostol (2
studies, 358 women, Analyses 12.1 to 12.7)
For women less than 13 weeks’ gestation
Two studies involving 358 women looked at this comparison (
Diop 2009; Paritakul 2010). The studies were at low risk of bias
with adequate sequence generation and allocation concealment.
However, the studies were not blinded (Figure 1).
Primary outcomes
Complete miscarriage
We found no difference between sublingual and oral misoprostol
in terms of complete miscarriage (RR 0.99, 95% CI 0.94 to 1.05;
2 studies, 358 women) (Analysis 12.1).
Surgical evacuation
There was also no difference in surgical evacuation between the
two routes of administration of misoprostol (RR 1.01, 95% CI
0.39 to 2.63; 1 study, 294 women) (Analysis 12.2).
Death or serious morbidity
There were no deaths or serious morbidity amongst the women
in these trials.
Secondary outcomes
Unplanned surgical intervention
There was no information reported on unplanned surgical interven-
tion.
Blood transfusion
There was no information reported on blood transfusion.
34Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Haemorrhage
There was no information reported on haemorrhage.
Blood loss
There was no information reported on blood loss.
Anaemia
There was no information reported on anaemia.
Days of bleeding
There was no information reported on days of bleeding.
Pain relief
There was no information reported on pain relief.
Pelvic infection
There was no information reported on pelvic infection.
Cervical damage
There was no information reported on cervical damage.
Digestive disorders
There was no difference in nausea between the two routes of ad-
ministration of misoprostol (RR 0.78, 95% CI 0.49 to 1.23; 2
studies, 358 women) (Analysis 12.4)
There was also no difference in vomiting between the two routes
of administration of misoprostol (RR 1.01, 95% CI 0.14 to 7.10;
2 studies, 358 women) (Analysis 12.5)
There was also no difference in diaorrhea between the two routes
of administration of misoprostol (RR 1.58, 95% CI 0.66 to 3.76;
2 studies, 358 women) (Analysis 12.6)
Hypertensive disorders
There was no information reported on hypertensive disorders.
Duration of stay in hospital
There was no information reported on duration of stay in the
hospital.
Psychological effects
There was no information reported on psychological effects.
Subsequent fertility
There was no information reported on subsequent fertility.
Women’s views/acceptability of method
We did not identify a difference between the two routes of admin-
istration of misoprostol for this outcome. (RR 0.99, 95% CI 0.95
to 1.03; 2 studies, 358 women) (Analysis 12.7)
Pathology of fetal/placental tissue
There was no information reported on pathology of
fetal/placental tissue.
Costs
There was no information reported on costs.
Oral misoprostol versus expectant care (no studies)
There were no studies that addressed this comparison.
Rectal misoprostol versus expectant care (no studies)
There were no studies that addressed this comparison.
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Sublingual misoprostol versus expectant care (no
studies)
There were no studies that addressed this comparison.
Rectal misoprostol versus surgery (no studies)
There were no studies that addressed this comparison.
Rectal misoprostol versus oral misoprostol (no
studies)
There were no studies that addressed this comparison.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Misoprostol compared to surgery for incomplete miscarriage
Patient or population: incomplete miscarriage
Setting: clinics and hospitals in Australia, Burkina Faso, Egypt, Ecuador, Ghana, India, Mauritania, Mozambique, Niger, Nigeria, South Af rica, Tanzania, Turkey, Uganda, USA
Intervention: misoprostol
Comparison: surgery
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with surgery Risk with M isoprostol
Complete miscarriage Study populat ion RR 0.96 (0.94 to 0.98) 3862
(15 RCTs)
⊕©©©
VERY LOW 1,2,3
992 per 1000 963 per 1000
(943 to 982)
Moderate
1000 per 1000 970 per 1000
(950 to 990)
Surgical evacuat ion Study populat ion RR 0.05
(0.02 to 0.11)
3070
(13 RCTs)
⊕©©©
VERY LOW 1,2,4,5
985 per 1000 49 per 1000
(20 to 108)
Moderate
1000 per 1000 50 per 1000
(20 to 110)
Unplanned surgical in-
tervent ion
Study populat ion RR 5.03
(2.71 to 9.35)
2690
(11 RCTs)
⊕⊕©©
LOW 1,6
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8 per 1000 38 per 1000
(21 to 71)
Moderate
9 per 1000 45 per 1000
(24 to 83)
Women’s views/
acceptability of method
Study populat ion RR 1.00
(0.99 to 1.00)
3349
(9 RCTs)
⊕⊕⊕©
MODERATE 7
981 per 1000 981 per 1000
(971 to 981)
Moderate
982 per 1000 982 per 1000
(972 to 982)
Nausea Study populat ion RR 2.50
(1.53 to 4.09)
3015
(11 RCTs)
⊕⊕©©
LOW 1,2
84 per 1000 210 per 1000
(128 to 343)
Moderate
44 per 1000 110 per 1000
(67 to 179)
Vomit ing Study populat ion RR 1.97
(1.36 to 2.85)
2977
(10 RCTs)
⊕⊕⊕©
MODERATE 1
29 per 1000 56 per 1000
(39 to 82)
Moderate
20 per 1000 39 per 1000
(27 to 56)
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Diarrhoea Study populat ion RR 4.82
(1.09 to 21.32)
757
(4 RCTs)
⊕⊕⊕©
MODERATE 1
0 per 1000 0 per 1000
(0 to 0)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High-quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Lack of blinding.
2 High heterogeneity.
3 Lack of smaller studies showing a RR more than 1.
4 Wide conf idence interval crossing the line of no ef fect and small sample size.
5 Asymmetrical funnel plot.
6 Variat ion of ef fect size regardless of the study size.
7 Downgraded for overall risk of bias (lim itat ions in design).
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D I S C U S S I O N
Virtually all the studies we identified involved women less than 13
weeks’ pregnant; there was one study that included three women
greater than 13 weeks’ pregnant (Niinimaki 2006). Misoprostol
was the drug studied most frequently and it was assessed against
expectant care and surgery, and the possible routes of administra-
tion were vaginal, oral, vaginal plus oral, sublingual, and rectal.
Summary of main results
The limited data available for all these comparisons can be sum-
marised as follows.
Misoprostol compared with expectant care (Comparison 1): we
did not identify any differences between misoprostol and expec-
tant care, although the review was underpowered to assess this
comparison with only three studies involving 335 women. Vagi-
nal misoprostol was the only route of administration used in these
comparisons and further studies would be needed to be sure of the
findings.
Misoprostol compared with surgery (Comparison 2): misoprostol
appeared slightly less effective than surgery, but the difference was
probably not clinically relevant, with the success rate for both
treatments being high. There was a large reduction in surgery
required when misoprostol was used. There was more blood loss
with misoprostol, although cervical damage seemed less; however,
this was assessed in only one study with possible risk of bias in
losses to follow-up. There was more nausea and vomiting with
misoprostol (particularly oral misoprostol), but we did not identify
a difference in women’s satisfaction.
Vaginal misoprostol compared with expectant care (Comparison
3): we did not identify any differences between vaginalmisoprostol
compared with expectant care in terms of women achieving a
complete miscarriage. However, in one study vaginal misoprostol
was more effective than expectant care (Blohm 2005), and in the
other study was equally effective (Shelley 2005). This difference
seems to lie in the differing success in the expectant care group
between the two studies. Complete miscarriage was 52% (32/64)
in the study assessing this at one week (Blohm 2005), and 85%
(12/14) in the study assessing it at two weeks (Shelley 2005).
This is in contrast to the success rates with vaginal misoprostol
which were 81% (52/64) and 80% (8/10), respectively. It may
be, therefore, that if women are prepared to wait longer, then
more might achieve spontaneous miscarriage without the use of
vaginal misoprostol. However, the numbers of participants in both
these studies was small. We did not identify any differences in
the other outcomes assessed (surgical evacuation, death or serious
complications, blood transfusions, pain relief, pelvic infection).
There was no information about women’s views of these two forms
of care.
Vaginalmisoprostol comparedwith surgery (Comparison 4): there
was a small reduction in women achieving a complete miscarriage
with vaginalmisoprostol comparedwith surgery.However, vaginal
misoprostol still showed a success rate of between 80% to 91%.
There was a large reduction in the use of surgery and no difference
in death or serious complications. The mean number of days of
bleeding was higher with misoprostol and there was more need for
pain relief. There was no difference in the other outcomes assessed
(blood transfusion, anaemia, pelvic infection, nausea, vomiting,
diarrhoea).
Oral misoprostol compared with surgery (Comparison 5): we did
not identify a difference between oral misoprostol compared with
surgery in terms of women achieving a complete miscarriage.
There was a large reduction in the use of surgery, and deaths or
serious complications were not reported. There was less pain relief
needed with oral misoprostol, but increased nausea and vomiting.
There were no difference in other outcomes assessed (pelvic infec-
tion, cervical damage, diarrhoea).
Vaginal plus oral misoprostol compared with surgery (Compari-
son 6): based on one study of 80 women, we did not identify any
differences for complete miscarriage (success rates from 95% to
100%), days of bleeding and pelvic infection. There was a reduc-
tion in the use of surgery with medical management.
Sublingual misoprostol compared with surgery (Comparison 7):
we did not identify a difference between sublingual misoprostol
compared with surgery in terms of women achieving a complete
miscarriage. There was a reduction in the use of surgery with
medical management. There was increased nausea and vomiting
with sublingual misoprostol.
Vaginal misoprostol compared with oral misoprostol (Compari-
son 8): we did not identify a difference between vaginal misopros-
tol compared with oral misoprostol in terms of women achieving
a complete miscarriage or in the need for additional surgical in-
tervention. The incidence of diarrhoea was less with vaginal miso-
prostol compared with the oral route, but there was no difference
in other outcomes assessed (pain relief, nausea, vomiting).
600 ug oral misoprostol compared with 1200 ug oral misoprostol
(Comparison 9): the only difference identified in this comparison
was that more women experienced diarrhoea with the higher dose.
Sublingualmisoprostol comparedwith oralmisoprostol (Compar-
ison 12): we did not identify a difference between the two groups.
Other comparisons: for other comparisons there were either no
studies or the studies provided insufficient data.
Women’s views: the only study that assessed women’s views in any
detail was a publication by Harwood 2008, as part of the study
on vaginal misoprostol versus surgery (Zhang 2005). The 652
women in this multicentre randomised controlled trial were asked
prospectively to complete a daily diary of any symptoms experi-
enced for the two weeks after treatment. The women also com-
pleted questionnaires assessing quality of life, depression, stress,
and treatment acceptability at twoweeks after treatment. Although
a fewdifferences were observed in some of the individualmeasures,
overall there was no difference in the mean scores for quality of
life, although vaginal misoprostol was associated with higher levels
of pain than surgery. Overall treatment acceptability was similar,
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and these findings can help to inform the focus of counselling for
women choosing a treatment option.
Overall completeness and applicability of
evidence
The review is probably underpowered to assess the effectiveness of
medical treatments for incomplete miscarriage. In addition, nearly
all studies were focused on women less than 13 weeks gestation
and there is a need for more evidence on women more than 13
weeks gestation.
In terms of study settings, the evidence stems from both low-
income to high-income countries. The majority of the studies
took place in Africa and Southeast Asia while the remaining seven
studies were in Europe and USA.
One study published by Smith 2009 but part of theMIST trial, un-
dertook long-term follow-up to assess any potential impact on sub-
sequent fertility (Trinder 2006). They concluded that the method
of miscarriage management did not affect subsequent pregnancy
rates with around four in five women giving birth within five years
of the index miscarriage. Women can be reassured that long-term
fertility concerns need not affect their choice of miscarriage man-
agement.
Quality of the evidence
The risk of bias of studies was generally low, although it is hard to
assess if there has been selective reporting bias.
We assessed the quality of evidence using GRADE for the two
main comparisons (Atkins 2004): misoprostol versus expectant
management and misoprostol versus surgery. The majority of the
evidence was of low-quality or very low-quality. For the miso-
prostol versus expectant management, we assessed the outcome of
’complete miscarriage’ as very low-quality due to lack of blinding,
heterogeneity of the studies, and the small sample size. Findings
for the outcome of surgical evacuation were based on low-quality
evidence because of high risk of bias in one of the studies and high
level of heterogeneity. For the misoprostol versus surgery compar-
ison, the high risk of bias in some included studies, inconsisten-
cies between results across studies, and suspected publication bias
were the reasons for downgrading the quality of evidence for the
complete miscarriage and surgical evacuation outcomes to very
low. We assessed the quality of evidence for unplanned surgical
intervention and nausea as low due to the high risk of bias and
inconsistencies in the results. We assessed the quality of evidence
for women’s views, vomiting, and diarrhoea as moderate due to
the lack of blinding.
Potential biases in the review process
We attempted to minimise bias by the following; two review au-
thors assessed eligibility for inclusion and two review authors car-
ried out data extraction and assessed risk of bias. Data entry into
Review Manager 5 was undertaken by one review author and
checked by another (RevMan 2014).However,many of these steps
involve subjective assessments and thus may carry some risk of
bias.
Agreements and disagreements with other
studies or reviews
We are unaware of other reviews on this topic. Our conclusions
seem to agree with most of those of the included studies that
women can be offered a choice of treatments because differences
are small and not of major consequence. Womenmay have partic-
ular preferences as to the adverse effects they wish to try to avoid
and this is likely to influence their choice of treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although it would be critical to have more data, the current ev-
idence suggests there appears to be no major differences, other
than avoiding surgery, between misoprostol, expectant care, and
surgery in the treatment of incomplete miscarriage for women
of less than 13 weeks’ gestation. Avoiding surgery has consider-
able benefits in terms of reducing adverse effects (although these
were not fully assessed systematically in the included studies) and
is particularly beneficial in low-income countries. We identified
some differences in nausea, vomiting, and diarrhoea with the use
of misoprostol which can be taken into account when counselling
women on the treatment options.
Implications for research
There is an urgent need for studies to assess medical interventions
for incomplete miscarriage for women between 13 to 24 weeks’
gestation, as currently there are no trials to guide practice. Multi-
centre trials would seem appropriate to give sufficient size to pro-
vide sound evidence.
There is a need for more trials comparing the use of medical treat-
ments, by the various routes, with expectant care and surgery to
confirm or refute these findings for women less than 13 weeks’
gestation. This should provide more evidence on the effectiveness
and adverse effects, so women can be provided with better in-
formation in order to support their choices. Future trials should
separate women with non-viable pregnancies prior to miscarriage,
from those with incomplete miscarriages.
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Women’s views and quality of life measures should be assessed
alongside the clinical outcome in any future trials. These trials
should be large enough to provide definitive findings and should
assess the important outcomes identified in this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bique 2007
Methods RCT with randomisation of individual women. Using computer-generated random
numbers in sequentially numbered opaque envelopes
Participants Inclusion criteria
• Women with confirmed incomplete spontaneous or induced miscarriage, less
than 12 weeks’ gestation
• Diagnosis was based on past or present history of vaginal bleeding during
pregnancy and an open cervical os
• > 18 years; no known allergy to misoprostol; no signs of severe infection; no
haemodynamic disturbance; lived or worked within the hospitals geographic area of
coverage
• N = 270 women but 23 lost due to a problem with randomisation, leaving 247
women
Exclusion criteria
• Nothing specified other than inclusion criteria
Interventions Intervention: oral misoprostol
• 600 ug single-dose
• N = 123
Comparison: surgery
• MVA
• N = 124
Outcomes Complete miscarriage without recourse to additional surgical intervention, experience
of side effects and acceptability of treatment
• Appears to be clinical assessment of complete miscarriage
• Women were assessed at 1 week
• If miscarriage was still incomplete, women were given the option to wait another
week or have surgery then
• Women who chose to wait were reassessed 1 week later and if still no complete
miscarriage, then surgery
Notes 1. Setting: tertiary hospital in Mozambique.
2. If miscarriage incomplete at 7 days, women were given the option to wait another
week or have surgery then. Women who chose to wait and were still incomplete at 2
weeks were then given surgery.
3. Additional outcomes assessed but not prespecified in the review: bleeding; pain/
cramps; fever; chills; tolerability; would choose method again; would recommend
method to a friend; best and worst features.
Risk of bias
Bias Authors’ judgement Support for judgement
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Bique 2007 (Continued)
Random sequence generation (selection
bias)
Low risk “The randomisation scheme was generated
by computer...”
Allocation concealment (selection bias) Low risk “...treatment allocations
printed on cards inserted into sequentially
numbered opaque envelopes...amember of
the study staff opened the next envelope in
the sequence and assigned to women to the
indicated treatment group.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind people and this
is discussed by authors
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It was not possible to blind people and this
is discussed by authors
Incomplete outcome data (attrition bias)
All outcomes
Low risk • 23 women were excluded after
randomisation because of a problem
identified with the randomisation process
as discussed by authors.
• 35 women did not return at 1 week:
12 from misoprostol group and 23 from
MVA group.
• 10 women in misoprostol group had
MVA prior to the 1 week follow-up time.
These were included in the misoprostol
group.
• Not strictly speaking ITT analysis,
but outcomes on the 23 women excluded
were reported and similar to those
included. Analysis was done on 212
women on whom data were available.
Selective reporting (reporting bias) Unclear risk As far as can tell, outcomes reported were
those prespecified, however the trial proto-
col was not assessed
Other bias Unclear risk The 2 groups were comparable on back-
ground characteristics. But the paper men-
tioned that “in the process of monitoring
the first 20 cases, it was noted that the
randomisation scheme was not being ap-
propriately followed - the study was re-
started”. More women were lost to follow-
up in theMVA group than the misoprostol
group
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Blanchard 2004
Methods RCT with randomisation of individual women. Sequentially numbered opaque en-
velopes, using pseudo-random number generator
Participants Inclusion criteria
• Women with signs of incomplete miscarriage
• Diagnosis confirmed by ultrasound
• 1st trimester; good general health; no allergy to misoprostol; good access to
emergency facilities
• N = 169 women
Exclusion criteria
• None specified
Interventions Intervention: oral misoprostol
• 600 ug, single-dose
• N = 86
Comparison: oral misoprostol
• 1200 ug, 2 doses, 4 hours apart
• N = 83
Outcomes Complete miscarriage at 48 hours; surgical evacuation; side effects and acceptability
• Assessed by ultrasound at 48 hours
• If miscarriage not complete at 48 hours, women were given the option to wait
additional 5 days (1 week from misoprostol administration) to see if miscarriage would
be complete without further intervention. If miscarriage not complete after 1 week or
if woman refused extension, then she underwent surgical evacuation according to
standard practice
Notes 1. Setting: 2 teaching hospitals in Bangkok, Thailand.
2. Additional outcomes assessed but not prespecified in the review: bleeding (heavy,
normal, spotting); pain; fever; medically necessary interventions; satisfied or very
satisfied with treatment.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Pseudo-random number generator in
SSPS 9.0.”
Allocation concealment (selection bias) Low risk Women given the next “...sequentially
numbered opaque envelope; the number in
the envelope became her study identifica-
tion number”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Neither the provider nor the woman was
blinded to the treatment regimes.”
58Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blanchard 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Neither the provider nor the woman was
blinded to the treatment regimes.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women in single-dose group and 1
woman in double-dose group were lost to
follow-up. 1.8% of total, so no real im-
pact.
Selective reporting (reporting bias) Unclear risk Appears to be free of selective reporting bias
but we did not assess the trial protocol
Other bias Low risk Appears to be free of other reporting bias.
Blohm 2005
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Women seeking medical attention due to signs of miscarriage in 1st trimester
• To be included, women had to be circulatory stable (stable blood pressure and Hb
> 90 g/L) and without any signs of genital infection. Only women with a gestational
residue (A-P diameter) between 15 mm and 50 mm were included. The non-viability
of the concepts had to be confirmed and accepted by both the physician and woman.
Only women above the age of 18 were included
• Vaginal ultrasound confirmed the miscarriage diagnosis
• N = 126 women
Exclusion criteria
• Women who were not able to understand the information provided regarding the
study and women with a possible allergy or medical contraindication for analgesics or
misoprostol were not included
Interventions Intervention: vaginal misoprostol
• 400 ug; 2 tablets of 200 ug, each self-administered at home
• N = 64
Comparison: placebo
• tablets identical with the misoprostol tablets
• N = 62
Outcomes Complete miscarriage assessed at 6-7 days; infection; bleeding; gastrointestinal side ef-
fects; subjective pain; use of analgesics and length of sick leave
• Assessed at 7 days
• Successful miscarriage was defined as A-P diameter for the gestational residue was
< 15 mm
Notes 1. Setting: University Hospital, Goteborg, Sweden
2. Confirmed with the author that the women had incomplete miscarriages
diagnosed by ultrasound and there were no IUFDs
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3. Additional outcomes assessed but not prespecified in the review: serum Hb;
reduction in serum Hb and days of sick leave
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...random table system...”
Allocation concealment (selection bias) Low risk “Patients were randomised...by drawing a
sealed envelope from a box...tablets were
delivered to the independent pharmacy
where they were inserted by the pharmacy
staff into numbered envelopes in blocks of
10...the randomisation list was retained by
the hospital pharmacy and was not broken
until after completion of the study when
statistical analyses were performed.” How-
ever, no mention of the envelopes being
opaque - so concealment allocation unclear
but because tablets are identical, it seems
unlikely there is a problem here
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The placebo tablets “...were identical in ap-
pearance to the active misoprostol tablets”
and clinicians “...unaware of the randomi-
sation sequence.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The placebo tablets “...were identical in ap-
pearance to the active misoprostol tablets”
and clinicians “...unaware of the randomi-
sation sequence.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no loss to follow-up and women
received their appropriate allocation. The
analysis appears to be ITT
Selective reporting (reporting bias) Unclear risk Seems to be free of bias here, although the
secondary outcome of ’total number of days
of bleeding’ was not reported. However, we
did not assess the trial protocol
Other bias Unclear risk 1. There was an imbalance in baseline
data for gestational age: misoprostol: 72.8
(SD 12.2) and placebo 77.8 (SD 12.9).
This might favour better outcomes for the
placebo group, but probably no important
bias here.
60Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blohm 2005 (Continued)
2. Women chose whether they wanted
a D&C if miscarriage not complete after 1
week or whether to wait longer. So we
used the outcome of complete miscarriage
at 1 week which excludes problems with
choice after that time, but the problem is
present for the outcome of surgical
evacuation.
Chigbu 2012
Methods Open-label RCT with randomisation of individual women.
Participants Inclusion criteria
• Open cervical os, vaginal bleeding or history of vaginal bleeding during this
pregnancy
• Uterine size less than or equal to 12 weeks’ LMP
• Willingness to return for follow-up in 1 week
• No known contraindications to misoprostol
• General good health
Exclusion criteria
• Signs of severe infection (foul-smelling discharge, fever > 38 degrees Celsius, pulse
> 110/minute)
• Known allergy to misoprostol or other prostaglandin
• Suspected ectopic pregnancy
• Haemodynamic instability or shock
Interventions Intervention: oral misoprostol
• Misoprostol 600 mcg orally
• N = 160
Control: surgical evacuation
• MVA
• N = 160
Outcomes Primary outcome measure: complete uterine evacuation after initial treatment
• Assessed at 1 week follow-up visit with bimanual exam and speculum
• If still incomplete, woman was given choice to wait one more week without any
further intervention or immediate surgical evacuation
• If at the 2nd follow-up visit, woman was still incomplete, underwent MVA
Other outcome measures included adverse effects from the treatment and satisfaction/
acceptability
• Assessed by observation and by exit interview
• Pain intensity measured by 7-point Likert scale
• Satisfaction measured by 5-point Likert scale
Notes Setting: a small private clinic with a large rural catchment area in a resource-poor country
in sub-Saharan Africa - South-Eastern Nigeria. Ekeakpara, a rural community in Osi-
sioma Ngwa Local Government Area of Abia State, Nigeria
All participants, regardless of assigned treatment were given prophylactic antibiotics, and
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paracetamol tablets to help manage their pain. They were observed in the clinic for a
maximum of 3 hours after treatment and, in absence of danger signs, discharged
Women allocated to MVA (Ipas, Chapel Hill, NC, USA) were given surgical evacuation
by a trained doctor in the MVA room at the clinic using reassurance alone and no
anaesthesia during the procedure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequentially numbered envelopes. When a
new participant was enrolled in the study,
a trained nurse would open the next en-
velope in the numbered series and the
woman would receive the treatment speci-
fied therein. No mention of random num-
ber table or using a computer randomnum-
ber generator to order envelopes
Allocation concealment (selection bias) Unclear risk Sealed envelopes - no mention of opaque
envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label; no blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding performed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition.
Selective reporting (reporting bias) Unclear risk Trial protocol not published.
Other bias Low risk We did not identify any other biases.
Clevin 2001
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Women with miscarriage up to 12 weeks’ gestation
• Transvaginal ultrasound used
• Only those women (N = 34) with endometrial thickness > 10 cm were
randomised, the remaining women (N = 27) had endometrial thickness < 10 cm an
were managed by expectancy
• N = 61 women
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Exclusion criteria
• Women with intrauterine device in situ, missed abortion flow/blighted ovum,
extrauterine pregnancy or molar
Interventions Intervention: vaginal prostaglandin
• Prostaglandin E1 analogue (gemeprost)
• N = 17
Comparison 1: surgical management
• Curettage
• N = 17
Comparison 2: expectant management
• Women were not randomised to this group but selected on clinical grounds
Outcomes Duration of vaginal bleeding; pain; discomfort experienced; sick days and days of absence
• Assessed at 5-8 days using transvaginal ultrasound
Notes 1. Setting: district hospital in Glostrup, Copenhagen, Denmark.
2. Paper written in Danish, with English abstract. Paper was translated.
3. Additional outcomes assessed but not prespecified in the review: bleeding; pain;
days of sick leave; women’s dissatisfaction.
The participants were divided into 2 groups:
• Group 1 (27) with an endometrial thickness of less than 10 mm; and
• Group 2 (34) with an endometrial thickness greater than 10 mm
Group 1 was managed by expectancy and Group 2 was further divided into 2 groups
again at random:
• Group 2 A (17) which was given Prostaglandin E1 analogue gemeprost (1 mg)
• Group 2 B (17) which underwent curettage
This review looked only at group 2A versus 2B.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The participating women were chosen at
random by the drawing of lots into 2 par-
allel groups.”
Allocation concealment (selection bias) Unclear risk “The participating women were chosen at
random by the drawing of lots into 2 par-
allel groups.” No further information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blindwomennor clinicians.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of whether assessors were
blinded or not.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4 women did not complete the trial period.
2 from gemeprost group and 0 from curet-
tage group (2 from expectant group). 6%
loss but both from the medical manage-
ment group
Selective reporting (reporting bias) Unclear risk There is no mention of the outcomes to be
measured although there was a question-
naire sent to women and this may well have
been designed before the study began. Also,
we did not assess the trial protocol
Other bias Low risk “The patients in all groups were compara-
ble regarding age, previous births and pre-
vious spontaneous or instigated abortions.
” There was no other information which
would suggest other biases
Dabash 2010
Methods Randomised trial.
Participants Inclusion criteria
• women with clinical diagnosis of incomplete miscarriage (open cervix, vaginal
bleeding, ultrasound confirmation in around a third of cases)
• attending two large tertiary maternity units in Egypt: in Cairo and Alexandria
• N = 697
Interventions Intervention: misoprostol
• 400 mcg sublingually
• N = 349 but one lost to follow-up, leaving 348
Comparison: surgery
• MVA
• N = 348 but one lost to follow-up, leaving 347
Outcomes Primary: completed miscarriage. Secondary: additional evacuation of uterus; drop in Hb
by > 2 g/dL; satisfaction; adverse effects
Notes Trial performed 2007-2008.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number allocation in batches of
10
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Allocation concealment (selection bias) Low risk Sequentially numbered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt at blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/697 women lost to follow-up.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk No other apparent biases.
Dao 2007
Methods RCT with randomisation of individual women, in blocks of 10 and stratified by site (2
sites involved)
Participants Inclusion criteria
• Women with incomplete spontaneous or induced miscarriage, less than 12 weeks’
gestation, diagnosed using ultrasound
• Uterine size equivalent to a gestation of less than 12 weeks LMP, open cervical os,
past or present history of vaginal bleeding during pregnancy and ultrasound evidence
of substantial uterine debris with evidence of fetal demise
• Women living or working within the hospital’s geographical area of coverage, no
known contraindications to misoprostol, no signs of severe infection, temperature < 38
oC and general good health
• N = 460 women
Exclusion criteria
• Women with very high fever; signs of severe infection
Interventions Intervention: oral misoprostol
• 600 ug, single-dose
• N = 233
Comparison: surgery
• MVA
• N = 227
Outcomes Completemiscarriage following initial treatment; adverse effects, bleeding; pain (7-point
Likert scale), acceptability (5-point Likert scale)
• Assessed at 1 week using clinical assessments and US. Women could wait a further
week before surgery (MVA) if they wished
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Notes 1. Setting: 2 large university teaching hospitals in Burkina Faso, sub-Saharan Africa.
2. Additional outcomes assessed but not prespecified in the review: pain/cramps;
fever; chills; bleeding; overall experience; overall satisfaction; would choose again;
would recommend to a friend; hospitalisation; managed pain with paracetamol; would
have liked stronger pain killers; sought contact with providers; made phone calls to
providers; best and worst features.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”...computer-generated random sequence
provided by Genunity Health Projects...“
Allocation concealment (selection bias) Low risk ”The assignment was concealed from
providers and participants until after in-
formed consent was givenwhen the next se-
quential opaque sealed study envelope was
opened to reveal allocation...”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Neither women nor providers were
blinded to treatment assignment...”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ”Neither women nor providers were
blinded to treatment assignment...”
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Lost after randomisation and before
prescription: 10 in misoprostol group and
3 in the MVA group
• Exclusion after randomisation: 5 in
the misoprostol group and 1 in the MVA
group
• Overall, there were uneven loses to
follow-up and some exclusions, but as
numbers are small, we think this is
unlikely to cause bias
Selective reporting (reporting bias) Unclear risk Prespecified outcomes reported on, but the
trial protocol not assessed
Other bias Low risk No apparent biases from other sources.
Baseline data showed no statistically signif-
icant differences between the groups
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Diop 2009
Methods RCT with randomisation of individual women. Non-equivalence trial
Participants Inclusion criteria
• Women with incomplete miscarriage with uterine size < 12 weeks’ gestation based
on clinical diagnosis (mainly open cervix, vaginal bleeding)
• Ultrasound sometimes used to confirm diagnosis
• N = 300 but 6 lost to follow-up, leaving 294
Interventions Intervention: sublingual misoprostol
• 400 mcg
• N = 150 but 4 lost to follow-up, leaving 146
Comparison: oral misoprostol
• 600 mcg
• N = 150 but 2 lost to follow-up, leaving 148
Outcomes Complete miscarriage, satisfaction, side effects and pain.
Notes Two settings: large tertiary maternity hospitals in Madagascar (n = 200) and Moldova
(n = 100)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number al-
location.
Allocation concealment (selection bias) Low risk Sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No apparent attempt at blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No apparent attempt at blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No follow-up on 6/300 participants (not
included in analyses)
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk None apparent.
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Ganguly 2010
Methods RCTwith randomisation of individual women. Randomisation performed by computer-
generated random number list. Opaque sealed envelopes were sequentially numbered.
Outcome assessors of the study were blinded
Participants Inclusion criteria
• women with incomplete spontaneous miscarriage diagnosed clinically by passage
of some POC and sonographically by endometrial lining exceeding 30 mm and uterine
size less than 12 weeks (N = 114)
• women with anembryonic gestation or embryonic or fetal death (N = 11)
• women with inevitable miscarriage (N = 55)
Interventions Intervention: vaginal misoprostol
• 800 mcg on day 1, second dose of 800 mcg on day 3, if incomplete expulsion
• N = 77
Control: surgery
• MVA
• N = 37
Outcomes Success (complete uterine evacuation without need for vacuum aspiration for medical
management group and without need for repeat aspiration in surgical management
group), adverse events, acceptability
Notes Setting was at RG Kar Medical College and Hospital in Kolkata, India. Study was
conducted between 1 May 2007 and 30 April 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number list.
Allocation concealment (selection bias) Low risk Opaque sealed envelopes with sequence
generation and envelope preparation was
not involved in the clinical assessment of
the subjects
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt at blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
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Other bias Low risk We did not identify any other biases.
Montesinos 2011
Methods RCTwith randomisation of individual women. Sequentially numbered sealed envelopes,
using a computer-generated number allocation. Stratified by site
Participants Inclusion criteria
• Women with incomplete miscarriage (open cervix, vaginal bleeding, uterine size <
12 weeks)
• confirmed by ultrasound
• N = 242
Interventions Intervention: oral misoprostol
• 600 ug
• N = 122
Comparison: surgery
• MVA (under general anaesthesia at public hospital, local anaesthesia at private
clinic)
• N = 120
Outcomes Primary: completeness of miscarriage at one week (based on questioning about symp-
toms, pelvic examination +/- ultrasound). Secondary: further treatment, adverse effects,
satisfaction
Notes Two centres in Ecuador: large public tertiary maternity hospital (N = 200), small private
clinic (N = 42)
Set-up as feasibility study aiming to recruit 500 women. Closed after a year with around
half recruited
Recruitment 2006-2007.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated in blocks of 10.
Allocation concealment (selection bias) Low risk Sealed numbered envelopes opened after
consent.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt at blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding.
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Incomplete outcome data (attrition bias)
All outcomes
High risk 39/242 (16.1%) women did not return for
assessment and were not included in anal-
yses
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk We did not identify any other biases.
Moodliar 2005
Methods RCTwith randomisation of individual women. Sequentially numbered sealed envelopes,
using a computer-generated number allocation
Participants Womenwith spontaneous incompletemiscarriage after up to 13weeks’ gestation assessed
by ultrasound
N = 94 women
Interventions Intervention: vaginal misoprostol
• 600 ug (plus a second dose 24 hours later if miscarriage still not complete)
• N = 47
Comparison: surgery
• surgical ERPC by sharp curettage following 20 U of oxytocin per litre of normal
saline under GA with no prophylactic antibiotics but oral analgesics were prescribed
• N = 47
Outcomes Women requiring ERPC after failed medical management; number of doses of miso-
prostol required; duration of bleeding; adverse effect profile (nausea, vomiting and/or
diarrhoea); time spent away from work; use of analgesia
Notes 1. Setting: Gynaecology Outpatient Dept, Durban, South Africa.
2. Additional outcomes assessed but not prespecified in the review: Hb at 4 days;
pain (VAS); duration of analgesia; days of sick leave; satisfaction (VAS); would use
same treatment again; would recommend treatment to friend.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated patient number al-
location.”
Allocation concealment (selection bias) Low risk “The number was sealed consecutively
numbered envelopes by staff not in-
volved in the study. Sealed envelopes were
opened and consecutively enrolled women
had their allocated treatment. It is not
clear, however, whether the envelopes were
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opaque or not.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Itwas not possible to blindwomennor clin-
icians,
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear whether assessors were
blinded for some of the outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss of participants nor exclusions re-
ported.
Selective reporting (reporting bias) Unclear risk It would appear so although the prespeci-
fied outcomes do not match the reported
outcomes fully. Also we did not assess the
trial protocol
Other bias Unclear risk No figures given on baseline data, only re-
ported as “thosewhowere randomisedwere
well matched for demographic and clinical
data”. Study not stopped early for benefit
and no other apparent biases
Ngoc 2005
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Women with incomplete miscarriage
• Women of 18 years or older, living or working within 1 hr of the study hospital,
no known contraindication to misoprostol and general good health
• N = 300 women
Exclusion criteria
• None specified
Interventions Intervention: oral misoprostol
• 600 ug
• N = 150
Comparison: oral misoprostol
• 1200 ug (2 x 600 ug, 4 hours apart)
• N = 150
Outcomes Complete evacuation without recourse to surgery; women’s satisfaction and acceptability
Notes 1. Setting: large tertiary facility in Ho Chi Minh City in Southern Vietnam.
2. Mean gestational age was 8.1 weeks, so we consider all to be less than 13 weeks’
gestation, this was confirmed by personal communication with co-author, J Blum, but
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we have emailed the first author to confirm as suggested.
3. Additional outcomes assessed but not prespecified in the review: bleeding; pain/
cramps; fever/chills; tolerability; would choose again; would recommend to a friend.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...computer generated random sequence..
”
Allocation concealment (selection bias) Unclear risk “...opening the next study envelope...”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although comparing drug doses, because
the comparator group were given second
dose 4 hours later, this was not blinded
from participants nor caregivers
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Although comparing drug doses, because
the comparator group were given second
dose 4 hours later, this was not blinded
from participants nor caregivers
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 women lost to follow-up: 1/150 for sin-
gle-dose and 4/150 for repeat dose. Au-
thors made every effort to contact women,
both by phone and visits but unsuccess-
fully for these 5 women. There were no ex-
clusions reported, although some outcomes
were only available on 145 of the women
in the double-dose group rather than 146.
The analysis was not by ITT because of the
lost data, but we considered the loss was
small enough for there to be no important
bias
Selective reporting (reporting bias) Unclear risk Seem to have reported all prespecified out-
comes, but we did not access the trial pro-
tocol
Other bias Low risk There was nothing to suggest any other risk
of bias.
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Niinimaki 2006
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Women with incomplete spontaneous miscarriage and IUFD, with only women
with incomplete miscarriage being included in this review
• Women aged > 18 years with positive pregnancy test and with one of the
following: in transvaginal ultrasonography an inhomogeneous mass with a diameter of
15-50 mm in the uterine cavity (incomplete spontaneous abortion); empty amnion sac
with a diameter of > 15 mm (anembryonic pregnancy ); or crown-rump length > 5 mm
without signs of fetal heart function (missed abortion). All kinds of miscarriage were
included (missed abortion; anembryonic pregnancies; incomplete spontaneous
abortion)
• N = 19 women (98 were randomised of which 19 had incomplete miscarriage)
Exclusion criteria
• Women with profuse bleeding; signs of endometritis, allergies to either drug;
severe asthma, suspected cases of molar or extrauterine pregnancy
Interventions Intervention: oral mifepristone + vaginal misoprostol
• Oral mifepristone (200 mg) + vaginal misoprostol (800 ug)
• N = 11
Comparison: surgery
• Curettage
• N = 8
• Some women (mainly nulliparous) were given 400 ug vaginal misoprostol 2 hours
before to ripen the cervix
Outcomes Complete abortion rate; bleeding; pain; satisfaction; complications including infection
(clinical signs or elevated infectionparameters in lab tests) treatedwith oral or intravenous
antibiotics; continuous and heavy bleeding; blood transfusions; curettage for any reason;
intense pain requiring admission
Notes Setting: Oulu University Hospital, Finland.
The 19 women with incomplete spontaneous miscarriage were part of a larger study of
98 women who had had various forms of miscarriage (incomplete spontaneous miscar-
riage; anembryonic pregnancy; missed miscarriage). Separate data were available from
the authors for the women with incomplete spontaneous miscarriage. Of the 19 women,
16 were < 13 weeks’ gestation and 3 were between 13 and 23 weeks’ gestation. This
information is held at the Cochrane Pregnancy and Childbirth Office
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...computer randomised programwith the
block length of 6.”
Allocation concealment (selection bias) Low risk “An independent consult performed the
randomisation and assigned the randomi-
sation list to a secretary, who made the
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numbered opaque envelopes for the study.
...Allocation concealment was used to con-
firm that neither the clinician nor the pa-
tient knew the type of treatment in ad-
vance...After informed consent the next
numbered envelope was opened to define
the type of treatment of each patient.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Cannot blind women nor clinicians to
the treatment because this study compared
medical versus surgical treatment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Cannot blind women nor clinicians to
the treatment because this study compared
medical versus surgical treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Authors randomised 98 women (19 with
ICM and 79 with IUFD) with 49 in each
group. Of these, they reported on 48 in
medical and 47 in surgical groups because 1
woman in the medical management group
had an ERPC and in the surgical group one
woman had an emergency ERPC and one
had a spontaneous complete miscarriage.
Of these women only 19 had incomplete
miscarriage (the remainder had intrauter-
ine deaths) and of these all appear to be ac-
counted for in the analysis
Selective reporting (reporting bias) Unclear risk We did not assess the protocol, and ad-
ditionally the authors did not report on
bleeding; blood transfusions
Other bias Low risk No apparent additional biases apparent.
Pang 2001
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Women with clinical diagnosis of incomplete miscarriage confirmed by
transvaginal ultrasound
• Specifically - women with clinical diagnosis of incomplete miscarriage, positive
urinary pregnancy test, confirmed by transvaginal ultrasonography (TVS) with
evidence of retained POC
• N = 201 women
Exclusion criteria
• Women with an intrauterine dimension measuring < 11 cm² (sagittal plus
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Pang 2001 (Continued)
transverse plane) were considered to have an empty uterus and excluded from
randomisation. Also excluded were women with: severe blood loss; sepsis; known
allergy to prostaglandins or analogue, history of asthma, clinician thought unsuitable
for misoprostol.
Interventions Intervention: vaginal misoprostol
• 800 ug - 2 doses if necessary
• N = 96
Comparison: oral misoprostol
• 800 ug - 2 doses if necessary
• N = 105
Outcomes Efficacy; side effects; short-term complications.
• outcomes assessed at 1 day following treatment and again at 2 weeks
Notes 1. Setting: The Chinsese University of Hong Kong.
2. Additional outcomes assessed but not prespecified in the review: bleeding; pain;
fever; drop in Hb.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated set of random num-
bers in blocks of 5.
Allocation concealment (selection bias) Low risk Opaque envelopes labelled serially.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information and differing routes of ad-
ministration suggest there was high risk of
performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information and differing routes of ad-
ministration suggest there was high risk of
detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 201 women randomised, 198 got
the treatment allocated, but only 186 were
analysed because 12 were lost to follow-up
- 7.5%. It is unclear whether ITT analysis
was undertaken
Selective reporting (reporting bias) Unclear risk No obvious outcome reporting bias but au-
thors do not list their outcomes and al-
though only report significant differences
in abstract, in paper they report several ad-
verse outcomes with data. We did not as-
sess the trial protocol.
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Pang 2001 (Continued)
Other bias Low risk Significantly more women in oral group
had a past history of termination, P < 0.
001, but this was thought to probably not
to create important bias
Paritakul 2010
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• women with incomplete miscarriage (clinical diagnosis confirmed by ultrasound)
attending one hospital in Bangkok, Thailand
• N = 64
Exclusion criteria
• haemodynamic instability, suspected sepsis, allergy to misoprostol, suspected
ectopic pregnancy
Interventions Intervention: misoprostol sublingually
• 600 mcg
• N = 32
Comparison: misoprostol orally
• 600 mcg
• N = 32
Outcomes Efficacy; side effects; short-term complications.
• outcomes assessed at 48 hours following treatment and again at 1 week.
’Treatment failure’ was incomplete miscarriage at 48 hours
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generated from random number
tables.
Allocation concealment (selection bias) Low risk Consecutively numbered, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt at blinding of participants or
staff.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding of participants or
staff.
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Paritakul 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk We did not identify any other biases.
Patua 2013
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Age 15-45 year with diagnosis of incomplete abortion
• Haemodynamically stable
• Amenorrhea of less than or equal to 84 days
• No prior history of intervention
• Spontaneous onset
Exclusion criteria
• Patients in shock, bleeding profusely, septic abortion
• History of previous caesarean section delivery
• Contraindication to misoprostol (allergy, asthma)
• Women presenting with products hanging from external os which were removed
digitally
Interventions Intervention: vaginal misoprostol
• Misoprostol 400 mcg vaginal every 3 hours x 3 doses regardless of POC expulsion
• N = 50
Control: surgical
• Traditional suction and curettage under deep sedation with 50 mg pethidine
injection
• N = 50
Outcomes Primary outcome: success of the procedure = no POC in follow-up scan (24 hours after
last dose/surgical evacuation) OR no need for curettage/repeat curettage (failure defined
as POC on follow-up scan, necessary surgical evacuation due to retained POC or profuse
bleeding following miso administration)
Secondary outcome: amount of procedure-related blood loss and side effects
The amount of blood loss was measured by the change in haemoglobin percentage and
by the number of pads changed in first 24 hours following treatment allocation. Women
were asked to change the pads only when the outer surface of the pads got stained
Complications related to the procedures were those which could be measured quantita-
tively (fever, i.e. temperature 100.4 °F) and subjectively (severe pain judged by VAS over
7 on a scale of 1-10)
Notes Study setting: Department of Gynecology and Obstetrics, Eden Hospital, Medical Col-
lege, Kolkata, India, in 2009
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk Women were allocated to 2 groups using
a random number table. No mention of
using sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Double-blinding could not be done as ob-
servers were responsible for clinical man-
agement of the patients and had to know
the treatment that each patient was offered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Sonographer blinded to intervention or
control group.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4 lost from the intervention group - 1
woman was detected having pre-existing
jaundice. Another 1 left the hospital with-
out intimation. 2 refused to continue treat-
ment following administration of the first
dose of misoprostol and urged for surgical
clearance. All 4 of themwere excluded from
the study
Selective reporting (reporting bias) Unclear risk Protocol not published.
Other bias Low risk We did not identify any other biases.
Sahin 2001
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Women with uncomplicated incomplete spontaneous miscarriage assessed with
ultrasound
• Women with a history of vaginal bleeding, cramping abdominal pain and passage
of some products of the conceptus; in good health with a normal Hb level (> 9 g/dL)
and haemodynamically stable; estimated gestational age was ≤ 10 weeks, if the
anterior-posterior diameter of any retained product of the conceptus was < 50 mm, and
if they had no contraindication to prostaglandin treatment
• N = 80 women
Exclusion criteria
• Women with temperature > 37.5 0C, excessive vaginal bleeding requiring
immediate surgical evacuation, haemodynamic instability or foul-smelling products of
the conceptus
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Interventions Intervention: oral + vaginal misoprostol
• 200 ug 4 times daily after application of 200 ug intravaginal misoprostol for 5 days
• N = 40
Comparison: surgical management
• Curettage, sometimes with general anaesthesia
• N = 40
Outcomes Number of days of vaginal bleeding; rate of complications (fall in Hb, infection, perfo-
ration) and women’s satisfaction
• Miscarriage assessed at 10 days but no indication on whether this was a clinical
assessment or by ultrasound
Notes 1. Setting: University hospital, Turkey.
2. Additional outcomes assessed but not prespecified in the review: mean change in
Hb; dissatisfaction.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided, except to say
women were randomised
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither participants nor clinicians can be
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk There is no mention as to whether the out-
come assessor was blinded. For outcomes
where participants assessed for themselves,
these were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses and no exclusions were reported,
but nothing is described. As there is no
deviation from protocol it is assumed that
analysis was by ITT
Selective reporting (reporting bias) Unclear risk Seem to report on all outcomes specified
in ‘Materials and methods’ but we did not
assess the trial protocol
Other bias Unclear risk No imbalances in baseline data identified
(assessed: age, gravity, parity, gestational
age, anterior-posterior diameter). Study
not stopped early and no apparent differ-
ential diagnosis
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Shelley 2005
Methods RCT with randomisation of individual women. Used a centralised computer-based en-
rolment and randomisation service. The Co-ordinating Centre used the biased coin
method of maintaining balance between study arms, and was stratified by hospital and
gestation (< 7 weeks; 8-10 weeks; 11-13 weeks)
Participants Inclusion criteria
• Women with incomplete or inevitable miscarriage at < 13 weeks’ gestation
assessed clinically
• Bleeding not excessive, haemodynamic system stable, temperature < 37.5 0C, no
history of current serious systemic medical or surgical condition, use of prostaglandins
not contraindicated (allergy, mitral stenosis, diabetes, blood dyscrasia, haemolytic
disease, glaucoma, sickle cell anaemia, hypertension, epilepsy or severe asthma), 18
years or older, not taking anticoagulants or oral corticosteroids, singleton pregnancy, no
intrauterine device in situ, and sufficient familiarity with English to complete written
questionnaires
• N = 40 women
Exclusion criteria
• A non-viable intrauterine pregnancy diagnosed on ultrasound but with no vaginal
bleeding
Interventions Intervention 1: vaginal misoprostol
• 400u g with repeat dose 4-6 hours later if needed (= 400 ug or 800 ug)
• N = 13 but 1 woman withdrew immediately after randomisation leaving. N = 12
Intervention 2: surgical management
• Aspiration curettage or D&C under GA
• N = 12
Comparison: expectant care
• N = 15
Outcomes Successful evacuation; infection; haemorrhage; pain; bleeding; physical and emotional
recovery; anxiety and depression
• Assessed clinically at 10-14 days and 8 weeks
Notes 1. Setting: 5 metropolitan hospitals, Melbourne, Australia.
2. Additional outcomes assessed but not prespecified in the review: pain; return to
usual activities after 2 and 6 days; HADS anxiety score at 2 and 6 days; would choose
this method again.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...a centralised computer-based enrolment
and randomisation service...using the bi-
ased coin method of maintaining balance
between study arms, and was stratified by
hospital and gestation (7 weeks or less, 8 -
10 weeks, 11 - 13 weeks).”
80Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shelley 2005 (Continued)
Allocation concealment (selection bias) Low risk “...a centralised computer-based enrolment
and randomisation service, available by
telephone 24 hours a day.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Participants and clinicians could not be
blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unclear if outcome assessor blind or not,
although not for outcomes assessed by
women. Reports that “The data analyst had
access to unblinded data but no contact
with any study participant.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk One woman randomised to medical pre-
scription (misoprostol) withdrew following
randomisation and was not included in the
analyses
Medical group: 1womanwas lost to follow-
up at 10 to 14 days; 1 woman was lost to
follow-up at 8 weeks
Surgical group: 1womanwas lost to follow-
up at 8 weeks.
Expectant group: 1 woman was lost to fol-
low-up at 8 weeks.
Selective reporting (reporting bias) Unclear risk Outcome measures are listed in the meth-
ods section and are those reported in the
results section. We did not assess the trial
protocol
Other bias Low risk Study was planned to recruit 831 women
from power calculation 80% power to de-
tect of 5% (99% to 91%) at 0.05 level, but
staff were recruiting < 50% eligible women
and of these only 22% agreed. So, in effect
stopped early but not because of benefit, so
probably no bias, just underpowered.
No data provided on baseline balance, but
reported that: “there were no marked or
systematic differences between the groups
at trial entry with regards to gestation,
women’s age, reproductive history, meth-
ods of diagnosis, days of bleeding, pain,
haemoglobin or white cell count.”
There seemed to be no differential diagno-
sis.
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Shochet 2012
Methods RCT with randomisation of individual women.
Participants Inclusion criteria
• Eligible incomplete abortion = past or present history of vaginal bleeding during
pregnancy and an open cervical os (if ultrasound not used) or evidence of incomplete
abortion with substantial debris in uterus, if ultrasound used
• Uterine site no larger than 12 weeks
• No contraindications to study drug
• No severe infection
• No haemodynamic disturbances
• General good health
• Willing to provide contact info for follow-up purposes
Exclusion criteria
• Suspicion of ectopic pregnancy
Interventions Intervention: sublingual misoprostol
• Misoprostol 400 mcg sublingual x 1 dose
• N = 480
Comparison: surgical evacuation
• Surgical evacuation per standard practice of each hospital (MVA or D&C)
• N = 380
Outcomes Primary: complete abortion at follow-up (success)
• Follow-up in 1 week; if incomplete, given a choice of additional week follow-up or
surgical evacuation; if still incomplete at 2nd follow-up, underwent surgical evacuation
• Diagnosis assessed by clinical exam and in event of continued heavy bleeding,
enlarged uterus, or suspicion of ectopic pregnancy, referred for ultrasound
Additional outcomes: side effects, acceptability.
Notes Study setting: data from 1 multi-site (Mauritania, Niger, and Senegal) and 2 country-
level (Burkina Faso and Nigeria) randomised trials comparing sublingual misoprostol to
standard surgical care for treatment of incomplete abortion were combined. Study sites
were located in Guédiawaye, Senegal; Nouakchott, Mauritania; Niamey, Niger; Ibadan,
Nigeria; and Ouagadougou and Bobo Dioulasso, Burkina Faso
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of randomisation.
Allocation concealment (selection bias) Unclear risk No details given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details given.
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Shochet 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details given.
Use of ultrasound to determine outcome
was more likely to occur with women in
the misoprostol arm than with those in the
surgical arm
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 15 in intervention and 6 in MVA group -
no information on whether this group Is
different
Selective reporting (reporting bias) Unclear risk Protocol not published.
Other bias Low risk We did not identify any other biases.
Shwekerela 2007
Methods RCT with randomisation of individual women in blocks of 10.
Participants Inclusion criteria
• Women with incomplete spontaneous or induced miscarriage, less than 12 weeks’
gestation
• Women living within 1 hour of hospital; past or present history of bleeding
during this pregnancy; cervical os open by visual/digital inspection; uterine size of no
greater than 12 weeks since last menstrual period; generally in good health; willing to
return for follow-up
• N = 300 women
Exclusion criteria
• Women with severe infection; known allergy to misoprostol; signs of severe
infection (foul-smelling discharge, fever > 39 oC, or pulse > 110/minute) or a known
allergy to misoprostol
Interventions Intervention: oral misoprostol
• 600 ug single-dose
• N = 150
Comparison: surgery
• MVA
• N = 150
Outcomes Successful miscarriage; adverse effects; women’s satisfaction
• Study protocol did not call for routine ultrasonography either for initial diagnosis
or for determination of treatment success
• Assessment at 1 week
Notes 1. Setting: Kagera Regional Hospital, Bukoba, Tanzania.
2. All women observed for 3 hours after prescription before being allowed home and
antibiotics were given as needed. If miscarriage still incomplete at 7 days, women
offered additional week or MVA. Any woman still with incomplete miscarriage at 14
days was offered MVA.
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Shwekerela 2007 (Continued)
3. Additional outcomes assessed but not prespecified in the review: bleeding; pain;
fever; tolerability.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “....computer-generated random code, cre-
ated in bocks of 10 at Genunity Health
Projects’ Office in New York City.”
Allocation concealment (selection bias) Low risk “The code was used by a Genunity em-
ployee who was not part of the research
team as a basis for sealing cards in consec-
utively numbered envelopes... staff would
open the next envelope in the numbered
series...”. Although not opaque enveloped,
we think the numbered series should be al-
right
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not able to blind participants or clinicians.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not able to blind participants or clinicians.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up and no deviations
from protocol allocation reported. ITT
analysis
Selective reporting (reporting bias) Unclear risk Report on prespecified outcomes, although
we have not assessed the trial protocol
Other bias Low risk On most characteristics, women did not
differ significantly. But significantly more
women in themisoprostol group had spon-
taneous miscarriage and were married.
However, we considered that this probably
will not have any impact on differences in
outcome
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Taylor 2011
Methods Randomised controlled trial.
Participants Inclusion criteria
• Women with incomplete miscarriage (clinical diagnosis - vaginal bleeding, open
cervix, uterus < 12 week size.
• Sometimes confirmed by ultrasound; attending one regional hospital in Ghana
• N = 229
Exclusion criteria
• Suspected sepsis (temperature > 38), allergy to misoprostol
Interventions Intervention: oral misoprostol
• 600 mcg
• N = 113, but 108 analysed
Comparison: surgery
• MVA
• N = 116, but 110 analysed
Outcomes Efficacy; side effects; short-term complications.
• Outcomes assessed at 7 days following treatment. ’Treatment failure’ was
incomplete miscarriage at 1 week
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence in blocks of 10.
Allocation concealment (selection bias) Low risk Sealed sequential envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt at blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11/229 women lost to follow-up.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk We did not identify any other biases.
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Trinder 2006
Methods RCT with randomisation of individual women. Randomisation was by a central tele-
phone system at the Clinical Trials Unit using minimisation to ensure comparability
Participants Inclusion criteria
• Women of less than 13 weeks’ gestation with a diagnosis of either incomplete
miscarriage or early fetal/embryonic demise
• Defined ICM as areas of mixed echogenicity within the uterine cavity with or
without a disordered gestational sac. Early embryonic demise was defined as an intact
gestational sac of greater than 20 mm mean diameter with no other internal structures
and early fetal demise as a fetus over 6 mm crown rump length with no heart activity
on transvaginal ultrasound scan
• N = 1200 women. Incomplete miscarriage N = 274; early fetal demise N = 924
Exclusion criteria
• Women with severe haemorrhage or pain; pyrexia > 38oC; severe asthma;
haemolytic disease or blood dyscrasias; current anticoagulation or systemic
corticosteroid prescription; twin or higher order pregnancy; smoker aged > 35; inability
to understand English
Interventions Intervention 1: vaginal misoprostol
• 800 ug
• N = 398 total; ICM = 90; IUFD = 308
Intervention 2: surgery
• Suction curettage
• N = 403 total; ICM = 92; IUFD = 310
Comparison: expectant care
• N = 399 total; ICM = 92; IUFD = 306
All women were given a specific information sheet, 30 co-dydramol tablets, and an
emergency telephone number
Outcomes Primary outcome: gynaecological infection within 14 days of trial entry
Secondary outcomes: antibiotics for presumed gynaecological infection within 14 days
and within 8 weeks; duration of clinical symptoms (pain, additional analgesia, vaginal
bleeding; days off work, days before return to usual daily activities); complications (fall
in Hb at 10-14 days, blood transfusion, unplanned consultations or admission within 14
days and within eight weeks); efficacy; psychological outcomes (depression and anxiety)
; and return to normal activity
• Unplanned curettage assessed at 2 weeks and 8 weeks
Notes 1. Setting: early pregnancy assessment unit in 7 hospitals in UK.
2. Results are reported by both IUFD and ICM. However, randomisation was not
reported as stratified so there will be risk of bias in using data from the subgroups.
3. Additional outcomes assessed but not prespecified in the review: none.
Risk of bias
Bias Authors’ judgement Support for judgement
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Trinder 2006 (Continued)
Random sequence generation (selection
bias)
Low risk “Randomisation was by a central telephone
system at the Clinical Trials Unit in Ox-
ford.We usedminimisation to ensure com-
parability between women with respect to
participating centres, parity, type ofmiscar-
riage and gestation.”
Allocation concealment (selection bias) Low risk Randomisation was by a central telephone
system at the Clinical Trials Unit in Ox-
ford, and although no specific information
given on randomisation, clinical trials units
generally use computer-generated random
numbers list
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blindwomennor clinicians,
because women given medical or surgical
interventionwere treatment in hospital and
women in expectant arm were able to go
home. Cannot blind surgery versusmedical
treatment or expectant care.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not possible to blindwomennor clinicians,
because women given medical or surgical
interventionwere treatment in hospital and
women in expectant arm were able to go
home. Cannot blind surgery versusmedical
treatment or expectant care.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss of participants to follow-up:
• loss immediately after
randomisation: misoprostol = 0; surgery =
1; expectant care = 1.
• loss at 14-day outcomes; misoprostol
= 9 ; surgery = 8; expectant care = 5.
• loss at 8-week outcomes: misoprostol
= 3; surgery = 2; expectant care = 6.
However, we do not know whether these
women had ICM or IUFD, but at a maxi-
mum loss would be 10%.
Exclusions after randomisation: In each
of the surgical group and expectant care
group, one woman with a viable pregnancy
was excluded. Analysis was by ITT
Selective reporting (reporting bias) Unclear risk All important prespecified outcomes were
reported, but we have not assessed the trial
protocol
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Trinder 2006 (Continued)
Other bias Unclear risk Study stopped early because struggling to
recruit and not because of benefit, so bias
unlikely. There were no important baseline
differences between the 3 groups
However, the randomisation was not re-
ported as stratified by women with ICM
and women with IUFD and so these may
not have similar groups for comparison
Weeks 2005
Methods RCT with randomisation of individual women. Consecutively numbered sealed opaque
envelopes, using a computer-generated random number
Participants Inclusion criteria
• Women with incomplete miscarriage of less than 13 weeks’ gestation
• Clinical diagnosis
• N = 317 women
Exclusion criteria
• Women presenting with haemorrhage causing haemodynamic changes; ay
suspicion of an ectopic pregnancy, severe asthma, signs of severe infection, known
sensitivity to misoprostol
Interventions Intervention: oral misoprostol
• 600 ug
• N = 160
Comparison: surgery
• MVA
• Women given 50 mg pethidine and 0.2 mg ergometrine
• N = 152
Outcomes Completeness of evacuation; adverse effects, maximum pain and blood loss
• Clinical assessment at 7 days
Notes 1. Setting: Mulago Hospital, Kampala, Uganda.
2. On discharge all women given doxycycline (100 mg/12 hours for 7 days) and
metronidazole (400 mg 3 times a day for 5 days) because of the high incidence of septic
abortion in Urganda.
3. Additional outcomes assessed but not prespecified in the review: severity of
bleeding; maximum pain; adverse effects; satisfaction; would choose method again;
would recommend to a friend; worst and best aspects of treatment.
4. Poor response in terms of women not returning for follow-up appointment
happened despite transport costs being provided.
Risk of bias
Bias Authors’ judgement Support for judgement
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Weeks 2005 (Continued)
Random sequence generation (selection
bias)
Low risk “Computer-generated random numbers...
”
Allocation concealment (selection bias) Low risk “The allocation was written on cards and
placed in consecutively numbered opaque
sealed envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Neither the patients, assessors, nor the
data analysers were blinded to the alloca-
tion.” It was not possible to blind women
or clinicians because a drug was compared
with surgery.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Neither the patients, assessors, nor the
data analysers were blinded to the alloca-
tion.” It was not possible to blind women
or clinicians because a drug was compared
with surgery.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss of participants to follow-up from 317
women randomised was considerable and
was discussed by authors. Many women in
the rural communities of Uganda did not
come for follow-up after discharge.
• At 6 days - no loss to follow-up.
• At 1-2 weeks: Misop had 53/160
(33%) lost to follow-up - leaving 107
women.
• MVA had 70/157 (45%) lost to
follow-up - leaving 82 women.
5 women were excluded in theMVA group
(3 for self-discharge and 2 women were in-
correctly excludedby the recruiter after ran-
domisation but before treatment, 1 because
she did not fit the entry criteria and 1 be-
cause no manual vacuum aspiration kit was
available)
• One woman in misoprostol group
and 7 in MVA group were given the
wrong prescription, but were included on
ITT for analysis.
• Included in MVA were 6 women for
whom MVA was not possible (5 amount
of retained products too great and 1 the os
had closed).
The study was analysed by ITT based on
available data.
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Weeks 2005 (Continued)
Selective reporting (reporting bias) Unclear risk Seem to report findings fully, there is just
the problem of large losses to follow-up
- due to the low-income country setting
probably.Wehave not assessed the trial pro-
tocol.
Other bias Unclear risk Study was stopped for pragmatic reasons
and not for benefit (principle investigator
moved) and os; probably no bias
Clinical characteristics at presentation were
similar between the 2 groups, although no
P values reported
Women in theMVA group were given rou-
tine analgesia, where women in the medi-
cal management group had analgesia on re-
quest. However, women in MVA still had
more pain, so pain with MVA likely to be
underestimated
Zhang 2005
Methods RCT with randomisation of individual women in ratio of 3:1.
Participants Inclusion criteria
• Women with incomplete miscarriage and intrauterine fetal death
• Women with anembryonic gestation or embryonic or fetal death, also women
with incomplete or inevitable miscarriage, were enrolled in the trial after assessment
using ultrasound
• N = 652 total; ICM - N = 39; IUFD - N = 613
Exclusion criteria
• Women with anaemia (< 9.5 g/dL); haemodynamic instability; history of clotting
disorder; using anticoagulants (not including aspirin); allergic to prostaglandins or
non-steroidal anti-inflammatory drugs; previously undergone surgical or medical
abortion either self-induced or induced by other physicians during this pregnancy.
Interventions Intervention: vaginal misoprostol
• 800 ug (4 x 200 ug)
• N = 30
Comparison: surgery
• Vacuum aspiration
• N = 9
Outcomes Success, Hb, fever, nausea, vomiting, diarrhoea, and acceptability
• Complete miscarriage assessed at 3 days and 8 days using transvaginal ultrasound
Notes 1. Setting: 4 university settings in US: Columbia University; University of Miami;
University of Pennsylvania; University of Pittsburgh.
2. Authors sent us data which separated the outcomes for women with incomplete
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Zhang 2005 (Continued)
miscarriage and those with intrauterine fetal deaths.
3. Additional outcomes assessed but not prespecified in the review: pain; hospital
admission; fever. One additional paper (Harwood 2008) compared women’s
assessment of quality of life between vaginal misoprostol and surgery.
4. It was reported in the Harwood 2008 publication on this study that despite
reporting greater pain and lower acceptability of treatment-related symptoms, quality of
life and treatment acceptability were similar for medical and surgical treatments. Here
women with incomplete miscarriage and intrauterine deaths were assessed together.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...centralised, computer-automated tele-
phone response system...” used to ran-
domly assign women to groups in a 3:1 ra-
tio
Allocation concealment (selection bias) Low risk A centralised, computer-automated tele-
phone response system. It was considered
that because it was an automated com-
puter response, then allocation conceal-
ment would be good
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind either women or clin-
icians.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not possible to blind either women or clin-
icians.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One woman lost to follow-up in the surgi-
cal group.
Selective reporting (reporting bias) Unclear risk Assessed all the prespecified outcomes from
the paper, but the trial protocol was not
assessed
Other bias Unclear risk No significant difference in baseline data
reported on the criteria assessed, but diffi-
cult to say anything about all other types of
bias
D&C: dilation and curettage
ERPC: evacuation of retained products of conception
GA: general anaesthetic
Hb: haemoglobin
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ICM: incomplete miscarriage
ITT: intention-to-treat
IUFD: intrauterine fetal death
LMP: last menstrual period
MVA: manual vacuum aspiration
POC: product of conception
RCT: randomised controlled trial
SD: standard deviation
US: ultrasound
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abd-El-Maeboud 2012 Participants were women with missed miscarriage.
Abdel 1997 Participants were women with an intrauterine fetal death.
Al Inizi 2003 Participants were women with an intrauterine fetal death.
Al-Bdour 2007 Participants were women with an intrauterine fetal death.
Almog 2005 Participants were women having a termination of pregnancy.
Altaf 2006 Mixed group of missed miscarriage, incomplete miscarriage, and termination of pregnancy for other
reasons
Amjad 1999 Participants were women with an intrauterine fetal death.
Anderman 2000 Participants were women with an intrauterine fetal death.
Anderson 2009 Medical treatment for non-viable pregnancies.
Ara 2009 Medical treatment for non-viable pregnancies.
Autry 1999 Participants were women with an intrauterine fetal death.
Avila-Vergara 1997 Participants were women with an intrauterine fetal death.
Ayudhaya 2006 Participants were women with an intrauterine fetal death.
Azra 2007 Termination of pregnancy for various reasons.
Bagratee 2004 Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have not
had a response
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(Continued)
Bani-Irshaid 2006 Participants were women having a termination of pregnancy.
Bebbington 2002 Participants were women having a termination of pregnancy.
Behrashi 2008 Participants were women having a termination of pregnancy.
Ben-Meir 2009 Participants mainly undergoing termination of pregnancy. Some with “late missed abortions”
Biswas 2007 Participants were women having a termination of pregnancy.
Cabrol 1990 Participants were women with an intrauterine fetal death.
Caliskan 2005 Participants were women having a termination of pregnancy.
Caliskan 2009 Participants were women having a second trimester termination of pregnancy, some of whom had an
intrauterine fetal death
Chittacharoen 2003 Participants were women having a termination of pregnancy.
Chung 1999 Study includedwomenwith ICMandwomenwith IUFD.We contacted the authors whowere extremely
helpful and did provide additional data which are held at the Pregnancy and Childbirth editorial office.
However, unfortunately they could not provide their data split by women with ICM and women with
IUFD so we were unable to include their data in this review
Cleeve 2015 A RCT comparing groups by provider type.
Creinin 1997 Participants were women with an intrauterine fetal death.
David 2003 Participants were women with an intrauterine fetal death.
David 2005 Participants were women with an intrauterine fetal death.
de Jonge 1995 Quasi-RCT.
Demetroulis 2001 Study included women with ICM and women with IUFD. We have contacted the authors who have
tried to help us but are unable to separate their data by women with ICM and women with IUFD
Dickinson 1998 Participants were women having a termination of pregnancy, including some with intrauterine fetal
death
Dickinson 2002 Participants were women having a termination of pregnancy, including some with intrauterine fetal
death
Dickinson 2003 Participants were women having a termination of pregnancy for fetal abnormality
Egarter 1995 Participants were women with an intrauterine fetal death.
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(Continued)
Elhassan 2008 Participants were women having a termination of pregnancy, including some with intrauterine fetal
death
Eng 1997 Participants were women with an intrauterine fetal death in the 2nd trimester
Eppel 2005 Participants were women having a termination of pregnancy in the 2nd trimester, including some with
intrauterine fetal death
Fadalla 2004 Participants were women having a termination of pregnancy in the 2nd trimester, including some with
intrauterine fetal death
Fang 2009 Participants were women with an intrauterine fetal death.
Feldman 2003 Participants were women having a termination of pregnancy in the 2nd trimester, including some with
intrauterine fetal death
Fiala 2005 Participants were women having a termination of pregnancy for fetal malformations and socioeconomic
reasons
Gazvani 2000 Study was of women with incomplete miscarriage, but it assessed surgery versus expectant care, rather
than medical management
Ghorab 1998 Participants were women having a termination of pregnancy for fetal malformations or intrauterine fetal
death
Gilles 2004 Participants were women with an intrauterine fetal death.
Gonzalez 2001 Participants were women having a termination of pregnancy for intrauterine fetal death or medical or
genetic reasons
Graziosi 2004 Participants were women with an intrauterine fetal death.
Grimes 2005 Participants were women having a termination of pregnancy, including some with intrauterine fetal
death
Gronlund 2002 Not a RCT, but a prospective cross-over study by alternate regimes every 4 months
Guix 2005 Participants were women having a termination of pregnancy. Also allocated to different treatments at
the discretion of the clinician, so not a RCT
Hassan 2007 Quasi-RCT, women allocated to groups based on alternate sequence
Hausler 1997 Participants were women with complete spontaneous miscarriage and endometrial width up to 8 mm
Heard 2002 Participants were women with an intrauterine fetal death.
Herabutya 1997a Participants were women with an intrauterine fetal death.
94Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Herabutya 1997b Participants were women with an intrauterine fetal death.
Herabutya 2005 Participants were women having a termination of pregnancy.
Hernandez-Valencia 2003 Participants were women with an intrauterine fetal death.
Hidar 2001 Participants were women having a termination of pregnancy.
Hidar 2005 Participants were women having a termination of pregnancy for intrauterine fetal death
Hill 1991 Participants were women with an intrauterine fetal death.
Hinshaw 1997 Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have not
had a response
Hogg 2000 Participants were women having a termination of pregnancy, with some for intrauterine fetal death but
mostly for fetal anomalies
Hombalegowda 2015 Reference refers to a conference abstract.
Igogo 2015 Reference refers to a conference abstract.
IRCT138902053797N1 Trial of techniques for termination of pregnancy for various reasons
Islam 2006 Participants were women with an intrauterine fetal death.
Jabir 2009 Randomised trial of medical treatments to ripen the cervix before surgical evacuation of the uterus
Jain 1994 Participants were women having a termination of pregnancy for intrauterine fetal death
Jain 1996 Participants were womenhaving a termination of pregnancy for intrauterine fetal death or fetal anomalies
Jain 1999 Participants were women having a termination of pregnancy.
Johnson 1997 Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have not
had a response
Kaluaarachchi 2015 Reference refers to a conference abstract.
Kanhai 1989 Participants were women with an intrauterine fetal death.
Kapp 2007 Participants were women having a termination of pregnancy, including women with an intrauterine
fetal death
Kara 1999 Participants were women with an intrauterine fetal death.
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(Continued)
Klingberg 2015 A RCT comparing groups by provider type.
Klingberg-Allvin 2015 A RCT comparing groups by provider type.
Kong 2013 Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have not
had a response
Kovavisarach 2002 Participants were women with an intrauterine fetal death.
Kovavisarach 2005 Participants were women with an intrauterine fetal death.
Kushwah 2009 Participants were women with an intrauterine fetal death.
Kushwah 2011 Participants were women with an intrauterine fetal death.
Lelaidier 1993 Participants were women with an intrauterine fetal death.
Lippert 1978 Not a RCT. Women were divided into 2 groups.
Lister 2005 Participants were women with an intrauterine fetal death.
Louey 2000 [pers comm] Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have not
had a response
Lu 2014 Participants were women with missed miscarriage.
Lughmani 2008 Participants were women with an intrauterine fetal death.
Machtinger 2004 Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have not
had a response
Makhlouf 2003 Participants were women having a termination of pregnancy.
Martin 1955 Not a RCT; alternate allocation.
Moran 2005 Medical treatment of ’pregnancies of undetermined location’.
Mostafa-Gharebaghi 2010 Termination of pregnancy.
Muffley 2002 Participants were women with an intrauterine fetal death.
Mulayim 2009 Participants were women with an intrauterine fetal death and some having a termination of pregnancy
Nakintu 2001 Participants were women with an intrauterine fetal death.
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(Continued)
Nasreen 2009 Participants were women with non-viable pregnancies.
NCT00141895 Participants were women with an intrauterine fetal death.
NCT00190294 Participants were women with an intrauterine fetal death.
NCT00468299 Participants were women with an intrauterine fetal death.
Ng 2015 A RCT comparing inpatient versus outpatient treatment.
Ngai 2001 Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have not
had a response
Ngoc 2004 Participants were women with an intrauterine fetal death, classified as ’missed abortion’
Nielsen 1999 Study included women with ICM and women with IUFD. We have tried to contact the authors to ask
if they could provide their data spilt by women with ICM and women with IUFD. To date we have had
no response but we are still trying to contact the authors using a different email address
Niromanesh 2005 Participants were women with an intrauterine fetal death.
Nor Azlin 2006 Participants were women having a termination of pregnancy, including women with an intrauterine
fetal death
Nuthalapaty 2005 Participants were women having a termination of pregnancy, including women with an intrauterine
fetal death
Nuutila 1997 Participants were women having a termination of pregnancy, including women with an intrauterine
fetal death
Owen 1999 Participants were women with indication for termination of pregnancy
Pansky 2011 Pilot RCT of Intercoat gel versus control for proventing adhesion
Paraskevaides 1992 Included both women with incomplete miscarriage and women with intrauterine fetal death. We were
unable to contact the authors to request split data
Perry 1999 Participants were women with indication for termination of pregnancy
Petersen 2013 Study includedwomenwith ICMandwomenwith IUFD.We contacted the authors whowere extremely
helpful and did provide additional data. However, unfortunately they could not provide their data split
by women with ICM and women with IUFD so we were unable to include their data in this review
Piotrowski 1979 Participants were women with an intrauterine fetal death.
Pongsatha 2004 Participants were women with indication for termination of pregnancy
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(Continued)
Ramsey 2004 Participants were women with indication for termination of pregnancy
Rausch 2012 Secondary analysis of study that included women with both incomplete miscarriages and non-viable
pregnancies
Rita 2006 Participants were women with an intrauterine fetal death.
Rivero-Lopez 1998 Participants were women with an intrauterine fetal death.
Roy 2003 Participants were women with indication for termination of pregnancy
Ruangchainikhom 2006 Participants were women with indication for termination of pregnancy
Saichua 2009 Participants were women with an intrauterine fetal death.
Salamalekis 1990 Not a RCT; no mention of randomisation.
Sathapanachai 2000 Participants were women with an intrauterine fetal death.
Shah 2010 Participants were women with an intrauterine fetal death.
Shaikh 2008 Participants were combined group women with an intrauterine fetal death and those with miscarriage.
Abstract only
Shobeira 2007 Participants were women with an intrauterine fetal death.
Shokry 2009 Trial of misoprostol after evacuation of uterus to try to decrease blood loss
Shuaib 2013 Participants were women with missed miscarriage.
Sonsanoh 2014 Participants were women with missed miscarriage.
Sripramote 2000 Trial of misoprostol to prime cervix before routine surgical uterine evacuation
Stockheim 2006 Participants were women with an intrauterine fetal death.
Su 2005 Participants were women with indication for termination of pregnancy
Suchonwanit 1999 Participants were women with an intrauterine fetal death.
Surita 1997 Participants were women with an intrauterine fetal death.
Tang 2003 Participantswerewomenwith ’silentmiscarriage’ andwomenwith complete and incompletemiscarriages
were excluded
Tang 2006a Participants were women with ’silent miscarriage’ and women with incomplete miscarriages were ex-
cluded
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(Continued)
Tanha 2010 Trial of treatment for non-viable pregnancies.
Thavarasah 1986 Participants were women with an intrauterine fetal death.
Thida 2015 Reference refers to a conference abstract.
Toppozada 1994 Participants were women with indication for termination of pregnancy for intrauterine fetal death
Torre 2012 Trial of treatment for combined incomplete miscarriages and non-viable pregnancies
Wood 2002 Participants were women with an intrauterine fetal death.
Yapar 1996 Participants were women with indication for termination of pregnancy including women with intrauter-
ine fetal death
Yilmaz 2005 Participants were women with indication for termination of pregnancy including women with intrauter-
ine fetal death
Yilmaz 2007 Participants were women having termination of pregnancy, some of whom had an intrauterine fetal
death
Yu 2000 Participants were women with missed miscarriage.
Zhang 2000 Study of techniques of induction of labour.
ICM: incomplete miscarriage
IUFD: intrauterine fetal death
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
ISRCTN65305620
Trial name or title Is misoprostol a safe alternative to manual vacuum aspiration in women with incomplete abortions in devel-
oping countries?
Methods Evaluator-blinded, single-centre, randomised controlled non-inferiority trial
Participants Women with first trimester pregnancy loss
Interventions Intervention: sublingual misoprostol - 600 mcg (3 doses of 200 ug each every 4 hours)
Comparison: surgery (MVA)
Outcomes Ultrasonagraphic thickness; change in Hb; pain; adverse effects; women’s satisfaction and acceptability
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ISRCTN65305620 (Continued)
Starting date 11 February 2008
Contact information Dr Regina Unkels, PO Box 97, Lindi, Tanzania
Notes Study No: ISRCTN65305620
Website: www.tgpsh.or.tz
NCT01033903
Trial name or title Which is the optimal treatment for miscarriage with a gestational sac in the uterus and which factors can
predict if the treatment will be successful?
Methods Open-label, randomised controlled trial
Participants Women with incomplete miscarriage before 14 weeks and a gestational sac retained in the uterus
Interventions Intervention: misoprostol 800 mcg intravaginally once
Comparison: expectant management
Outcomes Primary outcome: complete miscarriage at 10 day follow-up
Secondary outcome: complete miscarriage at 17 days, 24 days, 31 days follow-up
Starting date October 2008
Contact information Contact information no longer displayed due to end of recruitment
Notes Location: Sweden
Study identifier: NCT01033903
Hb: haemoglobin
MVA: manual vacuum aspiration
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D A T A A N D A N A L Y S E S
Comparison 1. Misoprostol versus expectant care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Vaginal misoprostol 2 150 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.72, 2.10]
1.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Vaginal misoprostol 2 308 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.17, 2.26]
2.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Death or serious complication 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Vaginal misoprostol 1 126 Risk Ratio (M-H, Random, 95% CI) 2.91 [0.12, 70.05]
3.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Unplanned surgical intervention 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Vaginal misoprostol 2 308 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.17, 2.26]
4.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Blood transfusion 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Vaginal misoprostol 3 332 Risk Ratio (M-H, Random, 95% CI) 3.07 [0.13, 74.28]
5.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Pain relief 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Vaginal misoprostol 2 308 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.67, 1.88]
6.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Pelvic infection < 14 days 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Vaginal misoprostol 3 333 Risk Ratio (M-H, Random, 95% CI) 2.42 [0.59, 9.98]
7.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Misoprostol versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 15 3862 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.94, 0.98]
1.1 Vaginal misoprostol 5 364 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.85, 0.95]
1.2 Oral misoprostol 7 1884 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.95, 1.00]
1.3 Vaginal + oral misoprostol 1 80 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.04]
1.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.5 Sublingual misoprostol 2 1534 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.92, 1.01]
2 Surgical evacuation 13 3070 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.02, 0.11]
2.1 Vaginal misoprostol 4 411 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.07, 0.35]
2.2 Oral misoprostol 7 1884 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.02, 0.07]
2.3 Vaginal + oral misoprostol 1 80 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.01, 0.18]
2.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Sublingual misoprostol 1 695 Risk Ratio (M-H, Random, 95% CI) 0.02 [0.01, 0.04]
3 Death or serious complication 5 1248 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.04, 22.64]
3.1 Vaginal misoprostol 2 132 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.04, 22.64]
3.2 Oral misoprostol 2 421 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Sublingual misoprostol 1 695 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Unplanned surgical intervention 11 2690 Risk Ratio (M-H, Random, 95% CI) 5.03 [2.71, 9.35]
4.1 Vaginal misoprostol 4 411 Risk Ratio (M-H, Random, 95% CI) 4.29 [1.24, 14.87]
4.2 Oral misoprostol 6 1584 Risk Ratio (M-H, Random, 95% CI) 5.25 [2.07, 13.32]
4.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Sublingual misoprostol 1 695 Risk Ratio (M-H, Random, 95% CI) 5.98 [0.72, 49.43]
5 Blood transfusion 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Vaginal misoprostol 3 241 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.19, 16.08]
5.2 Oral misoprostol 1 189 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Blood loss 1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Vaginal misoprostol 1 96 Mean Difference (IV, Random, 95% CI) 0.03 [-0.02, 0.08]
6.2 Oral misoprostol 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Vaginal + oral misoprostol 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 Rectal misoprostol 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.5 Sublingual misoprostol 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Anaemia 2 731 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.17, 4.12]
7.1 Vaginal misoprostol 1 36 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.24, 12.24]
7.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.5 Sublingual misoprostol 1 695 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.18]
8 Days of bleeding 3 211 Mean Difference (IV, Random, 95% CI) 2.12 [1.18, 3.07]
8.1 Vaginal misoprostol 2 131 Mean Difference (IV, Random, 95% CI) 2.76 [1.55, 3.97]
8.2 Oral misoprostol 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Vaginal + oral misoprostol 1 80 Mean Difference (IV, Random, 95% CI) 1.55 [0.58, 2.52]
8.4 Rectal misoprostol 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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8.5 Sublingual misoprostol 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Pain relief 4 525 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.67, 3.25]
9.1 Vaginal misoprostol 3 313 Risk Ratio (M-H, Random, 95% CI) 1.64 [1.05, 2.55]
9.2 Oral misoprostol 1 212 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.77, 0.92]
9.3 Vaginal + oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Pelvic infection < 14 days 7 907 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.25, 1.99]
10.1 Vaginal misoprostol 4 338 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.29, 4.44]
10.2 Oral misoprostol 2 489 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.03, 2.41]
10.3 Vaginal + oral
misoprostol
1 80 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.30]
10.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Cervical damage 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Vaginal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Oral misoprostol 1 189 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.25]
11.3 Vaginal + oral
misoprostol
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Digestive disorders 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Vaginal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Oral misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.3 Vaginal + oral
misoprostol
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.5 Sublingual misoprostol 1 516 Risk Ratio (M-H, Random, 95% CI) 3.90 [1.81, 8.42]
13 Women’s views/acceptability of
method
9 3349 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.99, 1.00]
13.1 Vaginal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Oral misoprostol 7 1875 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.99, 1.00]
13.3 Vaginal + oral
misoprostol
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.5 Sublingual misoprostol 2 1474 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.98, 1.01]
14 Women’s views/satisfaction -
continuous data
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Vaginal misoprostol 2 131 Std. Mean Difference (IV, Random, 95% CI) 1.01 [0.01, 2.00]
14.2 Oral misoprostol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.3 Vaginal + oral
misoprostol
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.4 Rectal misoprostol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.5 Sublingual misoprostol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Nausea 11 3015 Risk Ratio (M-H, Random, 95% CI) 2.50 [1.53, 4.09]
15.1 Vaginal misoprostol 3 156 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.61, 3.48]
15.2 Oral misoprostol 6 1700 Risk Ratio (M-H, Random, 95% CI) 2.97 [1.54, 5.74]
15.3 Vaginal + oral
misoprostol
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.5 Sublingual misoprostol 2 1159 Risk Ratio (M-H, Random, 95% CI) 2.85 [0.70, 11.53]
16 Vomiting 10 2977 Risk Ratio (M-H, Random, 95% CI) 1.97 [1.36, 2.85]
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16.1 Vaginal misoprostol 2 131 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.12, 13.73]
16.2 Oral misoprostol 6 1687 Risk Ratio (M-H, Random, 95% CI) 1.84 [1.07, 3.14]
16.3 Vaginal + oral
misoprostol
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.5 Sublingual misoprostol 2 1159 Risk Ratio (M-H, Random, 95% CI) 2.90 [0.84, 9.96]
17 Diarrhoea 4 757 Risk Ratio (M-H, Random, 95% CI) 4.82 [1.09, 21.32]
17.1 Vaginal misoprostol 2 131 Risk Ratio (M-H, Random, 95% CI) 4.09 [0.51, 32.97]
17.2 Oral misoprostol 2 626 Risk Ratio (M-H, Random, 95% CI) 5.72 [0.69, 47.40]
17.3 Vaginal + oral
misoprostol
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.4 Rectal misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.5 Sublingual misoprostol 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Vaginal misoprostol versus expectant care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 2 150 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.72, 2.10]
1.2 Geststion 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Gestation < 13 weeks 2 308 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.17, 2.26]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Death or serious complication 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Gestation < 13 weeks 1 126 Risk Ratio (M-H, Fixed, 95% CI) 2.91 [0.12, 70.05]
3.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Unplanned surgical intervention 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 2 308 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.17, 2.26]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Blood transfusion 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gestation < 13 weeks 3 332 Risk Ratio (M-H, Fixed, 95% CI) 3.07 [0.13, 74.28]
5.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Pain relief 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Gestation < 13 weeks 2 308 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.67, 1.88]
6.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Pelvic infection < 14 days 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Gestation < 13 weeks 3 333 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.77, 10.33]
7.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 4. Vaginal misoprostol versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 5 364 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.84, 0.95]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Gestation < 13 weeks 4 411 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.07, 0.35]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Death or serious complication 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Gestation < 13 weeks 2 132 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.04, 22.64]
3.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Unplanned surgical intervention 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 4 411 Risk Ratio (M-H, Random, 95% CI) 4.29 [1.24, 14.87]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Blood transfusion 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gestation < 13 weeks 3 241 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [0.21, 15.70]
5.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Anaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Gestation < 13 weeks 1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.24, 12.24]
6.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Days of bleeding 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Gestation < 13 weeks 2 131 Mean Difference (IV, Fixed, 95% CI) 2.76 [1.55, 3.97]
7.2 Gestation 13-23 weeks 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Gestation not specified 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Pain relief 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Gestation < 13 weeks 3 313 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.21, 2.54]
8.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Pelvic infection < 14 days 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Gestation < 13 weeks 4 338 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.37, 4.42]
9.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Women’s views/satisfaction -
continuous data
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Gestation < 13 weeks 2 131 Std. Mean Difference (IV, Random, 95% CI) 1.01 [0.01, 2.00]
10.2 Gestation 13-23 weeks 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Gestation not specified 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Nausea 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Gestation < 13 weeks 3 156 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.58, 3.22]
11.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Vomiting 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Gestation < 13 weeks 2 131 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.25, 8.93]
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12.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Diarrhoea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Gestation < 13 weeks 2 131 Risk Ratio (M-H, Fixed, 95% CI) 4.30 [0.52, 35.36]
13.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Oral misoprostol versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 7 1884 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.95, 1.00]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Gestation < 13 weeks 7 1884 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.02, 0.07]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Unplanned surgical intervention 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Gestation < 13 weeks 6 1584 Risk Ratio (M-H, Fixed, 95% CI) 6.27 [2.57, 15.31]
3.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Blood transfusion 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 1 189 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Pain relief 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gestation < 13 weeks 1 212 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.77, 0.92]
5.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Pelvic infection 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Gestation < 13 weeks 2 489 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.03, 2.41]
6.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Cervical damage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Gestation < 13 weeks 1 189 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.25]
7.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Women’s views/acceptability of
method
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Gestation < 13 weeks 7 1875 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.98, 1.01]
8.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Nausea 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Gestation < 13 weeks 6 1700 Risk Ratio (M-H, Fixed, 95% CI) 3.24 [2.10, 4.98]
9.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Vomiting 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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10.1 Gestation < 13 weeks 6 1687 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [1.18, 3.34]
10.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Diarrhoea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Gestation < 13 weeks 2 626 Risk Ratio (M-H, Fixed, 95% CI) 5.79 [0.70, 47.64]
11.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Vaginal + oral misoprostol versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.87, 1.04]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Gestation < 13 weeks 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.01, 0.18]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Days of bleeding 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Gestation < 13 weeks 1 80 Mean Difference (IV, Fixed, 95% CI) 1.55 [0.58, 2.52]
3.2 Gestation 13-23 weeks 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Pelvic infection 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.30]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Sublingual misoprostol versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 2 1534 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.95, 0.98]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Gestation <13 weeks 1 695 Risk Ratio (M-H, Fixed, 95% CI) 0.02 [0.01, 0.04]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Unplanned surgical intervention 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Gestation < 13 weeks 1 695 Risk Ratio (M-H, Fixed, 95% CI) 5.98 [0.72, 49.43]
3.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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4 Anaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 1 695 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.18]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Digestive disorders 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gestation < 13 weeks 1 516 Risk Ratio (M-H, Fixed, 95% CI) 3.90 [1.81, 8.42]
5.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Women’s views/acceptability of
method
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Gestation < 13 weeks 2 1474 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.98, 1.01]
6.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Nausea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Gestation < 13 weeks 2 1159 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.48, 2.32]
7.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Vomiting 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Gestation < 13 weeks 2 1159 Risk Ratio (M-H, Fixed, 95% CI) 2.42 [1.43, 4.10]
8.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 8. Vaginal misoprostol versus oral misoprostol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.76, 1.16]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Gestation < 13 weeks 1 198 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.77, 1.60]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Unplanned surgical intervention 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Gestation < 13 weeks 1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 8.80]
3.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Pain relief 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 1 186 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.93, 2.17]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gestation < 13 weeks 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.26, 1.54]
5.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Gestation < 13 weeks 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.75]
6.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Gestation < 13 weeks 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.12, 0.36]
7.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 9. Oral misoprostol: 600 ug versus 1200 ug
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 2 464 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.93, 1.07]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Gestation < 13 weeks 1 295 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.29, 1.99]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Death or serious complication 1 295 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.1 Gestation < 13 weeks 1 295 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Unplanned surgical intervention 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 1 295 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.29, 1.99]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Women’s views/acceptability of
method
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Gestation < 13 weeks 2 460 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.96, 1.09]
5.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Nausea 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Gestation < 13 weeks 2 463 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.57, 2.46]
6.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Gestation not specified 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Vomiting 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Gestation < 13 weeks 2 463 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.60, 1.72]
7.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Gestation < 13 weeks 1 294 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.55, 0.97]
8.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 10. Oral mifepristone + vaginal misoprostol versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 1 19 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.77, 1.31]
1.1 Gestation < 13 weeks 1 16 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.78, 1.27]
1.2 Gestation 13-23 weeks 1 3 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.39, 2.58]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Pelvic infection < 14 days 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.1 Gestation < 13 weeks 1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Gestation 13-23 weeks 1 3 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Vaginal prostaglandin E1 (gemeprost) versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Unplanned surgical intervention 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.1 Gestation < 13 weeks 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. Sublingual misoprostol versus oral misoprostol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete miscarriage 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Gestation < 13 weeks 2 358 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.94, 1.05]
1.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Surgical evacuation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Gestation < 13 weeks 1 294 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.39, 2.63]
2.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Death or serious complication 2 358 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.1 Gestation < 13 weeks 2 358 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Nausea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Gestation < 13 weeks 2 358 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.49, 1.23]
4.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Vomiting 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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5.1 Gestation < 13 weeks 2 358 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.14, 7.10]
5.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Diarrhoea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Gestation < 13 weeks 2 358 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.66, 3.76]
6.2 Gestation 13-23 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Gestation not specified 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Women’s views/acceptability of
method
2 358 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.95, 1.03]
Analysis 1.1. Comparison 1 Misoprostol versus expectant care, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 1 Misoprostol versus expectant care
Outcome: 1 Complete miscarriage
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Blohm 2005 52/64 32/62 53.0 % 1.57 [ 1.20, 2.06 ]
Shelley 2005 8/10 12/14 47.0 % 0.93 [ 0.64, 1.36 ]
Subtotal (95% CI) 74 76 100.0 % 1.23 [ 0.72, 2.10 ]
Total events: 60 (Misoprostol), 44 (Expectant care)
Heterogeneity: Tau2 = 0.12; Chi2 = 5.37, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
0.01 0.1 1 10 100
Favours expectant care Favours misoprostol
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(. . . Continued)
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours expectant care Favours misoprostol
Analysis 1.2. Comparison 1 Misoprostol versus expectant care, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 1 Misoprostol versus expectant care
Outcome: 2 Surgical evacuation
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Blohm 2005 8/64 25/62 47.9 % 0.31 [ 0.15, 0.63 ]
Trinder 2006 26/90 23/92 52.1 % 1.16 [ 0.72, 1.87 ]
Subtotal (95% CI) 154 154 100.0 % 0.62 [ 0.17, 2.26 ]
Total events: 34 (Misoprostol), 48 (Expectant care)
Heterogeneity: Tau2 = 0.78; Chi2 = 9.11, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.73 (P = 0.46)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
0.01 0.1 1 10 100
Favours misoprostol Favours expectant care
(Continued . . . )
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(. . . Continued)
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Misoprostol versus expectant care, Outcome 3 Death or serious complication.
Review: Medical treatments for incomplete miscarriage
Comparison: 1 Misoprostol versus expectant care
Outcome: 3 Death or serious complication
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Blohm 2005 1/64 0/62 100.0 % 2.91 [ 0.12, 70.05 ]
Subtotal (95% CI) 64 62 100.0 % 2.91 [ 0.12, 70.05 ]
Total events: 1 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Misoprostol versus expectant care, Outcome 4 Unplanned surgical intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 1 Misoprostol versus expectant care
Outcome: 4 Unplanned surgical intervention
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Blohm 2005 8/64 25/62 47.9 % 0.31 [ 0.15, 0.63 ]
Trinder 2006 26/90 23/92 52.1 % 1.16 [ 0.72, 1.87 ]
Subtotal (95% CI) 154 154 100.0 % 0.62 [ 0.17, 2.26 ]
Total events: 34 (Misoprostol), 48 (Expectant care)
Heterogeneity: Tau2 = 0.78; Chi2 = 9.11, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.73 (P = 0.46)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Misoprostol versus expectant care, Outcome 5 Blood transfusion.
Review: Medical treatments for incomplete miscarriage
Comparison: 1 Misoprostol versus expectant care
Outcome: 5 Blood transfusion
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Blohm 2005 0/64 0/62 Not estimable
Shelley 2005 0/10 0/14 Not estimable
Trinder 2006 1/90 0/92 100.0 % 3.07 [ 0.13, 74.28 ]
Subtotal (95% CI) 164 168 100.0 % 3.07 [ 0.13, 74.28 ]
Total events: 1 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Misoprostol versus expectant care, Outcome 6 Pain relief.
Review: Medical treatments for incomplete miscarriage
Comparison: 1 Misoprostol versus expectant care
Outcome: 6 Pain relief
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Blohm 2005 53/64 38/62 62.1 % 1.35 [ 1.08, 1.70 ]
Trinder 2006 17/90 21/92 37.9 % 0.83 [ 0.47, 1.46 ]
Subtotal (95% CI) 154 154 100.0 % 1.12 [ 0.67, 1.88 ]
Total events: 70 (Misoprostol), 59 (Expectant care)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.99, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Misoprostol versus expectant care, Outcome 7 Pelvic infection < 14 days.
Review: Medical treatments for incomplete miscarriage
Comparison: 1 Misoprostol versus expectant care
Outcome: 7 Pelvic infection < 14 days
Study or subgroup Misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Blohm 2005 3/64 0/62 23.2 % 6.78 [ 0.36, 128.70 ]
Shelley 2005 2/11 0/14 23.3 % 6.25 [ 0.33, 118.22 ]
Trinder 2006 2/90 2/92 53.5 % 1.02 [ 0.15, 7.10 ]
Subtotal (95% CI) 165 168 100.0 % 2.42 [ 0.59, 9.98 ]
Total events: 7 (Misoprostol), 2 (Expectant care)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Misoprostol versus surgery, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 1 Complete miscarriage
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Ganguly 2010 63/77 37/37 2.7 % 0.82 [ 0.74, 0.92 ]
Moodliar 2005 43/47 47/47 3.5 % 0.92 [ 0.83, 1.01 ]
Patua 2013 42/46 48/50 3.0 % 0.95 [ 0.86, 1.06 ]
Shelley 2005 8/10 11/11 0.4 % 0.81 [ 0.57, 1.13 ]
Zhang 2005 25/30 8/9 0.5 % 0.94 [ 0.71, 1.24 ]
Subtotal (95% CI) 210 154 10.0 % 0.90 [ 0.85, 0.95 ]
Total events: 181 (Misoprostol), 151 (Surgery)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.02, df = 4 (P = 0.40); I2 =0%
Test for overall effect: Z = 3.62 (P = 0.00030)
2 Oral misoprostol
Bique 2007 101/111 101/101 6.2 % 0.91 [ 0.86, 0.97 ]
Chigbu 2012 158/160 160/160 11.7 % 0.99 [ 0.97, 1.01 ]
Dao 2007 206/218 222/224 9.7 % 0.95 [ 0.92, 0.99 ]
Montesinos 2011 100/106 97/97 7.5 % 0.94 [ 0.90, 0.99 ]
Shwekerela 2007 149/150 150/150 12.0 % 0.99 [ 0.98, 1.01 ]
Taylor 2011 106/108 109/110 10.2 % 0.99 [ 0.96, 1.02 ]
Weeks 2005 103/107 75/82 4.8 % 1.05 [ 0.98, 1.14 ]
Subtotal (95% CI) 960 924 62.0 % 0.98 [ 0.95, 1.00 ]
Total events: 923 (Misoprostol), 914 (Surgery)
Heterogeneity: Tau2 = 0.00; Chi2 = 19.16, df = 6 (P = 0.004); I2 =69%
Test for overall effect: Z = 2.07 (P = 0.039)
3 Vaginal + oral misoprostol
Sahin 2001 38/40 40/40 4.1 % 0.95 [ 0.87, 1.04 ]
Subtotal (95% CI) 40 40 4.1 % 0.95 [ 0.87, 1.04 ]
Total events: 38 (Misoprostol), 40 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
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(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 342/348 346/347 12.4 % 0.99 [ 0.97, 1.00 ]
Shochet 2012 439/465 374/374 11.5 % 0.94 [ 0.92, 0.97 ]
Subtotal (95% CI) 813 721 23.9 % 0.97 [ 0.92, 1.01 ]
Total events: 781 (Misoprostol), 720 (Surgery)
Heterogeneity: Tau2 = 0.00; Chi2 = 11.95, df = 1 (P = 0.00055); I2 =92%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 2023 1839 100.0 % 0.96 [ 0.94, 0.98 ]
Total events: 1923 (Misoprostol), 1825 (Surgery)
Heterogeneity: Tau2 = 0.00; Chi2 = 52.74, df = 14 (P<0.00001); I2 =73%
Test for overall effect: Z = 3.48 (P = 0.00049)
Test for subgroup differences: Chi2 = 6.84, df = 3 (P = 0.08), I2 =56%
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Analysis 2.2. Comparison 2 Misoprostol versus surgery, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 2 Surgical evacuation
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 4/47 47/47 7.9 % 0.09 [ 0.04, 0.23 ]
Patua 2013 4/46 50/50 7.9 % 0.10 [ 0.04, 0.23 ]
Trinder 2006 26/90 78/92 8.8 % 0.34 [ 0.24, 0.48 ]
Zhang 2005 4/30 9/9 8.0 % 0.15 [ 0.06, 0.36 ]
Subtotal (95% CI) 213 198 32.6 % 0.16 [ 0.07, 0.35 ]
Total events: 38 (Misoprostol), 184 (Surgery)
Heterogeneity: Tau2 = 0.52; Chi2 = 15.37, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 4.54 (P < 0.00001)
2 Oral misoprostol
Bique 2007 10/111 101/101 8.5 % 0.09 [ 0.05, 0.17 ]
Chigbu 2012 2/160 160/160 7.2 % 0.02 [ 0.00, 0.05 ]
Dao 2007 12/218 222/224 8.5 % 0.06 [ 0.03, 0.10 ]
Montesinos 2011 6/106 97/97 8.2 % 0.06 [ 0.03, 0.13 ]
Shwekerela 2007 1/150 150/150 6.4 % 0.01 [ 0.00, 0.05 ]
Taylor 2011 1/108 110/110 6.4 % 0.01 [ 0.00, 0.07 ]
Weeks 2005 4/107 76/82 7.8 % 0.04 [ 0.02, 0.11 ]
Subtotal (95% CI) 960 924 52.8 % 0.04 [ 0.02, 0.07 ]
Total events: 36 (Misoprostol), 916 (Surgery)
Heterogeneity: Tau2 = 0.38; Chi2 = 17.99, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 10.79 (P < 0.00001)
3 Vaginal + oral misoprostol
Sahin 2001 1/40 40/40 6.4 % 0.04 [ 0.01, 0.18 ]
Subtotal (95% CI) 40 40 6.4 % 0.04 [ 0.01, 0.18 ]
Total events: 1 (Misoprostol), 40 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
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(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 6/348 347/347 8.2 % 0.02 [ 0.01, 0.04 ]
Subtotal (95% CI) 348 347 8.2 % 0.02 [ 0.01, 0.04 ]
Total events: 6 (Misoprostol), 347 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 10.25 (P < 0.00001)
Total (95% CI) 1561 1509 100.0 % 0.05 [ 0.02, 0.11 ]
Total events: 81 (Misoprostol), 1487 (Surgery)
Heterogeneity: Tau2 = 1.64; Chi2 = 145.09, df = 12 (P<0.00001); I2 =92%
Test for overall effect: Z = 7.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 14.82, df = 3 (P = 0.00), I2 =80%
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Analysis 2.3. Comparison 2 Misoprostol versus surgery, Outcome 3 Death or serious complication.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 3 Death or serious complication
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 0/47 0/47 Not estimable
Zhang 2005 1/29 0/9 100.0 % 1.00 [ 0.04, 22.64 ]
Subtotal (95% CI) 76 56 100.0 % 1.00 [ 0.04, 22.64 ]
Total events: 1 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Oral misoprostol
Montesinos 2011 0/106 0/97 Not estimable
Taylor 2011 0/108 0/110 Not estimable
Subtotal (95% CI) 214 207 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 0/348 0/347 Not estimable
Subtotal (95% CI) 348 347 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 638 610 100.0 % 1.00 [ 0.04, 22.64 ]
Total events: 1 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Misoprostol versus surgery, Outcome 4 Unplanned surgical intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 4 Unplanned surgical intervention
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 4/47 0/47 4.6 % 9.00 [ 0.50, 162.62 ]
Patua 2013 4/46 2/50 14.1 % 2.17 [ 0.42, 11.31 ]
Trinder 2006 26/90 2/92 19.4 % 13.29 [ 3.25, 54.35 ]
Zhang 2005 4/30 1/9 9.0 % 1.20 [ 0.15, 9.42 ]
Subtotal (95% CI) 213 198 47.1 % 4.29 [ 1.24, 14.87 ]
Total events: 38 (Misoprostol), 5 (Surgery)
Heterogeneity: Tau2 = 0.67; Chi2 = 5.18, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 2.30 (P = 0.021)
2 Oral misoprostol
Bique 2007 10/111 0/101 4.8 % 19.13 [ 1.14, 322.25 ]
Chigbu 2012 2/160 0/160 4.2 % 5.00 [ 0.24, 103.33 ]
Dao 2007 12/218 2/224 17.4 % 6.17 [ 1.40, 27.23 ]
Montesinos 2011 6/106 0/97 4.7 % 11.91 [ 0.68, 208.61 ]
Taylor 2011 1/108 1/110 5.0 % 1.02 [ 0.06, 16.08 ]
Weeks 2005 4/107 1/82 8.1 % 3.07 [ 0.35, 26.91 ]
Subtotal (95% CI) 810 774 44.3 % 5.25 [ 2.07, 13.32 ]
Total events: 35 (Misoprostol), 4 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.90, df = 5 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.49 (P = 0.00048)
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 6/348 1/347 8.6 % 5.98 [ 0.72, 49.43 ]
Subtotal (95% CI) 348 347 8.6 % 5.98 [ 0.72, 49.43 ]
Total events: 6 (Misoprostol), 1 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Total (95% CI) 1371 1319 100.0 % 5.03 [ 2.71, 9.35 ]
Total events: 79 (Misoprostol), 10 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.07, df = 10 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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Analysis 2.5. Comparison 2 Misoprostol versus surgery, Outcome 5 Blood transfusion.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 5 Blood transfusion
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Shelley 2005 0/10 0/11 Not estimable
Trinder 2006 1/90 0/92 48.9 % 3.07 [ 0.13, 74.28 ]
Zhang 2005 1/29 0/9 51.1 % 1.00 [ 0.04, 22.64 ]
Subtotal (95% CI) 129 112 100.0 % 1.73 [ 0.19, 16.08 ]
Total events: 2 (Misoprostol), 0 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Oral misoprostol
Weeks 2005 0/107 0/82 Not estimable
Subtotal (95% CI) 107 82 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Misoprostol versus surgery, Outcome 6 Blood loss.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 6 Blood loss
Study or subgroup Misoprostol Surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vaginal misoprostol
Patua 2013 46 0.22 (0.13) 50 0.19 (0.12) 100.0 % 0.03 [ -0.02, 0.08 ]
Subtotal (95% CI) 46 50 100.0 % 0.03 [ -0.02, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Misoprostol versus surgery, Outcome 7 Anaemia.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 7 Anaemia
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Zhang 2005 6/28 1/8 56.0 % 1.71 [ 0.24, 12.24 ]
Subtotal (95% CI) 28 8 56.0 % 1.71 [ 0.24, 12.24 ]
Total events: 6 (Misoprostol), 1 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 1/348 3/347 44.0 % 0.33 [ 0.03, 3.18 ]
Subtotal (95% CI) 348 347 44.0 % 0.33 [ 0.03, 3.18 ]
Total events: 1 (Misoprostol), 3 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 376 355 100.0 % 0.83 [ 0.17, 4.12 ]
Total events: 7 (Misoprostol), 4 (Surgery)
Heterogeneity: Tau2 = 0.18; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 1.15, df = 1 (P = 0.28), I2 =13%
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Analysis 2.8. Comparison 2 Misoprostol versus surgery, Outcome 8 Days of bleeding.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 8 Days of bleeding
Study or subgroup Misoprostol Surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vaginal misoprostol
Moodliar 2005 47 7 (3.4) 47 4.4 (3.2) 35.9 % 2.60 [ 1.27, 3.93 ]
Zhang 2005 28 11.3 (2.7) 9 7.8 (4.1) 10.1 % 3.50 [ 0.64, 6.36 ]
Subtotal (95% CI) 75 56 45.9 % 2.76 [ 1.55, 3.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.47 (P < 0.00001)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Sahin 2001 40 6.45 (2.23) 40 4.9 (2.19) 54.1 % 1.55 [ 0.58, 2.52 ]
Subtotal (95% CI) 40 40 54.1 % 1.55 [ 0.58, 2.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 115 96 100.0 % 2.12 [ 1.18, 3.07 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 2.66, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 4.39 (P = 0.000011)
Test for subgroup differences: Chi2 = 2.35, df = 1 (P = 0.13), I2 =57%
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Analysis 2.9. Comparison 2 Misoprostol versus surgery, Outcome 9 Pain relief.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 9 Pain relief
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 28/47 18/47 29.7 % 1.56 [ 1.01, 2.40 ]
Trinder 2006 17/90 12/92 26.3 % 1.45 [ 0.73, 2.86 ]
Zhang 2005 20/28 1/9 11.6 % 6.43 [ 1.00, 41.41 ]
Subtotal (95% CI) 165 148 67.5 % 1.64 [ 1.05, 2.55 ]
Total events: 65 (Misoprostol), 31 (Surgery)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.20 (P = 0.028)
2 Oral misoprostol
Bique 2007 92/111 99/101 32.5 % 0.85 [ 0.77, 0.92 ]
Subtotal (95% CI) 111 101 32.5 % 0.85 [ 0.77, 0.92 ]
Total events: 92 (Misoprostol), 99 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00022)
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 276 249 100.0 % 1.48 [ 0.67, 3.25 ]
Total events: 157 (Misoprostol), 130 (Surgery)
Heterogeneity: Tau2 = 0.50; Chi2 = 31.44, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 8.31, df = 1 (P = 0.00), I2 =88%
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Analysis 2.10. Comparison 2 Misoprostol versus surgery, Outcome 10 Pelvic infection < 14 days.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 10 Pelvic infection < 14 days
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 0/47 0/47 Not estimable
Shelley 2005 2/11 0/12 12.7 % 5.42 [ 0.29, 101.77 ]
Trinder 2006 2/90 3/92 35.0 % 0.68 [ 0.12, 3.98 ]
Zhang 2005 1/30 0/9 11.2 % 0.97 [ 0.04, 21.92 ]
Subtotal (95% CI) 178 160 58.8 % 1.14 [ 0.29, 4.44 ]
Total events: 5 (Misoprostol), 3 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Oral misoprostol
Shwekerela 2007 0/150 0/150 Not estimable
Weeks 2005 1/107 3/82 21.6 % 0.26 [ 0.03, 2.41 ]
Subtotal (95% CI) 257 232 21.6 % 0.26 [ 0.03, 2.41 ]
Total events: 1 (Misoprostol), 3 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
3 Vaginal + oral misoprostol
Sahin 2001 1/40 2/40 19.6 % 0.50 [ 0.05, 5.30 ]
Subtotal (95% CI) 40 40 19.6 % 0.50 [ 0.05, 5.30 ]
Total events: 1 (Misoprostol), 2 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: not applicable
Total (95% CI) 475 432 100.0 % 0.70 [ 0.25, 1.99 ]
Total events: 7 (Misoprostol), 8 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.78, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Chi2 = 1.34, df = 2 (P = 0.51), I2 =0.0%
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Analysis 2.11. Comparison 2 Misoprostol versus surgery, Outcome 11 Cervical damage.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 11 Cervical damage
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Oral misoprostol
Weeks 2005 0/107 5/82 100.0 % 0.07 [ 0.00, 1.25 ]
Subtotal (95% CI) 107 82 100.0 % 0.07 [ 0.00, 1.25 ]
Total events: 0 (Misoprostol), 5 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Misoprostol versus surgery, Outcome 12 Digestive disorders.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 12 Digestive disorders
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Shochet 2012 51/336 7/180 100.0 % 3.90 [ 1.81, 8.42 ]
Subtotal (95% CI) 336 180 100.0 % 3.90 [ 1.81, 8.42 ]
Total events: 51 (Misoprostol), 7 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Misoprostol versus surgery, Outcome 13 Women’s views/acceptability of
method.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 13 Women’s views/acceptability of method
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Oral misoprostol
Bique 2007 107/111 101/101 3.7 % 0.96 [ 0.93, 1.00 ]
Chigbu 2012 160/160 160/160 40.6 % 1.00 [ 0.99, 1.01 ]
Dao 2007 210/218 215/224 4.3 % 1.00 [ 0.97, 1.04 ]
Montesinos 2011 102/106 94/97 2.2 % 0.99 [ 0.94, 1.05 ]
Shwekerela 2007 149/150 150/150 17.7 % 0.99 [ 0.98, 1.01 ]
Taylor 2011 103/108 108/110 2.5 % 0.97 [ 0.93, 1.02 ]
Weeks 2005 99/105 71/75 1.2 % 1.00 [ 0.93, 1.07 ]
Subtotal (95% CI) 958 917 72.3 % 1.00 [ 0.99, 1.00 ]
Total events: 930 (Misoprostol), 899 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.95, df = 6 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 337/348 341/347 10.9 % 0.99 [ 0.96, 1.01 ]
Shochet 2012 452/459 314/320 16.8 % 1.00 [ 0.98, 1.02 ]
Subtotal (95% CI) 807 667 27.7 % 1.00 [ 0.98, 1.01 ]
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(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 789 (Misoprostol), 655 (Surgery)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI) 1765 1584 100.0 % 1.00 [ 0.99, 1.00 ]
Total events: 1719 (Misoprostol), 1554 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.06, df = 8 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 2.14. Comparison 2 Misoprostol versus surgery, Outcome 14 Women’s views/satisfaction -
continuous data.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 14 Women’s views/satisfaction - continuous data
Study or subgroup Misoprostol Surgery
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vaginal misoprostol
Moodliar 2005 47 8.43 (2.1) 47 7.3 (1.87) 56.7 % 0.56 [ 0.15, 0.98 ]
Zhang 2005 28 4.8 (0.5) 9 3.3 (1.7) 43.3 % 1.59 [ 0.75, 2.43 ]
Subtotal (95% CI) 75 56 100.0 % 1.01 [ 0.01, 2.00 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 4.58, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.98 (P = 0.047)
2 Oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal + oral misoprostol
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(. . . Continued)
Study or subgroup Misoprostol Surgery
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Misoprostol versus surgery, Outcome 15 Nausea.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 15 Nausea
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 0/47 1/47 2.1 % 0.33 [ 0.01, 7.98 ]
Shelley 2005 2/13 1/12 3.8 % 1.85 [ 0.19, 17.84 ]
Zhang 2005 15/28 3/9 11.0 % 1.61 [ 0.60, 4.31 ]
Subtotal (95% CI) 88 68 17.0 % 1.46 [ 0.61, 3.48 ]
Total events: 17 (Misoprostol), 5 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Oral misoprostol
Bique 2007 13/111 2/101 7.2 % 5.91 [ 1.37, 25.57 ]
Chigbu 2012 8/160 7/160 11.0 % 1.14 [ 0.42, 3.08 ]
Dao 2007 12/223 2/224 7.0 % 6.03 [ 1.36, 26.62 ]
Montesinos 2011 5/106 0/97 2.5 % 10.07 [ 0.56, 179.84 ]
Shwekerela 2007 38/150 9/150 14.3 % 4.22 [ 2.12, 8.42 ]
Taylor 2011 7/108 5/110 9.8 % 1.43 [ 0.47, 4.36 ]
Subtotal (95% CI) 858 842 51.9 % 2.97 [ 1.54, 5.74 ]
Total events: 83 (Misoprostol), 25 (Surgery)
Heterogeneity: Tau2 = 0.27; Chi2 = 8.80, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 3.25 (P = 0.0011)
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 132/327 83/316 19.2 % 1.54 [ 1.22, 1.93 ]
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(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Shochet 2012 56/336 5/180 12.0 % 6.00 [ 2.45, 14.71 ]
Subtotal (95% CI) 663 496 31.1 % 2.85 [ 0.70, 11.53 ]
Total events: 188 (Misoprostol), 88 (Surgery)
Heterogeneity: Tau2 = 0.92; Chi2 = 9.24, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 1.46 (P = 0.14)
Total (95% CI) 1609 1406 100.0 % 2.50 [ 1.53, 4.09 ]
Total events: 288 (Misoprostol), 118 (Surgery)
Heterogeneity: Tau2 = 0.31; Chi2 = 25.15, df = 10 (P = 0.01); I2 =60%
Test for overall effect: Z = 3.67 (P = 0.00024)
Test for subgroup differences: Chi2 = 1.72, df = 2 (P = 0.42), I2 =0.0%
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Analysis 2.16. Comparison 2 Misoprostol versus surgery, Outcome 16 Vomiting.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 16 Vomiting
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 0/47 1/47 1.4 % 0.33 [ 0.01, 7.98 ]
Zhang 2005 5/28 0/9 1.7 % 3.79 [ 0.23, 62.65 ]
Subtotal (95% CI) 75 56 3.1 % 1.26 [ 0.12, 13.73 ]
Total events: 5 (Misoprostol), 1 (Surgery)
Heterogeneity: Tau2 = 0.65; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Oral misoprostol
Bique 2007 5/111 0/101 1.7 % 10.02 [ 0.56, 178.93 ]
Chigbu 2012 6/160 6/160 11.1 % 1.00 [ 0.33, 3.03 ]
0.01 0.1 1 10 100
Favours misoprostol Favours surgery
(Continued . . . )
139Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dao 2007 5/223 4/224 8.1 % 1.26 [ 0.34, 4.61 ]
Montesinos 2011 2/106 0/97 1.5 % 4.58 [ 0.22, 94.21 ]
Shwekerela 2007 17/150 6/150 16.8 % 2.83 [ 1.15, 6.99 ]
Taylor 2011 5/93 4/112 8.3 % 1.51 [ 0.42, 5.45 ]
Subtotal (95% CI) 843 844 47.6 % 1.84 [ 1.07, 3.14 ]
Total events: 40 (Misoprostol), 20 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.22, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Dabash 2010 32/327 17/316 42.6 % 1.82 [ 1.03, 3.21 ]
Shochet 2012 24/336 2/180 6.7 % 6.43 [ 1.54, 26.89 ]
Subtotal (95% CI) 663 496 49.3 % 2.90 [ 0.84, 9.96 ]
Total events: 56 (Misoprostol), 19 (Surgery)
Heterogeneity: Tau2 = 0.54; Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 1.69 (P = 0.091)
Total (95% CI) 1581 1396 100.0 % 1.97 [ 1.36, 2.85 ]
Total events: 101 (Misoprostol), 40 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.57, df = 9 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Chi2 = 0.57, df = 2 (P = 0.75), I2 =0.0%
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Analysis 2.17. Comparison 2 Misoprostol versus surgery, Outcome 17 Diarrhoea.
Review: Medical treatments for incomplete miscarriage
Comparison: 2 Misoprostol versus surgery
Outcome: 17 Diarrhoea
Study or subgroup Misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vaginal misoprostol
Moodliar 2005 1/47 0/47 21.9 % 3.00 [ 0.13, 71.82 ]
Zhang 2005 7/28 0/9 28.8 % 5.17 [ 0.32, 82.63 ]
Subtotal (95% CI) 75 56 50.6 % 4.09 [ 0.51, 32.97 ]
Total events: 8 (Misoprostol), 0 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Oral misoprostol
Chigbu 2012 3/160 0/160 25.3 % 7.00 [ 0.36, 134.43 ]
Weeks 2005 2/159 0/147 24.1 % 4.63 [ 0.22, 95.55 ]
Subtotal (95% CI) 319 307 49.4 % 5.72 [ 0.69, 47.40 ]
Total events: 5 (Misoprostol), 0 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.11)
3 Vaginal + oral misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Rectal misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Sublingual misoprostol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 394 363 100.0 % 4.82 [ 1.09, 21.32 ]
Total events: 13 (Misoprostol), 0 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.01 0.1 1 10 100
Favours misoprostol Favours surgery
141Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Vaginal misoprostol versus expectant care, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 3 Vaginal misoprostol versus expectant care
Outcome: 1 Complete miscarriage
Study or subgroup Vag misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Blohm 2005 52/64 32/62 53.0 % 1.57 [ 1.20, 2.06 ]
Shelley 2005 8/10 12/14 47.0 % 0.93 [ 0.64, 1.36 ]
Subtotal (95% CI) 74 76 100.0 % 1.23 [ 0.72, 2.10 ]
Total events: 60 (Vag misoprostol), 44 (Expectant care)
Heterogeneity: Tau2 = 0.12; Chi2 = 5.37, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Geststion 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Vaginal misoprostol versus expectant care, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 3 Vaginal misoprostol versus expectant care
Outcome: 2 Surgical evacuation
Study or subgroup Vag misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Blohm 2005 8/64 25/62 47.9 % 0.31 [ 0.15, 0.63 ]
Trinder 2006 26/90 23/92 52.1 % 1.16 [ 0.72, 1.87 ]
Subtotal (95% CI) 154 154 100.0 % 0.62 [ 0.17, 2.26 ]
Total events: 34 (Vag misoprostol), 48 (Expectant care)
Heterogeneity: Tau2 = 0.78; Chi2 = 9.11, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.73 (P = 0.46)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Vaginal misoprostol versus expectant care, Outcome 3 Death or serious
complication.
Review: Medical treatments for incomplete miscarriage
Comparison: 3 Vaginal misoprostol versus expectant care
Outcome: 3 Death or serious complication
Study or subgroup Vag misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Blohm 2005 1/64 0/62 100.0 % 2.91 [ 0.12, 70.05 ]
Subtotal (95% CI) 64 62 100.0 % 2.91 [ 0.12, 70.05 ]
Total events: 1 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Vaginal misoprostol versus expectant care, Outcome 4 Unplanned surgical
intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 3 Vaginal misoprostol versus expectant care
Outcome: 4 Unplanned surgical intervention
Study or subgroup Vag misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Blohm 2005 8/64 25/62 47.9 % 0.31 [ 0.15, 0.63 ]
Trinder 2006 26/90 23/92 52.1 % 1.16 [ 0.72, 1.87 ]
Subtotal (95% CI) 154 154 100.0 % 0.62 [ 0.17, 2.26 ]
Total events: 34 (Vag misoprostol), 48 (Expectant care)
Heterogeneity: Tau2 = 0.78; Chi2 = 9.11, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.73 (P = 0.46)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vag misoprostol Favours expectant care
145Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.5. Comparison 3 Vaginal misoprostol versus expectant care, Outcome 5 Blood transfusion.
Review: Medical treatments for incomplete miscarriage
Comparison: 3 Vaginal misoprostol versus expectant care
Outcome: 5 Blood transfusion
Study or subgroup Vag misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Blohm 2005 0/64 0/62 Not estimable
Shelley 2005 0/10 0/14 Not estimable
Trinder 2006 1/90 0/92 100.0 % 3.07 [ 0.13, 74.28 ]
Subtotal (95% CI) 164 168 100.0 % 3.07 [ 0.13, 74.28 ]
Total events: 1 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Vaginal misoprostol versus expectant care, Outcome 6 Pain relief.
Review: Medical treatments for incomplete miscarriage
Comparison: 3 Vaginal misoprostol versus expectant care
Outcome: 6 Pain relief
Study or subgroup Vag misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Blohm 2005 53/64 38/62 62.1 % 1.35 [ 1.08, 1.70 ]
Trinder 2006 17/90 21/92 37.9 % 0.83 [ 0.47, 1.46 ]
Subtotal (95% CI) 154 154 100.0 % 1.12 [ 0.67, 1.88 ]
Total events: 70 (Vag misoprostol), 59 (Expectant care)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.99, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Vaginal misoprostol versus expectant care, Outcome 7 Pelvic infection < 14
days.
Review: Medical treatments for incomplete miscarriage
Comparison: 3 Vaginal misoprostol versus expectant care
Outcome: 7 Pelvic infection < 14 days
Study or subgroup Vag misoprostol Expectant care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Blohm 2005 3/64 0/62 17.3 % 6.78 [ 0.36, 128.70 ]
Shelley 2005 2/11 0/14 15.2 % 6.25 [ 0.33, 118.22 ]
Trinder 2006 2/90 2/92 67.5 % 1.02 [ 0.15, 7.10 ]
Subtotal (95% CI) 165 168 100.0 % 2.81 [ 0.77, 10.33 ]
Total events: 7 (Vag misoprostol), 2 (Expectant care)
Heterogeneity: Chi2 = 1.67, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Expectant care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Vaginal misoprostol versus surgery, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 1 Complete miscarriage
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Ganguly 2010 63/77 37/37 30.2 % 0.82 [ 0.74, 0.92 ]
Moodliar 2005 43/47 47/47 28.4 % 0.92 [ 0.83, 1.01 ]
Patua 2013 42/46 48/50 27.5 % 0.95 [ 0.86, 1.06 ]
Shelley 2005 8/10 11/11 6.6 % 0.81 [ 0.57, 1.13 ]
Zhang 2005 25/30 8/9 7.4 % 0.94 [ 0.71, 1.24 ]
Subtotal (95% CI) 210 154 100.0 % 0.89 [ 0.84, 0.95 ]
Total events: 181 (Vag misoprostol), 151 (Surgery)
Heterogeneity: Chi2 = 4.02, df = 4 (P = 0.40); I2 =0%
Test for overall effect: Z = 3.71 (P = 0.00021)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Vaginal misoprostol versus surgery, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 2 Surgical evacuation
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Moodliar 2005 4/47 47/47 23.1 % 0.09 [ 0.04, 0.23 ]
Patua 2013 4/46 50/50 23.1 % 0.10 [ 0.04, 0.23 ]
Trinder 2006 26/90 78/92 30.4 % 0.34 [ 0.24, 0.48 ]
Zhang 2005 4/30 9/9 23.3 % 0.15 [ 0.06, 0.36 ]
Subtotal (95% CI) 213 198 100.0 % 0.16 [ 0.07, 0.35 ]
Total events: 38 (Vag misoprostol), 184 (Surgery)
Heterogeneity: Tau2 = 0.52; Chi2 = 15.37, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 4.54 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Vaginal misoprostol versus surgery, Outcome 3 Death or serious complication.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 3 Death or serious complication
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Moodliar 2005 0/47 0/47 Not estimable
Zhang 2005 1/29 0/9 100.0 % 1.00 [ 0.04, 22.64 ]
Subtotal (95% CI) 76 56 100.0 % 1.00 [ 0.04, 22.64 ]
Total events: 1 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Vaginal misoprostol versus surgery, Outcome 4 Unplanned surgical
intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 4 Unplanned surgical intervention
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Moodliar 2005 4/47 0/47 14.1 % 9.00 [ 0.50, 162.62 ]
Patua 2013 4/46 2/50 29.2 % 2.17 [ 0.42, 11.31 ]
Trinder 2006 26/90 2/92 34.0 % 13.29 [ 3.25, 54.35 ]
Zhang 2005 4/30 1/9 22.7 % 1.20 [ 0.15, 9.42 ]
Subtotal (95% CI) 213 198 100.0 % 4.29 [ 1.24, 14.87 ]
Total events: 38 (Vag misoprostol), 5 (Surgery)
Heterogeneity: Tau2 = 0.67; Chi2 = 5.18, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 2.30 (P = 0.021)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Vaginal misoprostol versus surgery, Outcome 5 Blood transfusion.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 5 Blood transfusion
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Shelley 2005 0/10 0/11 Not estimable
Trinder 2006 1/90 0/92 39.7 % 3.07 [ 0.13, 74.28 ]
Zhang 2005 1/29 0/9 60.3 % 1.00 [ 0.04, 22.64 ]
Subtotal (95% CI) 129 112 100.0 % 1.82 [ 0.21, 15.70 ]
Total events: 2 (Vag misoprostol), 0 (Surgery)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.59)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Vaginal misoprostol versus surgery, Outcome 6 Anaemia.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 6 Anaemia
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Zhang 2005 6/28 1/8 100.0 % 1.71 [ 0.24, 12.24 ]
Subtotal (95% CI) 28 8 100.0 % 1.71 [ 0.24, 12.24 ]
Total events: 6 (Vag misoprostol), 1 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Vaginal misoprostol versus surgery, Outcome 7 Days of bleeding.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 7 Days of bleeding
Study or subgroup Vag misoprostol Surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Gestation < 13 weeks
Moodliar 2005 47 7 (3.4) 47 4.4 (3.2) 82.1 % 2.60 [ 1.27, 3.93 ]
Zhang 2005 28 11.3 (2.7) 9 7.8 (4.1) 17.9 % 3.50 [ 0.64, 6.36 ]
Subtotal (95% CI) 75 56 100.0 % 2.76 [ 1.55, 3.97 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.47 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Vaginal misoprostol versus surgery, Outcome 8 Pain relief.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 8 Pain relief
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Moodliar 2005 28/47 18/47 57.4 % 1.56 [ 1.01, 2.40 ]
Trinder 2006 17/90 12/92 37.8 % 1.45 [ 0.73, 2.86 ]
Zhang 2005 20/28 1/9 4.8 % 6.43 [ 1.00, 41.41 ]
Subtotal (95% CI) 165 148 100.0 % 1.75 [ 1.21, 2.54 ]
Total events: 65 (Vag misoprostol), 31 (Surgery)
Heterogeneity: Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.94 (P = 0.0033)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Vaginal misoprostol versus surgery, Outcome 9 Pelvic infection < 14 days.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 9 Pelvic infection < 14 days
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Moodliar 2005 0/47 0/47 Not estimable
Shelley 2005 2/11 0/12 11.4 % 5.42 [ 0.29, 101.77 ]
Trinder 2006 2/90 3/92 70.6 % 0.68 [ 0.12, 3.98 ]
Zhang 2005 1/30 0/9 18.0 % 0.97 [ 0.04, 21.92 ]
Subtotal (95% CI) 178 160 100.0 % 1.27 [ 0.37, 4.42 ]
Total events: 5 (Vag misoprostol), 3 (Surgery)
Heterogeneity: Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 Vaginal misoprostol versus surgery, Outcome 10 Women’s views/satisfaction -
continuous data.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 10 Women’s views/satisfaction - continuous data
Study or subgroup Vag misoprostol Surgery
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Gestation < 13 weeks
Moodliar 2005 47 8.43 (2.1) 47 7.3 (1.87) 56.7 % 0.56 [ 0.15, 0.98 ]
Zhang 2005 28 4.8 (0.5) 9 3.3 (1.7) 43.3 % 1.59 [ 0.75, 2.43 ]
Subtotal (95% CI) 75 56 100.0 % 1.01 [ 0.01, 2.00 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 4.58, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.98 (P = 0.047)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 Vaginal misoprostol versus surgery, Outcome 11 Nausea.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 11 Nausea
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Moodliar 2005 0/47 1/47 21.2 % 0.33 [ 0.01, 7.98 ]
Shelley 2005 2/13 1/12 14.7 % 1.85 [ 0.19, 17.84 ]
Zhang 2005 15/28 3/9 64.1 % 1.61 [ 0.60, 4.31 ]
Subtotal (95% CI) 88 68 100.0 % 1.37 [ 0.58, 3.22 ]
Total events: 17 (Vag misoprostol), 5 (Surgery)
Heterogeneity: Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.12. Comparison 4 Vaginal misoprostol versus surgery, Outcome 12 Vomiting.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 12 Vomiting
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Moodliar 2005 0/47 1/47 66.9 % 0.33 [ 0.01, 7.98 ]
Zhang 2005 5/28 0/9 33.1 % 3.79 [ 0.23, 62.65 ]
Subtotal (95% CI) 75 56 100.0 % 1.48 [ 0.25, 8.93 ]
Total events: 5 (Vag misoprostol), 1 (Surgery)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 Vaginal misoprostol versus surgery, Outcome 13 Diarrhoea.
Review: Medical treatments for incomplete miscarriage
Comparison: 4 Vaginal misoprostol versus surgery
Outcome: 13 Diarrhoea
Study or subgroup Vag misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Moodliar 2005 1/47 0/47 40.2 % 3.00 [ 0.13, 71.82 ]
Zhang 2005 7/28 0/9 59.8 % 5.17 [ 0.32, 82.63 ]
Subtotal (95% CI) 75 56 100.0 % 4.30 [ 0.52, 35.36 ]
Total events: 8 (Vag misoprostol), 0 (Surgery)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Oral misoprostol versus surgery, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 1 Complete miscarriage
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Bique 2007 101/111 101/101 9.0 % 0.91 [ 0.86, 0.97 ]
Chigbu 2012 158/160 160/160 19.9 % 0.99 [ 0.97, 1.01 ]
Dao 2007 206/218 222/224 15.7 % 0.95 [ 0.92, 0.99 ]
Montesinos 2011 100/106 97/97 11.3 % 0.94 [ 0.90, 0.99 ]
Shwekerela 2007 149/150 150/150 20.8 % 0.99 [ 0.98, 1.01 ]
Taylor 2011 106/108 109/110 16.6 % 0.99 [ 0.96, 1.02 ]
Weeks 2005 103/107 75/82 6.7 % 1.05 [ 0.98, 1.14 ]
Subtotal (95% CI) 960 924 100.0 % 0.98 [ 0.95, 1.00 ]
Total events: 923 (Oral misoprostol), 914 (Surgery)
Heterogeneity: Tau2 = 0.00; Chi2 = 19.16, df = 6 (P = 0.004); I2 =69%
Test for overall effect: Z = 2.07 (P = 0.039)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Oral misoprostol versus surgery, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 2 Surgical evacuation
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Bique 2007 10/111 101/101 19.4 % 0.09 [ 0.05, 0.17 ]
Chigbu 2012 2/160 160/160 11.7 % 0.02 [ 0.00, 0.05 ]
Dao 2007 12/218 222/224 19.7 % 0.06 [ 0.03, 0.10 ]
Montesinos 2011 6/106 97/97 17.3 % 0.06 [ 0.03, 0.13 ]
Shwekerela 2007 1/150 150/150 8.7 % 0.01 [ 0.00, 0.05 ]
Taylor 2011 1/108 110/110 8.7 % 0.01 [ 0.00, 0.07 ]
Weeks 2005 4/107 76/82 14.5 % 0.04 [ 0.02, 0.11 ]
Subtotal (95% CI) 960 924 100.0 % 0.04 [ 0.02, 0.07 ]
Total events: 36 (Oral misoprostol), 916 (Surgery)
Heterogeneity: Tau2 = 0.38; Chi2 = 17.99, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 10.79 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Oral misoprostol versus surgery, Outcome 3 Unplanned surgical intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 3 Unplanned surgical intervention
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Bique 2007 10/111 0/101 9.3 % 19.13 [ 1.14, 322.25 ]
Chigbu 2012 2/160 0/160 8.9 % 5.00 [ 0.24, 103.33 ]
Dao 2007 12/218 2/224 35.0 % 6.17 [ 1.40, 27.23 ]
Montesinos 2011 6/106 0/97 9.3 % 11.91 [ 0.68, 208.61 ]
Taylor 2011 1/108 1/110 17.6 % 1.02 [ 0.06, 16.08 ]
Weeks 2005 4/107 1/82 20.1 % 3.07 [ 0.35, 26.91 ]
Subtotal (95% CI) 810 774 100.0 % 6.27 [ 2.57, 15.31 ]
Total events: 35 (Oral misoprostol), 4 (Surgery)
Heterogeneity: Chi2 = 2.90, df = 5 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 4.03 (P = 0.000056)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Oral misoprostol versus surgery, Outcome 4 Blood transfusion.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 4 Blood transfusion
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Weeks 2005 0/107 0/82 Not estimable
Subtotal (95% CI) 107 82 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 5.5. Comparison 5 Oral misoprostol versus surgery, Outcome 5 Pain relief.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 5 Pain relief
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Bique 2007 92/111 99/101 100.0 % 0.85 [ 0.77, 0.92 ]
Subtotal (95% CI) 111 101 100.0 % 0.85 [ 0.77, 0.92 ]
Total events: 92 (Oral misoprostol), 99 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00022)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Oral misoprostol versus surgery, Outcome 6 Pelvic infection.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 6 Pelvic infection
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Shwekerela 2007 0/150 0/150 Not estimable
Weeks 2005 1/107 3/82 100.0 % 0.26 [ 0.03, 2.41 ]
Subtotal (95% CI) 257 232 100.0 % 0.26 [ 0.03, 2.41 ]
Total events: 1 (Oral misoprostol), 3 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Oral misoprostol versus surgery, Outcome 7 Cervical damage.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 7 Cervical damage
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Weeks 2005 0/107 5/82 100.0 % 0.07 [ 0.00, 1.25 ]
Subtotal (95% CI) 107 82 100.0 % 0.07 [ 0.00, 1.25 ]
Total events: 0 (Oral misoprostol), 5 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.8. Comparison 5 Oral misoprostol versus surgery, Outcome 8 Women’s views/acceptability of
method.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 8 Women’s views/acceptability of method
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Bique 2007 107/111 101/101 11.6 % 0.96 [ 0.93, 1.00 ]
Chigbu 2012 160/160 160/160 17.5 % 1.00 [ 0.99, 1.01 ]
Dao 2007 210/218 215/224 23.1 % 1.00 [ 0.97, 1.04 ]
Montesinos 2011 102/106 94/97 10.7 % 0.99 [ 0.94, 1.05 ]
Shwekerela 2007 149/150 150/150 16.4 % 0.99 [ 0.98, 1.01 ]
Taylor 2011 103/108 108/110 11.7 % 0.97 [ 0.93, 1.02 ]
Weeks 2005 99/105 71/75 9.0 % 1.00 [ 0.93, 1.07 ]
Subtotal (95% CI) 958 917 100.0 % 0.99 [ 0.98, 1.01 ]
Total events: 930 (Oral misoprostol), 899 (Surgery)
Heterogeneity: Chi2 = 4.95, df = 6 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.9. Comparison 5 Oral misoprostol versus surgery, Outcome 9 Nausea.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 9 Nausea
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Bique 2007 13/111 2/101 8.2 % 5.91 [ 1.37, 25.57 ]
Chigbu 2012 8/160 7/160 27.4 % 1.14 [ 0.42, 3.08 ]
Dao 2007 12/223 2/224 7.8 % 6.03 [ 1.36, 26.62 ]
Montesinos 2011 5/106 0/97 2.0 % 10.07 [ 0.56, 179.84 ]
Shwekerela 2007 38/150 9/150 35.2 % 4.22 [ 2.12, 8.42 ]
Taylor 2011 7/108 5/110 19.4 % 1.43 [ 0.47, 4.36 ]
Subtotal (95% CI) 858 842 100.0 % 3.24 [ 2.10, 4.98 ]
Total events: 83 (Oral misoprostol), 25 (Surgery)
Heterogeneity: Chi2 = 8.80, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 5.34 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.10. Comparison 5 Oral misoprostol versus surgery, Outcome 10 Vomiting.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 10 Vomiting
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Bique 2007 5/111 0/101 2.5 % 10.02 [ 0.56, 178.93 ]
Chigbu 2012 6/160 6/160 29.0 % 1.00 [ 0.33, 3.03 ]
Dao 2007 5/223 4/224 19.3 % 1.26 [ 0.34, 4.61 ]
Montesinos 2011 2/106 0/97 2.5 % 4.58 [ 0.22, 94.21 ]
Shwekerela 2007 17/150 6/150 29.0 % 2.83 [ 1.15, 6.99 ]
Taylor 2011 5/93 4/112 17.6 % 1.51 [ 0.42, 5.45 ]
Subtotal (95% CI) 843 844 100.0 % 1.99 [ 1.18, 3.34 ]
Total events: 40 (Oral misoprostol), 20 (Surgery)
Heterogeneity: Chi2 = 4.22, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0093)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.11. Comparison 5 Oral misoprostol versus surgery, Outcome 11 Diarrhoea.
Review: Medical treatments for incomplete miscarriage
Comparison: 5 Oral misoprostol versus surgery
Outcome: 11 Diarrhoea
Study or subgroup Oral misoprostol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Chigbu 2012 3/160 0/160 49.0 % 7.00 [ 0.36, 134.43 ]
Weeks 2005 2/159 0/147 51.0 % 4.63 [ 0.22, 95.55 ]
Subtotal (95% CI) 319 307 100.0 % 5.79 [ 0.70, 47.64 ]
Total events: 5 (Oral misoprostol), 0 (Surgery)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Vaginal + oral misoprostol versus surgery, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 6 Vaginal + oral misoprostol versus surgery
Outcome: 1 Complete miscarriage
Study or subgroup
Vag + oral
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Sahin 2001 38/40 40/40 100.0 % 0.95 [ 0.87, 1.04 ]
Subtotal (95% CI) 40 40 100.0 % 0.95 [ 0.87, 1.04 ]
Total events: 38 (Vag + oral misoprostol), 40 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag + oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag + oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Vaginal + oral misoprostol versus surgery, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 6 Vaginal + oral misoprostol versus surgery
Outcome: 2 Surgical evacuation
Study or subgroup
Vag + oral
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Sahin 2001 1/40 40/40 100.0 % 0.04 [ 0.01, 0.18 ]
Subtotal (95% CI) 40 40 100.0 % 0.04 [ 0.01, 0.18 ]
Total events: 1 (Vag + oral misoprostol), 40 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag + oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag + oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Vaginal + oral misoprostol versus surgery, Outcome 3 Days of bleeding.
Review: Medical treatments for incomplete miscarriage
Comparison: 6 Vaginal + oral misoprostol versus surgery
Outcome: 3 Days of bleeding
Study or subgroup
Vag + oral
misopros-
tol Surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Gestation < 13 weeks
Sahin 2001 40 6.45 (2.23) 40 4.9 (2.19) 100.0 % 1.55 [ 0.58, 2.52 ]
Subtotal (95% CI) 40 40 100.0 % 1.55 [ 0.58, 2.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Vaginal + oral misoprostol versus surgery, Outcome 4 Pelvic infection.
Review: Medical treatments for incomplete miscarriage
Comparison: 6 Vaginal + oral misoprostol versus surgery
Outcome: 4 Pelvic infection
Study or subgroup
Vag + oral
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Sahin 2001 1/40 2/40 100.0 % 0.50 [ 0.05, 5.30 ]
Subtotal (95% CI) 40 40 100.0 % 0.50 [ 0.05, 5.30 ]
Total events: 1 (Vag + oral misoprostol), 2 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag + oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag + oral misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Sublingual misoprostol versus surgery, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 1 Complete miscarriage
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Dabash 2010 342/348 346/347 45.5 % 0.99 [ 0.97, 1.00 ]
Shochet 2012 439/465 374/374 54.5 % 0.94 [ 0.92, 0.97 ]
Subtotal (95% CI) 813 721 100.0 % 0.96 [ 0.95, 0.98 ]
Total events: 781 (Sublingual misoprostol), 720 (Surgery)
Heterogeneity: Chi2 = 11.95, df = 1 (P = 0.00055); I2 =92%
Test for overall effect: Z = 5.25 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Sublingual misoprostol versus surgery, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 2 Surgical evacuation
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation <13 weeks
Dabash 2010 6/348 347/347 100.0 % 0.02 [ 0.01, 0.04 ]
Subtotal (95% CI) 348 347 100.0 % 0.02 [ 0.01, 0.04 ]
Total events: 6 (Sublingual misoprostol), 347 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 10.25 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Sublingual misoprostol versus surgery, Outcome 3 Unplanned surgical
intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 3 Unplanned surgical intervention
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Dabash 2010 6/348 1/347 100.0 % 5.98 [ 0.72, 49.43 ]
Subtotal (95% CI) 348 347 100.0 % 5.98 [ 0.72, 49.43 ]
Total events: 6 (Sublingual misoprostol), 1 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Sublingual misoprostol versus surgery, Outcome 4 Anaemia.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 4 Anaemia
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Dabash 2010 1/348 3/347 100.0 % 0.33 [ 0.03, 3.18 ]
Subtotal (95% CI) 348 347 100.0 % 0.33 [ 0.03, 3.18 ]
Total events: 1 (Sublingual misoprostol), 3 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Sublingual misoprostol versus surgery, Outcome 5 Digestive disorders.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 5 Digestive disorders
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Shochet 2012 51/336 7/180 100.0 % 3.90 [ 1.81, 8.42 ]
Subtotal (95% CI) 336 180 100.0 % 3.90 [ 1.81, 8.42 ]
Total events: 51 (Sublingual misoprostol), 7 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 3.47 (P = 0.00052)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Sublingual misoprostol versus surgery, Outcome 6Women’s views/acceptability
of method.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 6 Women’s views/acceptability of method
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Dabash 2010 337/348 341/347 48.0 % 0.99 [ 0.96, 1.01 ]
Shochet 2012 452/459 314/320 52.0 % 1.00 [ 0.98, 1.02 ]
Subtotal (95% CI) 807 667 100.0 % 0.99 [ 0.98, 1.01 ]
Total events: 789 (Sublingual misoprostol), 655 (Surgery)
Heterogeneity: Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.67 (P = 0.50)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.7. Comparison 7 Sublingual misoprostol versus surgery, Outcome 7 Nausea.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 7 Nausea
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Dabash 2010 132/327 83/316 92.8 % 1.54 [ 1.22, 1.93 ]
Shochet 2012 56/336 5/180 7.2 % 6.00 [ 2.45, 14.71 ]
Subtotal (95% CI) 663 496 100.0 % 1.86 [ 1.48, 2.32 ]
Total events: 188 (Sublingual misoprostol), 88 (Surgery)
Heterogeneity: Chi2 = 9.24, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 5.42 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.8. Comparison 7 Sublingual misoprostol versus surgery, Outcome 8 Vomiting.
Review: Medical treatments for incomplete miscarriage
Comparison: 7 Sublingual misoprostol versus surgery
Outcome: 8 Vomiting
Study or subgroup
Sublingual
misopros-
tol Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Dabash 2010 32/327 17/316 86.9 % 1.82 [ 1.03, 3.21 ]
Shochet 2012 24/336 2/180 13.1 % 6.43 [ 1.54, 26.89 ]
Subtotal (95% CI) 663 496 100.0 % 2.42 [ 1.43, 4.10 ]
Total events: 56 (Sublingual misoprostol), 19 (Surgery)
Heterogeneity: Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 3.30 (P = 0.00096)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours surgery Favours SL misoprostol
184Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.1. Comparison 8 Vaginal misoprostol versus oral misoprostol, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 8 Vaginal misoprostol versus oral misoprostol
Outcome: 1 Complete miscarriage
Study or subgroup Vag misoprostol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Pang 2001 58/95 67/103 100.0 % 0.94 [ 0.76, 1.16 ]
Subtotal (95% CI) 95 103 100.0 % 0.94 [ 0.76, 1.16 ]
Total events: 58 (Vag misoprostol), 67 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Vaginal misoprostol versus oral misoprostol, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 8 Vaginal misoprostol versus oral misoprostol
Outcome: 2 Surgical evacuation
Study or subgroup Vag misoprostol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Pang 2001 37/95 36/103 100.0 % 1.11 [ 0.77, 1.60 ]
Subtotal (95% CI) 95 103 100.0 % 1.11 [ 0.77, 1.60 ]
Total events: 37 (Vag misoprostol), 36 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Vaginal misoprostol versus oral misoprostol, Outcome 3 Unplanned surgical
intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 8 Vaginal misoprostol versus oral misoprostol
Outcome: 3 Unplanned surgical intervention
Study or subgroup Vag misoprostol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Pang 2001 0/89 1/97 100.0 % 0.36 [ 0.01, 8.80 ]
Subtotal (95% CI) 89 97 100.0 % 0.36 [ 0.01, 8.80 ]
Total events: 0 (Vag misoprostol), 1 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Vaginal misoprostol versus oral misoprostol, Outcome 4 Pain relief.
Review: Medical treatments for incomplete miscarriage
Comparison: 8 Vaginal misoprostol versus oral misoprostol
Outcome: 4 Pain relief
Study or subgroup Vag misoprostol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Pang 2001 34/89 26/97 100.0 % 1.43 [ 0.93, 2.17 ]
Subtotal (95% CI) 89 97 100.0 % 1.43 [ 0.93, 2.17 ]
Total events: 34 (Vag misoprostol), 26 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Vaginal misoprostol versus oral misoprostol, Outcome 5 Nausea.
Review: Medical treatments for incomplete miscarriage
Comparison: 8 Vaginal misoprostol versus oral misoprostol
Outcome: 5 Nausea
Study or subgroup Vag misoprostol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Pang 2001 7/95 12/103 100.0 % 0.63 [ 0.26, 1.54 ]
Subtotal (95% CI) 95 103 100.0 % 0.63 [ 0.26, 1.54 ]
Total events: 7 (Vag misoprostol), 12 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Vaginal misoprostol versus oral misoprostol, Outcome 6 Vomiting.
Review: Medical treatments for incomplete miscarriage
Comparison: 8 Vaginal misoprostol versus oral misoprostol
Outcome: 6 Vomiting
Study or subgroup Vag misoprostol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Pang 2001 2/95 6/103 100.0 % 0.36 [ 0.07, 1.75 ]
Subtotal (95% CI) 95 103 100.0 % 0.36 [ 0.07, 1.75 ]
Total events: 2 (Vag misoprostol), 6 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 Vaginal misoprostol versus oral misoprostol, Outcome 7 Diarrhoea.
Review: Medical treatments for incomplete miscarriage
Comparison: 8 Vaginal misoprostol versus oral misoprostol
Outcome: 7 Diarrhoea
Study or subgroup Vag misoprostol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Pang 2001 12/95 62/103 100.0 % 0.21 [ 0.12, 0.36 ]
Subtotal (95% CI) 95 103 100.0 % 0.21 [ 0.12, 0.36 ]
Total events: 12 (Vag misoprostol), 62 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 5.55 (P < 0.00001)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 1 Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 1 Complete miscarriage
Study or subgroup Oral misop 600ug Oral misop 1200ug Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Blanchard 2004 57/86 58/83 29.9 % 0.95 [ 0.77, 1.17 ]
Ngoc 2005 142/149 137/146 70.1 % 1.02 [ 0.96, 1.07 ]
Subtotal (95% CI) 235 229 100.0 % 1.00 [ 0.93, 1.07 ]
Total events: 199 (Oral misop 600ug), 195 (Oral misop 1200ug)
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 2 Surgical evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 2 Surgical evacuation
Study or subgroup Oral misop 600ug Oral misop 1200ug Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Ngoc 2005 7/149 9/146 100.0 % 0.76 [ 0.29, 1.99 ]
Subtotal (95% CI) 149 146 100.0 % 0.76 [ 0.29, 1.99 ]
Total events: 7 (Oral misop 600ug), 9 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Favours
193Medical treatments for incomplete miscarriage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.3. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 3 Death or serious
complication.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 3 Death or serious complication
Study or subgroup Oral misop 600ug Oral misop 1200ug Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Ngoc 2005 0/149 0/146 Not estimable
Subtotal (95% CI) 149 146 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 149 146 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 9.4. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 4 Unplanned surgical
intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 4 Unplanned surgical intervention
Study or subgroup Oral misop 600ug Oral misop 1200ug Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Ngoc 2005 7/149 9/146 100.0 % 0.76 [ 0.29, 1.99 ]
Subtotal (95% CI) 149 146 100.0 % 0.76 [ 0.29, 1.99 ]
Total events: 7 (Oral misop 600ug), 9 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 5 Women’s
views/acceptability of method.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 5 Women’s views/acceptability of method
Study or subgroup
Oral
misoprostol
- 600ug
Oral
misoprostol -
1200ug Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Blanchard 2004 68/85 63/81 31.9 % 1.03 [ 0.88, 1.20 ]
Ngoc 2005 143/149 136/145 68.1 % 1.02 [ 0.97, 1.08 ]
Subtotal (95% CI) 234 226 100.0 % 1.02 [ 0.96, 1.09 ]
Total events: 211 (Oral misoprostol - 600ug), 199 (Oral misoprostol - 1200ug)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol - 600ug), 0 (Oral misoprostol - 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misoprostol - 600ug), 0 (Oral misoprostol - 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 9.6. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 6 Nausea.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 6 Nausea
Study or subgroup Oral misop 600ug Oral misop 1200ug Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation < 13 weeks
Blanchard 2004 15/86 18/83 47.4 % 0.80 [ 0.43, 1.49 ]
Ngoc 2005 33/149 19/145 52.6 % 1.69 [ 1.01, 2.83 ]
Subtotal (95% CI) 235 228 100.0 % 1.19 [ 0.57, 2.46 ]
Total events: 48 (Oral misop 600ug), 37 (Oral misop 1200ug)
Heterogeneity: Tau2 = 0.19; Chi2 = 3.29, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 9.7. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 7 Vomiting.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 7 Vomiting
Study or subgroup Oral misop 600ug Oral misop 1200ug Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Blanchard 2004 6/86 7/83 29.3 % 0.83 [ 0.29, 2.36 ]
Ngoc 2005 19/149 17/145 70.7 % 1.09 [ 0.59, 2.01 ]
Subtotal (95% CI) 235 228 100.0 % 1.01 [ 0.60, 1.72 ]
Total events: 25 (Oral misop 600ug), 24 (Oral misop 1200ug)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Oral misoprostol: 600 ug versus 1200 ug, Outcome 8 Diarrhoea.
Review: Medical treatments for incomplete miscarriage
Comparison: 9 Oral misoprostol: 600 ug versus 1200 ug
Outcome: 8 Diarrhoea
Study or subgroup Oral misop 600ug Oral misop 1200ug Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Ngoc 2005 51/149 68/145 100.0 % 0.73 [ 0.55, 0.97 ]
Subtotal (95% CI) 149 145 100.0 % 0.73 [ 0.55, 0.97 ]
Total events: 51 (Oral misop 600ug), 68 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral misop 600ug), 0 (Oral misop 1200ug)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Oral mifepristone + vaginal misoprostol versus surgery, Outcome 1
Complete miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 10 Oral mifepristone + vaginal misoprostol versus surgery
Outcome: 1 Complete miscarriage
Study or subgroup
Oral mifepri
+ vag
mispro Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Niinimaki 2006 10/10 6/6 79.9 % 1.00 [ 0.78, 1.27 ]
Subtotal (95% CI) 10 6 79.9 % 1.00 [ 0.78, 1.27 ]
Total events: 10 (Oral mifepri + vag mispro), 6 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Gestation 13-23 weeks
Niinimaki 2006 1/1 2/2 20.1 % 1.00 [ 0.39, 2.58 ]
Subtotal (95% CI) 1 2 20.1 % 1.00 [ 0.39, 2.58 ]
Total events: 1 (Oral mifepri + vag mispro), 2 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral mifepri + vag mispro), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 11 8 100.0 % 1.00 [ 0.77, 1.31 ]
Total events: 11 (Oral mifepri + vag mispro), 8 (Surgery)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 10.2. Comparison 10 Oral mifepristone + vaginal misoprostol versus surgery, Outcome 2 Pelvic
infection < 14 days.
Review: Medical treatments for incomplete miscarriage
Comparison: 10 Oral mifepristone + vaginal misoprostol versus surgery
Outcome: 2 Pelvic infection < 14 days
Study or subgroup
Oral mifepri
+ vag
mispro Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Niinimaki 2006 0/10 0/6 Not estimable
Subtotal (95% CI) 10 6 Not estimable
Total events: 0 (Oral mifepri + vag mispro), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gestation 13-23 weeks
Niinimaki 2006 0/1 0/2 Not estimable
Subtotal (95% CI) 1 2 Not estimable
Total events: 0 (Oral mifepri + vag mispro), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oral mifepri + vag mispro), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 11 8 Not estimable
Total events: 0 (Oral mifepri + vag mispro), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 11.1. Comparison 11 Vaginal prostaglandin E1 (gemeprost) versus surgery, Outcome 1 Unplanned
surgical intervention.
Review: Medical treatments for incomplete miscarriage
Comparison: 11 Vaginal prostaglandin E1 (gemeprost) versus surgery
Outcome: 1 Unplanned surgical intervention
Study or subgroup Vag gemeprost Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Clevin 2001 0/17 0/17 Not estimable
Subtotal (95% CI) 17 17 Not estimable
Total events: 0 (Vag gemeprost), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag gemeprost), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vag gemeprost), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 17 17 Not estimable
Total events: 0 (Vag gemeprost), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 12.1. Comparison 12 Sublingual misoprostol versus oral misoprostol, Outcome 1 Complete
miscarriage.
Review: Medical treatments for incomplete miscarriage
Comparison: 12 Sublingual misoprostol versus oral misoprostol
Outcome: 1 Complete miscarriage
Study or subgroup
Sublingual
misopros-
tol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Diop 2009 138/146 140/148 83.2 % 1.00 [ 0.95, 1.06 ]
Paritakul 2010 27/32 28/32 16.8 % 0.96 [ 0.79, 1.18 ]
Subtotal (95% CI) 178 180 100.0 % 0.99 [ 0.94, 1.05 ]
Total events: 165 (Sublingual misoprostol), 168 (Oral misoprostol)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Sublingual misoprostol versus oral misoprostol, Outcome 2 Surgical
evacuation.
Review: Medical treatments for incomplete miscarriage
Comparison: 12 Sublingual misoprostol versus oral misoprostol
Outcome: 2 Surgical evacuation
Study or subgroup
Sublingual
misopros-
tol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Diop 2009 8/146 8/148 100.0 % 1.01 [ 0.39, 2.63 ]
Subtotal (95% CI) 146 148 100.0 % 1.01 [ 0.39, 2.63 ]
Total events: 8 (Sublingual misoprostol), 8 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 Sublingual misoprostol versus oral misoprostol, Outcome 3 Death or serious
complication.
Review: Medical treatments for incomplete miscarriage
Comparison: 12 Sublingual misoprostol versus oral misoprostol
Outcome: 3 Death or serious complication
Study or subgroup
Sublingual
misopros-
tol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Diop 2009 0/146 0/148 Not estimable
Paritakul 2010 0/32 0/32 Not estimable
Subtotal (95% CI) 178 180 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 178 180 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 12.4. Comparison 12 Sublingual misoprostol versus oral misoprostol, Outcome 4 Nausea.
Review: Medical treatments for incomplete miscarriage
Comparison: 12 Sublingual misoprostol versus oral misoprostol
Outcome: 4 Nausea
Study or subgroup
Sublingual
misopros-
tol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Diop 2009 19/146 28/148 79.9 % 0.69 [ 0.40, 1.18 ]
Paritakul 2010 8/32 7/32 20.1 % 1.14 [ 0.47, 2.78 ]
Subtotal (95% CI) 178 180 100.0 % 0.78 [ 0.49, 1.23 ]
Total events: 27 (Sublingual misoprostol), 35 (Oral misoprostol)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 12.5. Comparison 12 Sublingual misoprostol versus oral misoprostol, Outcome 5 Vomiting.
Review: Medical treatments for incomplete miscarriage
Comparison: 12 Sublingual misoprostol versus oral misoprostol
Outcome: 5 Vomiting
Study or subgroup
Sublingual
misopros-
tol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Diop 2009 2/146 2/148 100.0 % 1.01 [ 0.14, 7.10 ]
Paritakul 2010 0/32 0/32 Not estimable
Subtotal (95% CI) 178 180 100.0 % 1.01 [ 0.14, 7.10 ]
Total events: 2 (Sublingual misoprostol), 2 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 12.6. Comparison 12 Sublingual misoprostol versus oral misoprostol, Outcome 6 Diarrhoea.
Review: Medical treatments for incomplete miscarriage
Comparison: 12 Sublingual misoprostol versus oral misoprostol
Outcome: 6 Diarrhoea
Study or subgroup
Sublingual
misopros-
tol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestation < 13 weeks
Diop 2009 2/146 2/148 28.4 % 1.01 [ 0.14, 7.10 ]
Paritakul 2010 9/32 5/32 71.6 % 1.80 [ 0.68, 4.78 ]
Subtotal (95% CI) 178 180 100.0 % 1.58 [ 0.66, 3.76 ]
Total events: 11 (Sublingual misoprostol), 7 (Oral misoprostol)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
2 Gestation 13-23 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation not specified
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Oral misoprostol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 12.7. Comparison 12 Sublingual misoprostol versus oral misoprostol, Outcome 7 Women’s
views/acceptability of method.
Review: Medical treatments for incomplete miscarriage
Comparison: 12 Sublingual misoprostol versus oral misoprostol
Outcome: 7 Women’s views/acceptability of method
Study or subgroup
Sublingual
misopros-
tol Oral misoprostol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Diop 2009 142/146 145/148 83.7 % 0.99 [ 0.96, 1.03 ]
Paritakul 2010 27/32 28/32 16.3 % 0.96 [ 0.79, 1.18 ]
Total (95% CI) 178 180 100.0 % 0.99 [ 0.95, 1.03 ]
Total events: 169 (Sublingual misoprostol), 173 (Oral misoprostol)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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WH A T ’ S N E W
Last assessed as up-to-date: 13 May 2016.
Date Event Description
13 May 2016 New search has been performed Search updated and21new reportswere identified.Of the
21 new reports, four additional trials have been included
in the review update
13 May 2016 New citation required but conclusions have not changed The inclusion of the four new studies has not changed
the overall conclusions of the review
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H I S T O R Y
Protocol first published: Issue 3, 2008
Review first published: Issue 1, 2010
Date Event Description
7 January 2013 New citation required but conclusions have not
changed
The inclusion of five new studies has not changed the
overall conclusions of the review
30 November 2012 New search has been performed Search updated.
Thie review has been updated. Five new trials have
been included (Dabash 2010, Diop 2009,Montesinos
2011, Paritakul 2010, Taylor 2011), and 21 new trials
have been excluded.
This updated review is now comprised of 20 included
studies (involving 4208 women), 135 excluded stud-
ies, one ongoing study (Yu 2000a) and one other study
that is awaiting classification (ISRCTN65305620).
Themethods text has been updated andwe have added
a ’Summary of findings’ table
23 July 2012 Amended Search updated. Thirty reports added to Studies await-
ing classification
C O N T R I B U T I O N S O F A U T H O R S
JP Neilson, J Vazquez, and M Hickey prepared the first draft of the Background section of the original publication. L Dou did the
data extraction. L Dou checked the data and all authors checked the text and contributed to the discussions and conclusions. For the
update, trials were assessed for inclusion and data were extracted independently by C Kim and S Barnard. All review authors reviewed
the final text.
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S O U R C E S O F S U P P O R T
Internal sources
• The University of Liverpool, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have modified the wording in the Methods sections for Assessment of heterogeneity, Assessment of reporting biases, and Data
synthesis to update them with the new methods being used by Cochrane Pregnancy and Childbirth, developed in conjunction with
Cochrane Pregnancy and Childbirth’s statisticians, Simon Gates and Richard Riley. We have used these new methods in the review.
We have added GRADE methods for assessing the quality of the evidence for this update (2016) and the secondary outcomes death
and serious morbidity have been removed as both of these appear in the composite primary outcome “Death or serious complications”.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Watchful Waiting; Abortifacient Agents, Nonsteroidal [∗administration & dosage; adverse effects]; Abortion, Incomplete [∗therapy];
Administration, Intravaginal; Administration, Oral; Diarrhea [chemically induced]; Extraction, Obstetrical [∗methods]; Gestational
Age; Misoprostol [∗administration & dosage; adverse effects]; Nausea [chemically induced]; Pregnancy Trimester, First; Randomized
Controlled Trials as Topic; Vomiting [chemically induced]
MeSH check words
Female; Humans; Pregnancy
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